---
title: "Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Product information and disease description. Covers Product description and Place of product in therapy. 379 evidence topics quoted from 173 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Regulatory status: Submission planned; NDA filing anticipated in the first half of 2027

> “On track for DT120 ODT NDA filing in first half of 2027”

Source: [Definium Therapeutics third quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/259/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights)

> “Pre-NDA meeting scheduled in 4Q 2026; NDA filing anticipated in 1H 2027”
> “Building on this momentum, we are advancing toward an NDA submission and look forward to aligning with the FDA at our upcoming pre-NDA meeting.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “the timing of our pre-NDA meeting scheduled for the fourth quarter of 2026; our anticipated NDA filing in the first half of 2027”
> “Regulatory filing strategy for GAD & MDD to be discussed at pre-NDA meeting.”
> “Robust data package aligned with FDA guidance supports advancement of NDA submission for DT120 ODT”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-2.1.1-2"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-3"></a>

##### Commercial readiness and launch preparation: no launch date stated

> “Advancing commercial readiness activities and expanding organizational capabilities to support the Company’s transition toward commercialization.”
> “The Company is also planning its first Commercial Day in the first half of 2027 to highlight the market opportunity for DT120 ODT and provide greater detail on its commercialization strategy and launch preparations.”

Source: [Definium Therapeutics third quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/259/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights)

> “Timing estimates subject to clinical progress and regulatory interactions.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-2.1.1-4"></a>

##### Investigational status and current development phase

> “Our lead product candidate, DT120 (Lysergide) orally disintegrating tablet (“ODT”), is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that we are developing for the treatment of adults with generalized anxiety disorder (“GAD”), major depressive disorder (“MDD”) and posttraumatic stress disorder (“PTSD”).”
> “Our Phase 3 clinical program for DT120 ODT for GAD consists of two clinical trials: the Voyage study (DT120-300) and the Panorama study (DT120-301).”
> “Both trials are comprised of two parts: Part A, which is a 12-week, randomized, double-blind, placebo-controlled, parallel-group trial assessing the efficacy and safety of DT120 ODT versus placebo; and Part B, which is a 40-week extension period during which participants will be eligible for open-label treatment with DT120 ODT, subject to certain conditions for treatment eligibility.”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

> “The Company's products will not be commercialized prior to applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the intended uses is successfully developed.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-2.1.1-5"></a>

##### Phase 3 topline results: Voyage reported August 2026 and Panorama reported September 2026

> “On August 12, 2026, we announced that the Voyage study met its primary endpoint and all key secondary efficacy endpoints, demonstrating a statistically significant and clinically meaningful improvement from baseline compared with placebo, as measured by the change in HAM-A total score at Week 12.”
> “On September 14, 2026, we announced that the Panorama study met its primary endpoint and all key secondary efficacy endpoints”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

> “Reported positive topline Phase 3 results from two Phase 3 studies of DT120 ODT in generalized anxiety disorder (GAD)”

Source: [Definium Therapeutics third quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/259/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights)

<a id="topic-2.1.1-6"></a>

##### Phase 3 initiation: first participant dosed in Voyage in December 2024

> “today announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD) for the treatment of GAD.”

Source: [MindMed Voyage first patient dosed announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/169/mindmed-announces-first-patient-dosed-in-phase-3-voyage-study-of-mm120-in-generalized-anxiety-disorder-gad)

<a id="topic-2.1.1-7"></a>

##### Breakthrough Therapy designation for generalized anxiety disorder: March 2024

> “today announced that FDA has granted breakthrough designation to its MM120 (lysergide d-tartrate) program for the treatment of generalized anxiety disorder (GAD).”
> “Based on the significant unmet medical need in the treatment of GAD – especially in patients who do not respond to or tolerate currently available medications – along with the initial clinical data from Phase 2b and other research conducted by MindMed, the U.S. Food & Drug Administration (FDA) has designated MM120 for GAD as a breakthrough therapy.”

Source: [MindMed Breakthrough Therapy designation announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/137/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder)

> “In March 2024, we announced that the U.S. Food and Drug Administration (“FDA”) granted breakthrough designation to our DT120 program for the treatment of GAD.”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

<a id="topic-2.1.1-8"></a>

##### Breakthrough Therapy designation for major depressive disorder: September 2026

> “today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for DT120 (lysergide) ODT.”
> “This milestone marks the second Breakthrough Therapy designation from the FDA for the DT120 development program, following its initial designation for the potential treatment of GAD.”

Source: [Definium Therapeutics MDD Breakthrough Therapy designation announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/247/definium-therapeutics-receives-breakthrough-therapy-designation-for-dt120-lysergide-orally-disintegrating-tablet-odt-in-major-depressive-disorder-mdd-following-positive-phase-3-results)

<a id="topic-2.1.1-9"></a>

##### End-of-phase 2 meeting with the FDA: completed June 2024

> “today announced the completion of the End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of MM120 (lysergic acid diethylamide [LSD] D-tartrate) into pivotal trials for the treatment of adults with GAD.”
> “Following a constructive End-of-Phase 2 meeting with the FDA, we are pleased to have reached alignment on our Phase 3 development strategy for MM120 in GAD,”
> “The EOP2 meeting was supported by results from MindMed’s completed Phase 2b clinical trial, MMED008.”

Source: [MindMed end-of-phase 2 meeting announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/149/mindmed-announces-constructive-end-of-phase-2-meeting-with-u-s-fda-for-mm120-in-generalized-anxiety-disorder-gad)

<a id="topic-2.1.1-10"></a>

##### Investigational new drug application for the phase 2b trial: cleared January 2022

> “announced today that the U.S. Food and Drug Administration (FDA) has cleared MindMed's Investigational New Drug (IND) application, allowing the Company's Phase 2b dose-optimization trial of MM-120 for the treatment of generalized anxiety disorder (GAD) to proceed.”
> “The previously announced clinical hold on the IND was lifted following MindMed's rapid responses for additional information related to the participant monitoring protocol in the upcoming study.”

Source: [MindMed IND clearance announcement (2022)](https://ir.definiumtx.com/news-events/press-releases/detail/54/fda-clears-mindmed-ind-for-mm-120-in-treatment-of-generalized-anxiety-disorder)

<a id="topic-2.1.1-11"></a>

##### Innovation Passport under the UK Innovative Licensing and Access Pathway: December 2024

> “today announced that MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD), has been granted an Innovation Passport for the potential treatment of GAD under ILAP by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).”
> “Specific benefits of ILAP include the potential for a 150-day accelerated Marketing Authorization Application assessment, rolling review and a continuous benefit risk assessment.”

Source: [MindMed Innovation Passport announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/167/mindmed-awarded-innovation-passport-designation-by-the-united-kingdom-uk-innovative-licensing-and-access-pathway-ilap-steering-group-for-mm120-orally-disintegrating-tablet-odt-for-generalized-anxiety-disorder-gad)

<a id="topic-2.1.1-12"></a>

##### Development outside the United States: regulatory strategy

> “evaluate the market potential and regulatory pathways for our product candidates in the UK, European Union (the “EU”), and other countries or regions outside the United States, and determine the best strategic and business opportunities to advance our product candidates in these markets;”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-2.1.1-13"></a>

##### Controlled substance scheduling: rescheduling by the DEA and states required after approval

> “Certain product candidates we are developing contain Schedule I controlled substances, like lysergide or MDMA, as defined in the Controlled Substances Act (“CSA”). Our product candidates must be approved by the FDA through the NDA process, and will need to be rescheduled by the Drug Enforcement Administration (“DEA”) and states, before they may be legally marketed in the U.S.”
> “If DT120 and DT402 receive FDA approval, HHS and the DEA must complete a scheduling analysis and make a scheduling determination to deschedule or place either the substance or the drug product in a schedule other than Schedule I in order for them to be able to be prescribed to patients in the United States.”
> “The rescheduling process requires the DEA to conduct notice-and-comment rulemaking, including issuing an interim final rule 90 days after the later of notice of FDA approval or DEA receipt of the HHS scheduling analysis and recommendation.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

> “legislative and regulatory developments, including decisions by the Drug Enforcement Administration and states to reschedule any of the Company's product candidates, if approved, containing Schedule I controlled substances, before they may be legally marketed in the U.S.”

Source: [Definium Therapeutics third quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/259/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights)

<a id="topic-2.1.1-14"></a>

##### Executive Order 14401 of April 2026: priority vouchers and timely rescheduling of psychedelic drugs

> “The Commissioner of Food and Drugs shall provide Commissioner's National Priority Vouchers to appropriate psychedelic drugs that have received a Breakthrough Therapy designation and are in accordance with the criteria of the National Priority Voucher Program.”
> “Timely Rescheduling. The Attorney General shall, in consultation with HHS, initiate and complete review of any product containing a Schedule I substance that has successfully completed Phase 3 clinical trials for a serious mental health disorder, so that rescheduling, if appropriate under 21 U.S.C. 811, may proceed as quickly as practicable for such specific products that are ultimately approved under section 505 of the Federal Food, Drug, and Cosmetic Act.”

Source: [Executive Office of the President (2026)](https://www.federalregister.gov/documents/2026/04/22/2026-07907/accelerating-medical-treatments-for-serious-mental-illness)

> “The Executive Order directs coordinated federal action to prioritize mental health therapies, streamline regulatory pathways, and expand cross-agency collaboration, consistent with the Administration’s policy to accelerate innovative research models and appropriate drug approvals to increase access to psychedelic medicines that could help save lives and address the serious mental health crisis in America.”

Source: [Definium Therapeutics executive order statement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/221/definium-therapeutics-applauds-white-house-executive-order-to-accelerate-mental-health-innovation-and-expand-access-to-psychedelic-medical-treatments)

<a id="topic-2.1.1-15"></a>

##### Patent protection for the orally disintegrating tablet

> “The newly issued patent (USPN 12,036,220) includes claims covering the pharmaceutical formulation, methods of manufacturing and method of treatment for MM120 ODT, MindMed’s proprietary and pharmaceutically optimized form of lysergide (LSD).”
> “The pharmaceutical formulation patent is the first US patent issued on the MM120 ODT formulation and extends the Company’s intellectual property protection for MM120 through 2041.”

Source: [MindMed ODT patent announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/152/mindmed-announces-issuance-of-new-patent-for-mm120-orally-disintegrating-tablet-odt)

> “For lysergide, these patents and patent applications are directed to methods of treatment, analytical methods, compositions of matter, and formulations.”
> “If issued, the 20-year term expiration dates from which our patents will expire is between 2041 to 2044, not including any extension of the patent term that may be available in certain jurisdictions.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-2.1.1-16"></a>

##### NDA submission timing: no date stated, April 2026, superseded in September 2026

> “Together, these trial outcomes will inform our regulatory approach, including an expeditious path to a potential NDA submission.”

Source: [Definium Therapeutics Investor and Analyst Day announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/223/definium-therapeutics-highlights-dt120-odt-lysergide-tartrate-clinical-advancements-and-commercial-strategy-at-investor-and-analyst-day)

<a id="topic-2.1.1-17"></a>

##### Voyage topline timing: first half of 2026, stated March 2025 to November 2025, superseded in January 2026

> “the Company’s anticipated topline readout (Part A results) for the Phase 3 Voyage study of MM120 ODT in GAD in the first half of 2026”

Source: [MindMed full-year 2024 results announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/175/mindmed-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-business-updates)

> “Topline data for Voyage is expected in the first half of 2026 and for Panorama and Emerge in the second half of 2026.”

Source: [MindMed JAMA publication announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/192/journal-of-the-american-medical-association-jama-publishes-results-from-first-ever-randomized-placebo-controlled-clinical-trial-assessing-the-dose-dependent-efficacy-of-mm120-lysergide-d-tartrate-lsd-in-generalized-anxiety-disorder-gad)

> “the Company’s anticipated topline readout (Part A results) for the Phase 3 Voyage study of MM120 ODT in GAD in the first half of 2026”

Source: [MindMed third quarter 2025 results announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/203/mindmed-reports-q3-2025-financial-results-and-business-updates)

<a id="topic-2.1.1-18"></a>

##### Voyage topline timing: second quarter of 2026, stated January 2026, superseded in February 2026

> “Topline Data from Three Phase 3 Studies Evaluating DT120 Orally Disintegrating Tablet (ODT) for GAD and MDD Expected in 2026: Voyage in 2Q, Panorama in 2H, and Emerge Mid-Year”

Source: [Definium Therapeutics rebrand announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/207/mindmed-rebrands-to-definium-therapeutics-advancing-a-leading-late-stage-psychiatry-pipeline-with-three-phase-3-readouts-expected-in-2026)

<a id="topic-2.1.1-19"></a>

##### Voyage topline timing: early third quarter of 2026, stated February 2026 to May 2026, superseded in August 2026

> “the Company’s anticipated topline readout (Part A results) for the Phase 3 Voyage study of DT120 ODT in GAD in early 3Q 2026”

Source: [Definium Therapeutics full-year 2025 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/215/definium-therapeutics-reports-full-year-2025-financial-results-and-business-updates)

> “GAD: Voyage enrollment complete with 214 patients with topline data readout on track for early 3Q 2026”

Source: [Definium Therapeutics Investor and Analyst Day announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/223/definium-therapeutics-highlights-dt120-odt-lysergide-tartrate-clinical-advancements-and-commercial-strategy-at-investor-and-analyst-day)

> “the Company’s anticipated topline readout (Part A results) for the Phase 3 Voyage study of DT120 ODT in GAD in early 3Q 2026”

Source: [Definium Therapeutics first quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/225/definium-therapeutics-reports-first-quarter-2026-financial-results-and-recent-highlights)

<a id="topic-2.1.1-20"></a>

##### Panorama topline timing: second half of 2026, stated March 2025 to February 2026, superseded in April 2026

> “the Company’s anticipated topline readout (Part A results) for the Phase 3 Panorama study for MM120 ODT in GAD in the second half of 2026”

Source: [MindMed full-year 2024 results announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/175/mindmed-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-business-updates)

> “the Company’s anticipated topline readout (Part A results) for the Phase 3 Panorama study for MM120 ODT in GAD in the second half of 2026”

Source: [MindMed third quarter 2025 results announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/203/mindmed-reports-q3-2025-financial-results-and-business-updates)

> “Panorama: study enrollment on track with topline data anticipated in 2H 2026.”

Source: [Definium Therapeutics full-year 2025 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/215/definium-therapeutics-reports-full-year-2025-financial-results-and-business-updates)

<a id="topic-2.1.1-21"></a>

##### Panorama topline timing: late third quarter of 2026, stated April 2026 and May 2026, superseded in August 2026

> “Topline data now anticipated in late 3Q 2026 (updated from 2H 2026).”

Source: [Definium Therapeutics Investor and Analyst Day announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/223/definium-therapeutics-highlights-dt120-odt-lysergide-tartrate-clinical-advancements-and-commercial-strategy-at-investor-and-analyst-day)

> “Topline data expected in late 3Q 2026 (updated from 2H 2026).”

Source: [Definium Therapeutics first quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/225/definium-therapeutics-reports-first-quarter-2026-financial-results-and-recent-highlights)

> “the Company’s anticipated topline readout (Part A results) for the Phase 3 Panorama study for DT120 ODT in GAD in September 2026”

Source: [Definium Therapeutics second quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/242/definium-therapeutics-reports-second-quarter-2026-financial-results-and-recent-highlights)

<a id="topic-2.1.1-22"></a>

##### Phase 3 initiation planned for the second half of 2024, stated March 2024 and June 2024, superseded in December 2024

> “The Company plans to hold an End-of-Phase 2 meeting with the FDA in the first half of 2024 and initiate a Phase 3 clinical program in the second half of 2024.”

Source: [MindMed Breakthrough Therapy designation announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/137/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder)

> “We are on schedule to initiate our Phase 3 clinical program for MM120 oral dissolving tablet (ODT) in GAD in the second half of this year and look forward to sharing additional details on the design of our pivotal program in the coming months.”

Source: [MindMed end-of-phase 2 meeting announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/149/mindmed-announces-constructive-end-of-phase-2-meeting-with-u-s-fda-for-mm120-in-generalized-anxiety-disorder-gad)

<a id="topic-2.1.1-23"></a>

##### FDA clinical hold on the phase 2b IND, December 2021, superseded in January 2022

> “today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its IND submission intended to support the initiation of a Phase 2b trial of lysergic acid diethylamide (LSD) for the treatment of generalized anxiety disorder (GAD).”
> “Additional detail regarding the FDA's decision is expected within 30 days.”

Source: [MindMed IND clinical hold announcement (2021)](https://ir.definiumtx.com/news-events/press-releases/detail/60/mindmed-provides-status-update-on-ind-for-phase-2b-trial-of-lsd-for-the-treatment-of-generalized-anxiety-disorder)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Definium Therapeutics

> “Definium is developing DT120 ODT, the tartrate salt form of lysergide, for generalized anxiety disorder (GAD), major depressive disorder (MDD), and posttraumatic stress disorder (PTSD), and is exploring its potential applications in other serious brain health disorders.”

Source: [Definium Therapeutics third quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/259/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights)

> “Our lead product candidate, DT120 (Lysergide) orally disintegrating tablet (“ODT”), is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that we are developing for the treatment of adults with generalized anxiety disorder (“GAD”), major depressive disorder (“MDD”) and posttraumatic stress disorder (“PTSD”).”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

<a id="topic-2.1.2.1-2"></a>

###### Corporate name change from Mind Medicine (MindMed) Inc. to Definium Therapeutics, January 2026

> “On January 9, 2026, the Company filed a Notice of Alteration with the Province of British Columbia Registrar of Companies to alter its Notice of Articles to change the Company’s corporate name from “Mind Medicine (MindMed) Inc.” to “Definium Therapeutics, Inc.” (the ”Amendment”).”
> “The Amendment was approved by the Company’s Board of Directors on January 9, 2026.”

Source: [Definium Therapeutics Form 8-K name change (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526009854/mnmd-20260109.htm)

> “On January 9, 2026, we changed our corporate name from Mind Medicine (MindMed) Inc. to Definium Therapeutics, Inc. On January 12, 2026, we changed the name of our wholly-owned subsidiary from Mind Medicine, Inc. to Definium Therapeutics US, Inc. ("Definium US"). In connection with our rebrand, we began trading on Nasdaq under the symbol “DFTX” on January 15, 2026.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-2.1.2.1-3"></a>

###### Nasdaq ticker DFTX effective January 15, 2026

> “The Company now expects its Common Shares to begin trading on Nasdaq under the ticker symbol “DFTX” effective at market open on January 15, 2026.”

Source: [Definium Therapeutics ticker change announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/208/definium-therapeutics-common-shares-to-trade-under-new-nasdaq-ticker-symbol-dftx-effective-january-15-2026)

<a id="topic-2.1.2.1-4"></a>

###### Nasdaq ticker effective date of January 13, 2026, stated January 12, 2026, superseded on January 13, 2026

> “The Common Shares will continue to trade on the Nasdaq Stock Market under the new ticker symbol “DFTX” as of market open on January 13, 2026.”

Source: [Definium Therapeutics Form 8-K name change (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526009854/mnmd-20260109.htm)

> “In conjunction with the rebrand, the Company’s Nasdaq ticker symbol will change to "DFTX" effective at market open on January 13, 2026.”

Source: [Definium Therapeutics rebrand announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/207/mindmed-rebrands-to-definium-therapeutics-advancing-a-leading-late-stage-psychiatry-pipeline-with-three-phase-3-readouts-expected-in-2026)

<a id="topic-2.1.2.1-5"></a>

###### Product names: development codes DT120, MM120, and MM-120

> “This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes including DT120 (previously referred to as MM120), and DT402 (previously referred to as MM402), our lead product candidates.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

> “Under the terms of the licensing agreement, Catalent has granted MindMed access to its Zydis technology for the development of MindMed’s lead product candidate MM-120 (lysergide D-tartrate), which is a proprietary, pharmaceutically optimized form of lysergide.”

Source: [MindMed Catalent license announcement (2023)](https://ir.definiumtx.com/news-events/press-releases/detail/121/mindmed-announces-exclusive-license-agreement-with-catalent-for-its-patented-zydis-fast-dissolve-technology-for-use-with-mm-120)

<a id="topic-2.1.2.1-6"></a>

###### Nonproprietary names: United States adopted name lysergide tartrate and international nonproprietary name lysergide

> “Formerly known as MM120; USAN: lysergide tartrate.”
> “Lysergide tartrate, or DT120, is our proprietary product candidate, a pharmaceutically optimized form of lysergide D-tartrate being developed for GAD, MDD and other brain health disorders.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

> “Formerly known as MM120; rINN: lysergide.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-2.1.2.1-7"></a>

###### Brand name

> “In addition, any proprietary name we propose to use with our current or any other product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-2.1.2.1-8"></a>

###### Therapeutic class: ergoline derivative and classic serotonergic psychedelic, partial agonist at 5-HT2A receptors

> “DT120 ODT is an ergoline derivative belonging to the group of classic serotonergic psychedelics, which acts as a partial agonist at 5-hydroxytryptamine serotonin-2A (5-HT2A) receptors.”
> “DT120 ODT is Definium's proprietary and pharmaceutically optimized formulation of Lysergide (LSD).”

Source: [Definium Therapeutics third quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/259/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights)

> “Lysergide is a synthetic ergotamine belonging to the group of classic, or serotonergic, psychedelics, which acts as a partial agonist at human serotonin-2A (5-hydroxytryptamine-2A [5-HT2A]) receptors.”

Source: [MindMed Breakthrough Therapy designation announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/137/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder)

<a id="topic-2.1.2.1-9"></a>

###### Ownership history: exclusive collaboration with the University Hospital Basel Liechti Lab from April 2020

> “On April 1, 2020, we entered into a multi-year, exclusive collaboration with Dr. Matthias Liechti’s lab at UHB (the “UHB Liechti Lab”), a leading pharmacology and clinical research group studying psychedelic substances based in Basel, Switzerland. Pursuant to the agreement, we acquired exclusive worldwide rights to data, compounds, and patent rights associated with the UHB Liechti Lab’s research with lysergide and other psychedelic compounds, including data from preclinical studies and completed or ongoing clinical trials of lysergide and MDMA.”
> “Subject to terms and conditions, the UHB Liechti Lab may receive royalties and development revenue on any commercially marketed products developed through the collaboration.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-2.1.2.1-10"></a>

###### Ownership history: exclusive license to Catalent Zydis orally disintegrating tablet technology, August 2023

> “In August 2023, we announced an exclusive licensing agreement with Catalent for its patented Zydis® ODT technology.”
> “The agreement also provides us with exclusive rights for the use of the Zydis technology to develop all known forms of lysergide in the United States, United Kingdom, and European Union among other key jurisdictions.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

> “MindMed holds exclusive rights to the Zydis technology for all salt and polymorphic forms of lysergide for pharmaceutical usage for the treatment of human disease and disorders in the United States, the United Kingdom, the European Union, Switzerland, Israel, and Canada.”

Source: [MindMed ODT patent announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/152/mindmed-announces-issuance-of-new-patent-for-mm120-orally-disintegrating-tablet-odt)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Phase 3 dosage form: orally disintegrating tablet using Zydis technology

> “DT120 ODT is an advanced formulation incorporating Catalent's Zydis® ODT fast-dissolve technology, designed to deliver several unique advantages, including faster absorption and onset of transient cognitive, perceptual, and affective changes, improved bioavailability, and a lower incidence of gastrointestinal side effects.”

Source: [Definium Therapeutics third quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/259/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights)

> “Zydis ODT is a unique, freeze-dried, oral solid dosage form that disperses almost instantly in the mouth, without the need for water.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-2.1.2.2-2"></a>

###### Strengths studied in phase 3: 100 µg, and 50 µg as a control arm in Panorama

> “Eligible participants were randomized 2:1:2 to receive a single dose of DT120 ODT 100 µg, DT120 ODT 50 µg, or matching placebo, with the 50 µg arm included to help mitigate functional unblinding.”
> “during which participants may be eligible to receive up to four additional doses of DT120 ODT 100 μg based on symptom severity”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “Voyage is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of a single 100 µg dose of DT120 ODT versus placebo in adults with generalized anxiety disorder (GAD).”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-2.1.2.2-3"></a>

###### Strengths studied in phase 2b: 25, 50, 100, and 200 µg freebase equivalent

> “Participants were randomized to receive a single (freebase equivalent) treatment dose with 25 µg (n = 39), 50 µg (n = 40), 100 µg (n = 40), or 200 µg (n = 40) of MM120 or placebo (n = 39).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-2.1.2.2-4"></a>

###### Phase 1 bridging study: four 25-µg capsules compared with one 100-µg orally disintegrating tablet

> “This phase 1 study compared the pharmacokinetic (PK), subjective effect, and safety profiles of the phase 2b capsule formulation at 100µg with a new 100µg orally disintegrating tablet (ODT) formulation that was subsequently included in the phase 3 program.”
> “Participants were randomized equally to receive either four 25-μg MM120 capsules followed by 100μg MM120 ODT or ODT followed by capsules.”
> “Considering the efficacy and safety profile observed in the phase 2b study, MM120 100μg (freebase-equivalent) is considered an acceptable therapeutic dose.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-2.1.2.2-5"></a>

###### Salt form: lysergide D-tartrate

> “Definium is developing DT120 ODT, the tartrate salt form of lysergide, for generalized anxiety disorder (GAD), major depressive disorder (MDD), and posttraumatic stress disorder (PTSD), and is exploring its potential applications in other serious brain health disorders.”

Source: [Definium Therapeutics third quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/259/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights)

<a id="topic-2.1.2.2-6"></a>

###### Commercial dosage form, strengths, and package configuration

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### Pharmacologic classification stated by the sponsor

> “DT120 ODT is an ergoline derivative belonging to the group of classic serotonergic psychedelics, which acts as a partial agonist at 5-hydroxytryptamine serotonin-2A (5-HT2A) receptors.”

Source: [Definium Therapeutics third quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/259/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights)

<a id="topic-2.1.2.4-2"></a>

###### Controlled Substances Act classification: Schedule I hallucinogenic substance, DEA controlled substance code 7315

| Field | Quoted record |
| --- | --- |
| Schedule I category | “Hallucinogenic substances” |
| Substance | “Lysergic acid diethylamide” |
| Administration Controlled Substances Code Number | “7315” |

Source: [eCFR 21 CFR 1308.11](https://www.ecfr.gov/current/title-21/chapter-II/part-1308/subject-group-ECFR3cfa0fa9ca4d0b5/section-1308.11)

> “In the United States, lysergide and MDMA are controlled as Schedule I substances under the CSA. Schedule I substances by definition have a high potential for abuse, have no currently “accepted medical use” in the United States, lack accepted safety for use under medical supervision, and may not be prescribed, marketed or sold in the United States.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-2.1.2.4-3"></a>

###### AHFS Pharmacologic-Therapeutic Classification and Anatomical Therapeutic Chemical code

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Indication under development: adults with generalized anxiety disorder

> “Our lead product candidate, DT120 (Lysergide) orally disintegrating tablet (“ODT”), is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that we are developing for the treatment of adults with generalized anxiety disorder (“GAD”), major depressive disorder (“MDD”) and posttraumatic stress disorder (“PTSD”).”
> “The primary endpoint for each trial is the change from baseline on the Hamilton Anxiety Rating Scale (“HAM-A”) at Week 12 between DT120 ODT 100 µg and placebo.”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

<a id="topic-2.1.2.5-2"></a>

###### Population studied in the phase 3 Panorama trial

> “The study enrolled participants 18 to 74 years of age with a DSM-5-confirmed primary diagnosis of GAD and a minimum Hamilton Anxiety Rating Scale (HAM-A) total score of 20 at screening and baseline.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-2.1.2.5-3"></a>

###### Labeling scope sought and filing strategy across generalized anxiety disorder and major depressive disorder

> “Robust Phase 3 DT120 ODT Development Program Aiming for Broad Label”
> “Regulatory filing strategy for GAD & MDD to be discussed at pre-NDA meeting.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-2.1.2.5-4"></a>

###### Other indications in development: major depressive disorder and posttraumatic stress disorder

> “Continuing enrollment for the Phase 3 Ascend study in MDD.”
> “DT120 ODT in PTSD: Planning to initiate the Phase 3 Haven study in PTSD in 2027 with approximately 200 participants randomized 1:1 to receive DT120 ODT 100 µg or placebo.”

Source: [Definium Therapeutics third quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/259/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights)

<a id="topic-2.1.2.5-5"></a>

###### Proposed labeled indication submitted to a regulator

No evidence found.

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Classic serotonergic psychedelic and partial agonist at serotonin-2A receptors

> “DT120 ODT is an ergoline derivative belonging to the group of classic serotonergic psychedelics, which acts as a partial agonist at serotonin-2A (5-HT2A) receptors.”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-2.1.2.6.1-2"></a>

###### Registry description of the investigational product

> “A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)”

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

<a id="topic-2.1.2.6.1-3"></a>

###### Mechanism in anxiety not established

> “Lysergide, or lysergic acid diethylamide (LSD), is a semisynthetic psychedelic drug in the ergoline family.”
> “Although LSD’s precise mechanism of action in the treatment of psychiatric illness is unknown, mechanistic hypotheses implicate its acute psychological effects (mediated by agonism of the 5-HT2A receptor) and its sustained increases in neuroplasticity in a variety of brain regions as potentially responsible.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

> “The precise mechanism by which lysergide modulates anxiety and depression is still under investigation, but recent neuroimaging studies have provided a plausible explanation for clinical efficacy in these disease areas.”
> “This increase in connectivity between brain regions is correlated with perceptual alterations that are believed to contribute to subsequent and persistent improvements in psychological functioning.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-2.1.2.6.1-4"></a>

###### Dependence of the acute response on serotonin-2A receptors: ketanserin studies

> “Administration of the 5-HT 2A antagonist ketanserin before LSD almost fully blocks the acute subjective response to LSD.”
> “These findings are consistent with an interaction between ketanserin and LSD and the view that LSD produces its psychedelic effects only when occupying 5-HT 2A receptors.”

Source: [Becker et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9926053/)

> “Ketanserin effectively prevented the response to 200 µg LSD.”
> “The full psychedelic effects of LSD are primarily mediated by serotonin 5-HT 2A receptor activation.”

Source: [Holze et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8027607/)

<a id="topic-2.1.2.6.1-5"></a>

###### Serotonin receptor activity of LSD and its metabolites in vitro

> “LSD and nor-LSD were pharmacologically active at the 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT2C receptors.”
> “Nor-LSD mainly differed from the parent compound by having a lower affinity to the 5-HT2C receptor.”
> “O-H-LSD displayed substantially weaker affinity and activity at serotonergic receptors in comparison to LSD.”

Source: [Luethi et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30981875/)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Thorough QT study of DT120 ODT: design and QT result

> “Phase 1 TQT (n = 59)”
> “Randomized, double-blind in healthy volunteers”
> “Single DT120: 100-μg ODT or 300-μg ODT”
> “DT120 was not shown to prolong the QT interval”
> “Dose increases beyond 100 μg showed similar AE profiles with no observed increased physiological or psychological safety risks”

Source: [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf)

<a id="topic-2.1.2.6.2-2"></a>

###### Thorough QT study of DT120 ODT: treatment-emergent adverse events

| Measure | Phase 1 TQT study, DT120 ODT (n = 58) |
| --- | --- |
| Any TEAE | “57 (98.3)” |
| TEAE leading to treatment withdrawal | “0” |
| Mild | “27 (46.6)” |
| Moderate | “27 (46.6)” |
| Severe | “3 (5.2)” |
| Any related TEAE | “57 (98.3)” |

Source: [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf)

<a id="topic-2.1.2.6.2-3"></a>

###### QTc interval after LSD with and without paroxetine in healthy participants

> “LSD did not increase the QTc interval at its peak effect at 3.5 h after administration compared with 1 h before in either the paroxetine or placebo condition.”
> “There were no cases of QTc time increases >450 ms.”

Source: [Becker et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12087691/)

<a id="topic-2.1.2.6.2-4"></a>

###### Vital signs across DT120 phase 1 and phase 2b studies

> “Changes in vital signs were not clinically significant”
> “Clinically insignificant physiological effects”

Source: [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf)

<a id="topic-2.1.2.6.2-5"></a>

###### Heart rate, blood pressure, and body temperature by dose in healthy participants

> “The physiologic effects of LSD were moderate.”
> “None of the subjects had systolic blood pressure > 180 mmHg at any time.”
> “Peak heart rate > 100 beats/min was observed in 0%, 6%, 20%, and 25% of the subjects at 25, 50, 100, and 200 µg, respectively.”
> “Peak body temperature > 38° was observed in 0%, 11%, 7%, and 34% at 25, 50, 100, and 200 µg, respectively.”
> “Kidney and liver function parameters were unaltered.”

Source: [Holze et al. (2022a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9166834/)

> “LSD moderately increased blood pressure and heart rate.”

Source: [Holze et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8027607/)

<a id="topic-2.1.2.6.2-6"></a>

###### Dose-response of subjective effects and ceiling at 100 µg in healthy participants

> “LSD showed dose-proportional pharmacokinetics and first-order elimination and dose-dependently induced subjective responses starting at the 25 µg dose.”
> “A ceiling effect was observed for good drug effects at 100 µg.”
> “The 200 µg dose of LSD induced greater ego dissolution than the 100 µg dose and induced significant anxiety.”
> “The average duration of subjective effects increased from 6.7 to 11 h with increasing doses of 25–200 µg.”

Source: [Holze et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8027607/)

> “Maximal ratings of > 50% good drug effects were reached in 37%, 91%, 96%, and 91% of the LSD administrations at 25, 50, 100, and 200 µg.”
> “Maximal ratings of > 50% bad drug effects were reached in 0%, 9%, 27%, 31% at 25, 50, 100, and 200 µg, respectively.”

Source: [Holze et al. (2022a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9166834/)

<a id="topic-2.1.2.6.2-7"></a>

###### Concentration-effect relationship

> “A close relationship was observed between the LSD concentration and subjective response within subjects, with moderate counterclockwise hysteresis.”
> “Half-maximal effective concentration values were in the range of 1 ng/mL.”
> “The effects of LSD were related to changes in plasma concentrations over time, with no evidence of acute tolerance.”

Source: [Dolder et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5591798/)

<a id="topic-2.1.2.6.2-8"></a>

###### Onset and peak of subjective effects: ODT versus capsule

> “Similar to PK profiles, the VAS scores showed an earlier onset of effects for MM120 ODT compared with capsules.”
> “Maximum drug effect VAS scores were reported at 3 and 4 hours post-dose for participants receiving MM120 ODT or capsules, respectively.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-2.1.2.6.2-9"></a>

###### Time course of a dosing session described by the sponsor

> “The experience can generally be divided into 5 phases: onset (approximately 15-30 minutes after taking the dose), maximum effect (approximately 2 to 3 hours after dosing), plateau (approximately 3 to 5 hours after dosing), resolution (approximately 4 to 6 hours after dosing), and completion (approximately 6 to 10 hours after dosing).”

Source: [Definium Therapeutics LSD fact sheet (2026)](https://definiumtx.com/wp-content/uploads/2026/08/DFTX-FactSheet-LSD-080526.pdf)

<a id="topic-2.1.2.6.2-10"></a>

###### Duration of subjective effects by dose in healthy participants

> “The subjective effects lasted (mean ± standard deviation) 8.2 ± 2.1 and 11.6 ± 1.7 h for the 100- and 200-µg LSD doses, respectively.”
> “Subjective peak effects were reached 2.8 and 2.5 h after administration of LSD 100 and 200 µg, respectively.”

Source: [Dolder et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5591798/)

> “Mean (±standard deviation) durations of subjective effects were 9.3 ± 3.2 and 11 ± 3.7 h, and maximal effects (any drug effects) were 77 ± 18% and 87 ± 13% after 85 and 170 μg of LSD, respectively.”

Source: [Holze et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/37596682/)

<a id="topic-2.1.2.6.2-11"></a>

###### Serotonin-2B receptor activity and valvulopathy: regulatory expectations

> “For psychedelic drugs with serotonin (5-HT) activity, the 5-HT2B receptor subtype has been linked to heart valvulopathy in humans”
> “sponsors should assess functional activity at the 5-HT2B receptor subtype”
> “Long-term exposure to drugs that have 5-HT2B agonism may induce cardiac valve stiffening.”

Source: [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### ODT versus capsule: relative bioavailability study design (MM-120-101)

> “This phase 1 study compared the pharmacokinetic (PK), subjective effect, and safety profiles of the phase 2b capsule formulation at 100μg with a new 100μg orally disintegrating tablet (ODT) formulation that was subsequently included in the phase 3 program.”
> “This was a phase 1, multicenter (two sites), open-label, randomized, 2-period, 2-sequence, cross-over, within-subject study designed to compare the plasma PK profile of 2 MM120 formulations in healthy adults aged 18 to 55 years.”
> “Participants were randomized equally to receive either four 25-μg MM120 capsules followed by 100μg MM120 ODT or ODT followed by capsules.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-2.1.2.6.3-2"></a>

###### ODT versus capsule: published abstract results

> “A total of 29 participants were randomized, and 24 participants received each MM120 formulation as a single dose.”
> “MM120 ODT showed a faster onset of plasma concentrations than MM120 capsules, retaining similar relative bioavailability for Cmax.”
> “For AUC, the GMR for MM120 ODT was 16% higher compared with MM120 capsules.”
> “The ODT formulation had bioavailability similar to that of the capsule.”
> “ODT absorption occurred faster compared with capsules and there was a more rapid onset of acute drug effects in the ODT formulation.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-2.1.2.6.3-3"></a>

###### ODT versus capsule: company analysis of pharmacokinetic parameters, March 2024

| Parameter | MM120 capsule | MM120 ODT |
| --- | --- | --- |
| Tmax (hr) | “2.25” | “2.0” |
| Cmax (ng/mL) | “2.63” | “2.68” |
| AUC0-∞ (ng*hr/mL) | “15.7” | “18.7” |
| AUC>1ng/mL (ng*hr/mL) | “9.7” | “12.0” |

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

> “Company analysis of pharmacokinetic data from Study MM120-101. PK analysis based on n=24 subjects that completed both dosing sessions.”
> “50% faster onset of action”
> “17% improved bioavailability”
> “23% increase in AUC at target conc.”
> “Based on time to reach target concentration of >1 ng/mL.”
> “Based on comparison of geometric mean ratio of total area under the curve.”
> “Based on ratio of mean AUC>1ng/mL. Target concentrations defined as level above which perceptual effects are present.”

Source: [MindMed Phase 2b and ODT bridging presentation (2024)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23397/pdf/MindMed%27s_Conference_Call_and_Webcast_on_MM120_for_Generalized_Anxiety_Disorder_%28GAD%29%3B_March_2024_FINAL.pdf)

<a id="topic-2.1.2.6.3-4"></a>

###### Formulation rationale stated by the sponsor

> “DT120 ODT is an advanced formulation incorporating Catalent’s Zydis® ODT fast-dissolve technology, designed to deliver several unique advantages, including faster absorption and onset of transient cognitive, perceptual, and affective changes, improved bioavailability, and a lower incidence of gastrointestinal side effects.”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-2.1.2.6.3-5"></a>

###### Food effect study of DT120 ODT: design

> “Phase 1 PK Food Effect (n = 64)”
> “Cohort 1: 100-μg ODT fasted vs high-fat meal”
> “Cohort 2: 100-μg ODT fasted vs low-fat meal”
> “Open-label, crossover in healthy volunteers”

Source: [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf)

<a id="topic-2.1.2.6.3-6"></a>

###### Food effect study of DT120 ODT: treatment-emergent adverse events by cohort

| Measure | DT120 ODT + high-fat meal (n = 31) | DT120 ODT + low-fat meal (n = 28) |
| --- | --- | --- |
| Any TEAE | “31 (100.0)” | “28 (100.0)” |
| TEAE leading to treatment withdrawal | “1 (3.2)” | “2 (7.1)” |
| Mild | “24 (77.4)” | “22 (78.6)” |
| Moderate | “7 (22.6)” | “5 (17.9)” |
| Severe | “0” | “1 (3.6)” |
| Any related TEAE | “31 (100.0)” | “28 (100.0)” |

Source: [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf)

<a id="topic-2.1.2.6.3-7"></a>

###### Food effect study of DT120 ODT: UK research ethics and registry records

> “Phase 1 PK study of MM-120 under fed and fasted conditions in healthy volunteers”
> “REC reference 24/WA/0003”
> “Date of REC Opinion 22 Mar 2024”

Source: [HRA Phase 1 PK study of MM-120 under fed and fasted conditions (2024)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/phase-1-pk-study-of-mm-120-under-fed-and-fasted-conditions-in-healthy-volunteers/)

> “Phase I trial MM-120-102”
> “Approved 22/03/2024, Wales Research Ethics Committee 1”
> “ref: 24/WA/0003”
> “Phase I study in 32 healthy volunteers”
> “Non randomised study”
> “Completion date 29/08/2024”

Source: [ISRCTN ISRCTN15997848](https://www.isrctn.com/ISRCTN15997848)

<a id="topic-2.1.2.6.3-8"></a>

###### Food effect: regulatory expectation for oral psychedelic drugs

> “Sponsors should evaluate the effect of a high-fat meal on the pharmacokinetics of an oral psychedelic drug early in development to inform clinical study design and potential labeling.”

Source: [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-2.1.2.6.3-9"></a>

###### Absorption, peak concentration, and half-life of oral LSD

> “Mean (95% confidence interval) maximal LSD concentrations were 1.8 ng/mL (1.6-2.0) and 3.4 ng/mL (3.0-3.8) after the administration of 85 and 170 μg LSD, respectively.”
> “Maximal concentrations were achieved on average after 1.7 h.”
> “Elimination half-lives were 3.7 h (3.4-4.1) and 4.0 h (3.6-4.4), for 85 and 170 μg LSD, respectively.”
> “LSD exhibited dose-proportional pharmacokinetics and first-order elimination kinetics and dose-dependent duration and intensity of subjective effects.”

Source: [Holze et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/37596682/)

> “Geometric mean (95% confidence interval) maximum plasma concentration values of 1.3 (1.2–1.9) and 3.1 (2.6–4.0) ng/mL were reached 1.4 and 1.5 h after administration of 100 and 200 µg LSD, respectively.”
> “The plasma half-life was 2.6 h (2.2–3.4 h).”
> “Oral LSD presented dose-proportional pharmacokinetics and first-order elimination up to 12 h.”

Source: [Dolder et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5591798/)

<a id="topic-2.1.2.6.3-10"></a>

###### Absolute oral bioavailability and bioequivalence of LSD base and tartrate

> “We used a randomized, double‐blind, placebo‐controlled, five‐period crossover design in 20 healthy participants to investigate an ethanolic drinking solution of LSD base, a watery drinking solution of LSD tartrate, a rapid dissolvable tablet of LSD base, an intravenous formulation of LSD tartrate, and corresponding placebos.”
> “All oral formulations were bioequivalent, with the ethanolic base solution as a reference.”
> “The absolute bioavailability of oral LSD was 80% and similar for all tested formulations.”
> “In conclusion, dosing with LSD base and tartrate can be considered bioequivalent with high and similar oral bioavailability.”

Source: [Arikci et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12355019/)

<a id="topic-2.1.2.6.3-11"></a>

###### Metabolism and urinary excretion

> “Only 1% of the administered dose was recovered from urine unchanged within the first 24 h, 16% was eliminated as 2-oxo-3-hydroxy-LSD.”
> “LSD is extensively metabolized and shows dose-proportional urinary recovery.”

Source: [Holze et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/37596682/)

> “Plasma O‐H‐LSD but not nor‐LSD (< 0.01 ng/mL) concentrations could be quantified in all subjects.”

Source: [Holze et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6595343/)

<a id="topic-2.1.2.6.3-12"></a>

###### Cytochrome P450 enzymes in LSD metabolism

> “CYP2D6, 2E1, and 3A4 significantly contributed to the formation of nor-LSD, and CYP1A2, 2C9, 2E1, and 3A4 were significantly involved in the formation of O-H-LSD.”
> “To conclude, human liver microsomes converted only small amounts of LSD to nor-LSD and O-H-LSD but several CYPs significantly contributed.”

Source: [Luethi et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30981875/)

> “Thus, CYP2D6 is likely a crucial player in the degradation of LSD but not in the formation of its main metabolite O-H-LSD.”

Source: [Vizeli et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8149637/)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

Not applicable.

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### CYP2D6 poor metabolizers

> “Individuals with no functional CYP2D6 (i.e., poor metabolizers) had longer LSD half-lives and approximately 75% higher parent drug and main metabolite 2-oxo-3-hydroxy LSD area-under-the-curve blood plasma concentrations compared with carriers of functional CYP2D6.”
> “Non-functional CYP2D6 metabolizers also exhibited greater alterations of mind and longer subjective effect durations in response to LSD compared with functional CYP2D6 metabolizers.”
> “CYP2D6 is associated with several phenotypes, ranging from poor metabolizers (PMs; 5–10% in Caucasians) to ultra-rapid metabolizers (UMs; 3–5% in Caucasians), with different underlying genotypes”
> “Geno- or phenotyping may be useful in patients who undergo LSD-assisted therapy.”
> “Based on the present findings, CYP2D6 PMs may benefit from approximately 50% lower doses than those that are used in functional CYP2D6 individuals.”

Source: [Vizeli et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8149637/)

<a id="topic-2.1.2.8-2"></a>

###### Sex

> “No differences in these pharmacokinetic parameters were found between male and female subjects.”

Source: [Holze et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6595343/)

> “We found no sex differences in LSD concentrations or effects consistent with previous studies using no body weight adjustment of LSD doses”

Source: [Holze et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8027607/)

<a id="topic-2.1.2.8-3"></a>

###### Age range studied in the generalized anxiety disorder trials

> “The study enrolled 214 participants aged 18 to 74 years with a primary diagnosis of GAD who had a minimum Hamilton Anxiety Rating Scale (HAM-A) total score of ≥20 at screening and baseline”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

> “The eligibility criteria included age of 18 to 74 years”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-2.1.2.8-4"></a>

###### Personal or family history of psychotic or bipolar disorder and other excluded conditions

> “First degree relative with or lifetime history of a psychotic disorder or bipolar disorder”
> “Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)”
> “Any clinically significant unstable illness”

Source: [ClinicalTrials.gov NCT06741228](https://clinicaltrials.gov/study/NCT06741228)

> “Contraindicated medical or psychiatric conditions”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-2.1.2.8-5"></a>

###### Pregnancy and contraception in the trials

> “Use of highly effective methods of contraception”
> “If dosing day is >14 days from meeting the retreatment threshold, safety laboratory assessments, drug screen, and serum pregnancy test (if applicable) must be repeated.”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

> “Eligibility was evaluated at screening and baseline, with final confirmation on dosing day via a urine drug screening, urine pregnancy test, and collection of vital signs.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-2.1.2.8-6"></a>

###### Renal and hepatic impairment

> “Only 1% of the administered dose was recovered from urine unchanged within the first 24 h, 16% was eliminated as 2-oxo-3-hydroxy-LSD.”

Source: [Holze et al. (2024a)](https://pubmed.ncbi.nlm.nih.gov/37596682/)

> “Sponsors should evaluate the pharmacokinetics of a psychedelic drug in patients with impaired renal function and patients with impaired hepatic function to provide dose adjustment recommendations and inform labeling.”

Source: [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-2.1.2.8-7"></a>

###### Preexisting valvulopathy or pulmonary hypertension in multiple-dose studies

> “Currently, FDA recommends that sponsors exclude subjects with preexisting valvulopathy or pulmonary hypertension from multiple-dose studies of drugs with this mechanism until this risk can be better characterized.”

Source: [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Lysergide

<a id="topic-2.1.2.9.1-1"></a>

###### Paroxetine (selective serotonin reuptake inhibitor and strong CYP2D6 inhibitor)

> “The present study investigated the acute response to single doses of LSD (100 μg) after daily administration of paroxetine (10 mg for 7 days, followed by 20 mg for 35 days) or placebo (42 days) using a randomized, double‐blind, cross‐over design in 23 healthy participants.”
> “Paroxetine did not alter pleasant subjective effects of LSD”

Source: [Becker et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12087691/)

> “The strong cytochrome P450 2D6 (CYP2D6) inhibitor paroxetine led to higher maximal concentrations and total exposures of LSD (geometric mean ratios of 1.4 and 1.5, respectively) indicating relevant involvement of CYP2D6 in its metabolism.”
> “The extent of this inhibition was nominally highest in genetic CYP2D6 normal metabolizers and lowest in poor metabolizers.”
> “The pharmacokinetic and pharmacodynamic interactions indicate that no dose adjustment of LSD seems necessary in the presence of an SSRI that inhibits CYP2D6.”
> “For SSRIs that do not relevantly inhibit CYP2D6, a dose increase of LSD might be appropriate, but due to lacking data and potential other pharmacokinetic interactions with these compounds, no definitive dose recommendation can be made.”

Source: [Becker et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12087691/)

<a id="topic-2.1.2.9.1-2"></a>

###### Other CYP2D6 inhibitors

> “A similar or substantial increase in plasma LSD concentrations could be expected when patients who are on antidepressants that inhibit CYP2D6 (e.g., fluoxetine, paroxetine, duloxetine, and bupropion) and are treated with LSD-assisted therapy.”
> “This interaction warrants further study.”

Source: [Straumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10584820/)

> “Consideration should also be given to discontinuing CYP2D6 inhibitors and allowing sufficient time for the enzyme to regenerate (up to 2 weeks) before LSD is used.”
> “Alternatively, in the presence of CYP2D6 inhibitors, the dose of LSD should be reduced, based on the present findings.”

Source: [Vizeli et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8149637/)

<a id="topic-2.1.2.9.1-3"></a>

###### MDMA co-administration

> “MDMA slightly altered the pharmacokinetics of LSD.”
> “The plasma LSD elimination half-life was longer in the LSD + MDMA condition (5.2 h) compared with LSD alone (3.9 h; T = 5.00; p < 0.001).”
> “Thus, MDMA and LSD primarily interact pharmacokinetically and not pharmacodynamically.”
> “MDMA is a strong inhibitor of CYP2D6, turning any CYP2D6 extensive or rapid metabolizer into a poor metabolizer within approximately 2 h”

Source: [Straumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10584820/)

<a id="topic-2.1.2.9.1-4"></a>

###### Ketanserin given after LSD

> “Ketanserin reversed the acute response to LSD, thereby significantly reducing the duration of subjective effects from 8.5 hours with placebo to 3.5 hours.”
> “Ketanserin did not alter the pharmacokinetics of LSD.”
> “Ketanserin can effectively be used as a planned or rescue option to shorten and attenuate the LSD experience in humans in research and LSD-assisted therapy.”

Source: [Becker et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9926053/)

<a id="topic-2.1.2.9.1-5"></a>

###### Ketanserin, olanzapine, and lorazepam as rescue medications: registered study

> “The main objective of this study is to determine whether administration of ketanserin (40 mg), olanzapine (10 mg), and lorazepam (2 mg) after administration of LSD (150 µg) attenuates and shortens the subjective LSD response (any drug effect) compared to administration of LSD (150 µg) alone”

Source: [ClinicalTrials.gov NCT05964647](https://clinicaltrials.gov/study/NCT05964647)

<a id="topic-2.1.2.9.1-6"></a>

###### Enzyme induction and inhibition in vitro

> “Enzyme induction with rifampicin distinctly increased the formation of both metabolites, whereas treatment with omeprazole only slightly increased formation of nor-LSD.”
> “Genetic polymorphisms and drug interactions could therefore influence pharmacokinetics and pharmacodynamics of LSD.”
> “Drug-drug interaction studies in humans are required to further assess the clinical relevance of these findings.”

Source: [Luethi et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30981875/)

<a id="topic-2.1.2.9.1-7"></a>

###### Antidepressants and lithium: regulatory guidance on pharmacodynamic interactions

> “Use of selective serotonin reuptake inhibitors, serotonin/norepinephrine reuptake inhibitors, or monoamine oxidase inhibitors for 3 weeks or more may reduce the subjective effects of psychedelic drugs.”
> “Use of tricyclic antidepressants or lithium for 3 weeks or more may potentiate the subjective effects of psychedelic drugs, creating a potential psychiatric safety concern.”
> “Use of selective serotonin reuptake inhibitors, serotonin/norepinephrine reuptake inhibitors, or monoamine oxidase inhibitors for less than 3 weeks may also potentiate the subjective effects of psychedelic drugs.”

Source: [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Lysergide on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

###### MDMA pharmacokinetics with and without LSD 100 µg

| Parameter (MDMA) | MDMA + placebo | LSD + MDMA |
| --- | --- | --- |
| Cmax (ng/mL) | “233 (215–252)” | “208 (189–228)” |
| tmax (h) | “2.8 (2.5–3.2)” | “3.5 (3.0–4.0)” |
| t1/2 (h) | “8.3 (7.5–9.1)” | “8.2 (7.5–9.1)” |
| AUC∞ (ng·h/mL) | “3083 (2713–3505)” | “3068 (2712–3472)” |

Source: [Straumann et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10584820/)

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Phase 3 dose: single 100 µg DT120 ODT

> “Single dose regimen is being studied in pivotal clinical trials with primary and secondary outcome measures through 12 weeks after administration.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

> “Voyage is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of a single 100 µg dose of DT120 ODT versus placebo in adults with generalized anxiety disorder (GAD).”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-2.1.2.10.1-2"></a>

###### Panorama: 50 µg comparator arm

> “randomized 2:1:2 to receive a single dose of DT120 ODT 100 µg, DT120 ODT 50 µg, or matching placebo, with the 50 µg arm included to help mitigate functional unblinding.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-2.1.2.10.1-3"></a>

###### Symptom-triggered open-label redosing in the 40-week extension

> “during which participants may be eligible to receive up to four additional doses of DT120 ODT 100 μg based on symptom severity, for a total study duration of approximately 56 weeks.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “Open-label DT120 ODT 100 μg ≥4 weeks after last dose and ≤4 weeks of meeting threshold”
> “Max of 4 doses in extension period”
> “Total of up to 5 doses over 52-week period with final dose no later than week 50.”
> “To maintain data integrity, participants who met retreatment thresholds and had no safety concerns were required to re-treat”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

> “Eligible for open-label treatment if HAM-A ≥16”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-2.1.2.10.1-4"></a>

###### Dose selection from the phase 2b dose-finding trial

> “In this phase 2b, multicenter, double-blind, placebo-controlled trial, participants with GAD were randomized equally to receive a single (freebase equivalent) treatment dose with 25 µg, 50 µg, 100 µg, or 200 µg of MM120 or placebo without stratification (Figure 1).”
> “The 100-µg dose of MM120 was determined to be optimal, demonstrating a statistically significant change in GAD that exceeded the changes seen with lower MM120 doses or with placebo.”
> “The 200-µg dose of MM120 was associated with more frequent AEs without improvements in efficacy.”
> “These findings support the selection of 100-µg dose of MM120 for pivotal trials to assess its efficacy, durability, and safety in the treatment of GAD.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

> “Considering the efficacy and safety profile observed in the phase 2b study, MM120 100μg (freebase-equivalent) is considered an acceptable therapeutic dose.”

Source: [Powdar et al. (2025)](https://psychedelicalpha.com/wp-content/uploads/2025/05/Sarah-Karas-ASCP-2025.pdf)

<a id="topic-2.1.2.10.1-5"></a>

###### Dose-response in healthy participants above 100 µg

> “Therefore, LSD doses higher than 100 µg produced no further increases in good drug effects but more ego dissolution and anxiety.”
> “These results may assist with dose finding for future LSD research.”

Source: [Holze et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8027607/)

<a id="topic-2.1.2.10.1-6"></a>

###### Characterization of the 100 µg dose in an independent drug review

> “The phase 2b dose-finding study provides a credible signal of rapid and durable anxiolytic activity after one 100 microgram administration without protocol-mandated psychotherapy.”
> “However, DT120 should not be described as microdosing or modified release: 100 micrograms is a perceptible psychedelic dose, whereas controlled microdosing studies have generally used 5-20 micrograms, and the pivotal product is described publicly as a fast-dissolving orally disintegrating tablet.”

Source: [Cubała (2026)](https://pubmed.ncbi.nlm.nih.gov/42848417/)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Orally disintegrating tablet

> “Zydis ODT is a unique, freeze-dried, oral solid dosage form that disperses almost instantly in the mouth, without the need for water.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

> “DT120 ODT disintegrates in seconds”
> “Normal activities resume the next day, including driving”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-2.1.2.10.2-2"></a>

###### Required 8-hour monitoring and end-of-session checklist in the Phase 3 trials

> “Required monitoring period for all participants in pivotal studies is 8 hours and requires that participants clear the End of Session Checklist.”
> “Dosing and monitoring paradigm based on Phase 3 clinical protocols.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

> “Participants were monitored for a minimum of 8 hours on dosing day and were assessed hourly beginning 5 hours after dosing on a structured end-of-session checklist (EoSC).”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “The EoSC is an 8-question checklist used to assess participant readiness for completion of monitoring after receiving DT120.”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-2.1.2.10.2-3"></a>

###### End-of-session checklist content and development

> “Predetermined safety criteria were used to assess readiness to end the dosing session, such as orientation to person, place, and time; resolution of cognitive, perceptual, and emotional effects; and no evidence of suicidal ideation”

Source: [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf)

> “12-hour monitoring requirement based on inclusion of 200 μg dose of DT120 in Phase 2b”
> “The required monitoring period in pivotal studies of DT120 is 8 hours and requires that participants clear the End of Session Checklist.”
> “EOSC intended to inform & reflect requirements under potential REMS program”
> “Refined based on discussions with the FDA”

Source: [Definium Therapeutics Investor and Analyst Day presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23529/pdf/DFTX+Investor+%26+Analyst+Day+Deck_April+22+2026.pdf)

<a id="topic-2.1.2.10.2-4"></a>

###### Session length in Voyage: topline announcement

> “On the day of dosing, participants were assessed hourly beginning at hour 5 post-dose on a structured end-of-session checklist (EoSC).”
> “The average time to meeting EoSC criteria was 6.4 hours for participants receiving DT120 ODT in Part A, with a median of 6.1 hours and 92% of participants meeting the EoSC criteria by hour 8.”

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-2.1.2.10.2-5"></a>

###### Session length in Voyage: congress poster

> “Average time to End-of-Session Checklist (EoSC) clearance was 6.4 hours (Figure 6).”
> “More than half of participants met all EoSC criteria at hour 6, and the majority of participants (90%) met all EoSC criteria by hour 8”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-2.1.2.10.2-6"></a>

###### Session length in Panorama and across the Phase 3 trials

> “The average time to meet EoSC criteria was 6.2 hours for participants receiving DT120 ODT 100 μg, with a median of 6.0 hours and 94% of participants meeting EoSC criteria by hour 8.”
> “Across over 1,000 treatment sessions in the Phase 3 program through September 10, 2026, 97% of participants met EoSC criteria by hour 8.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “Consistent average time to clearance of EoSC of ~6 hours across studies”
> “Two thirds of participants clear EoSC at hour 6”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-2.1.2.10.2-7"></a>

###### Dosing session monitors and on-call clinician in the Phase 3 trials

> “Two qualified and trained DSMs monitored dosing, with the second DSM having the option to monitor remotely via video.”
> “A total of 3 DSMs were onsite, and a licensed HCP was available or on call ≤15 minutes from the site”
> “Standardized EoSC was used to assess participant status and ability to end the dosing session”
> “Site raters could not serve as the DSM or HCP for the same participant after the screening or baseline assessments to mitigate functional unblinding”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

> “In a clinical trial, an LSD dosing session is conducted in a comfortable, supportive environment with medical professionals called Dosing Session Monitors (DSMs) who passively observe and assist participants.”
> “A healthcare provider is on call to provide medical oversight.”

Source: [Definium Therapeutics LSD fact sheet (2026)](https://definiumtx.com/wp-content/uploads/2026/08/DFTX-FactSheet-LSD-080526.pdf)

<a id="topic-2.1.2.10.2-8"></a>

###### Phase 2b dosing session procedures and 12-hour monitoring

> “On the dosing day, participants received a single oral dose of MM120 or placebo.”
> “Each participant was continuously monitored on-site for safety and comfort by the same 2 dosing session monitors who conducted the participant’s educational session during the baseline visit.”
> “Participant dosing sessions were conducted individually in a private aesthetically pleasant room.”
> “Participants were offered standardized music and eyeshades and they could lie down, move freely around the room, read, write, or draw.”
> “Vital signs were measured throughout the dosing session and a physician was on-site in case comfort medications were needed.”
> “Starting 8 hours after the dose, participants were assessed hourly to characterize the resolution of the drug effects.”
> “Continuous monitoring was required for a minimum of 12 hours.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-2.1.2.10.2-9"></a>

###### Phase 2b: time to meet criteria to end the session at 100 µg

> “In the 100-µg dose group, 45.0% of participants met criteria to safely end the session at 8 hours, 70.0% at 9 hours, 87.5% at 10 hours, 90.0% at 11 hours, and 97.5% at 12 hours.”
> “All participants remained at the study site until 12 hours after the dosing session regardless of meeting criteria to safely end the session per the trial protocol (Supplement 1).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-2.1.2.10.2-10"></a>

###### Regulatory expectations for monitoring a psychedelic treatment session

> “Subjects receiving active treatment with psychedelic drugs may remain in a vulnerable state for several hours or longer.”
> “Observation by two monitors for the duration of the treatment session.”
> “If the lead monitor is not a physician, availability of a licensed on-call physician able to reach the clinical site within 15 minutes in the event of a medical emergency.”
> “Sponsors should plan to provide a quantitative and qualitative assessment of the drug effects, including effects on orientation to time and place, thought and perception, and subjective effects across time that could inform recommendations for monitoring, safety of discharge, and impact on driving.”

Source: [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Current access through clinical trials only

> “Definium recognizes the value that expanded access programs provide; however, at this time, we believe that the most appropriate way to receive our investigational medication is through one of our clinical trials.”
> “Definium recognizes that patients in need may not be able to participate in clinical trials and is evaluating the appropriate timing and conditions under which Expanded Access may be made available.”

Source: [Definium Therapeutics expanded access policy (2025)](https://definiumtx.com/expanded-access-policy/)

<a id="topic-2.1.2.11-2"></a>

###### Schedule I status: product rescheduling required before commercial distribution

> “For any product containing a Schedule I substance, such as lysergide or MDMA, to be available for commercial marketing in the United States, the substance or drug product containing the substance must be rescheduled under the CSA to Schedule II, III, IV or V or removed from the Schedules.”
> “Even assuming our product candidates are controlled in Schedule II or lower at the federal level, such substances or products may require separate rescheduling or descheduling determinations under state laws and regulations.”
> “While some states automatically schedule (or reschedule) a drug based on federal action, other states schedule drugs through rule making or a legislative action. State scheduling may delay commercial sale of any product for which we obtain federal regulatory approval and adverse scheduling could have a material adverse effect on the commercial attractiveness of such product.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-2.1.2.11-3"></a>

###### DEA registration of clinical trial sites and importation for the trials

> “Because our product candidates fall into categories of substances that are “controlled substances”, to conduct clinical trials on our product candidates in the United States prior to approval, each of our research sites must submit a research protocol to the DEA and obtain and maintain a DEA researcher registration that will allow those sites to handle and dispense our product candidates and to obtain our product candidates from our importer.”
> “The importer for the clinical trials must also obtain a Schedule I importer registration and an import permit for each import.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-2.1.2.11-4"></a>

###### Manufacturing quotas for the active ingredient after approval

> “Additionally, regardless of the scheduling of our product candidates if approved, the active ingredient in the final dosage form is currently a Schedule I controlled substance and would be subject to such quotas as these substances could remain listed on Schedule I.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-2.1.2.11-5"></a>

###### Planned delivery through certified third-party treatment sites and a possible REMS

> “If we are able to commercialize our product candidates, our success will be dependent upon our ability to identify, qualify, prepare, certify and support third-party treatment sites that can offer and administer our product candidates.”
> “Because we intend to work only with third-party sites and providers who agree to adhere strictly to the administration protocols described in labeling or a REMS program, we may face limitations on the number of sites available to administer our product candidates.”
> “Given the novel nature of our product candidates, third-party treatment sites may face additional financial and administrative burdens in order to deliver any approved product candidate, including adhering to a REMS program in the United States or a Risk Management Plan (“RMP”) in the EU.”
> “Furthermore, third-party treatment sites will need to ensure that they have the necessary infrastructure and equipment in order to deliver our product candidates, such as adequate audio-visual equipment, ancillary equipment and sufficient administration rooms.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-2.1.2.11-6"></a>

###### Monitoring requirement in the pivotal trials and the end-of-session checklist as a basis for a potential REMS

> “The required monitoring period in pivotal studies of DT120 is 8 hours and requires that participants clear the End of Session Checklist.”
> “EOSC intended to inform & reflect requirements under potential REMS program”
> “Refined based on discussions with the FDA”
> “12-hour monitoring requirement based on inclusion of 200 µg dose of DT120 in Phase 2b”

Source: [Definium Therapeutics May 2026 corporate presentation (2026)](https://ir.definiumtx.com/sec-filings/all-sec-filings/content/0001193125-26-229657/dftx-ex99_1.htm)

> “Dosing and monitoring paradigm based on Phase 3 clinical protocols. Required monitoring period for all participants in pivotal studies is 8 hours and requires that participants clear the End of Session Checklist.”
> “Existing coding systems could potentially be applied or be changed for DT120. Reimbursement and coding for DT120 have yet to be established.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-2.1.2.11-7"></a>

###### Planned sites of care: interventional psychiatry clinics

> “Represents approximately half of estimated number of sites in the Spravato® REMS program.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

> “Definium is advancing a focused, patient-centric commercial strategy, including a scalable delivery model designed to support efficient adoption and long-term utilization. In parallel, the Company is proactively positioning for access and reimbursement with plans to leverage established and emerging practice patterns and existing administrative pathways to enable timely market uptake.”

Source: [Definium Therapeutics Investor and Analyst Day announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/223/definium-therapeutics-highlights-dt120-odt-lysergide-tartrate-clinical-advancements-and-commercial-strategy-at-investor-and-analyst-day)

<a id="topic-2.1.2.11-8"></a>

###### Manufacturing and supply: contract manufacturers and a single supplier of lysergide tartrate

> “We neither own nor operate, and currently have no plans to own or operate, any manufacturing facilities.”
> “For example, we have engaged a single supplier for the production of lysergide tartrate.”
> “While we seek to enhance our market protection strategy by identifying unique and/or proprietary methods of manufacturing and/or dosage forms and entering into exclusive long-term or commercial supply agreements, we do not currently have arrangements in place for either commercial supply or redundant supply of drug substance or drug product for our research compounds and product candidates.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-2.1.2.11-9"></a>

###### Distribution channel and specialty pharmacy arrangements

No evidence found.

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Phase 3: exclusion of medications that could not be discontinued

> “Participants were excluded if they had medical or psychiatric conditions that were contraindicated, or if they were taking concomitant medications, supplements, or other therapeutics with potential drug–drug interactions or anxiolytic or antidepressant effects that could not be discontinued”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

> “Use of prohibited concomitant medications, supplements, or other therapeutics”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-2.1.2.12-2"></a>

###### Phase 2b: taper and washout of mood and anxiety medications

> “The exclusion criteria included contraindicated medical or psychiatric conditions and inability or unwillingness to discontinue therapeutics with potential drug-drug interaction or anxiolytic effects.”
> “Participants taking mood or anxiety medications at screening were required to discontinue them under the supervision of site physicians.”
> “Before the baseline visit, a medication washout period of 5 half-lives or greater was required.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

> “Prior to treatment with MM120, study participants were clinically tapered and then washed out from any anxiolytic or antidepressant treatments and were not provided study-related psychotherapy for the duration of their participation in the study.”

Source: [MindMed APA presentation announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/144/mindmed-presents-phase-2b-study-of-mm120-for-generalized-anxiety-disorder-gad-at-american-psychiatric-association-apa-annual-meeting-in-new-york)

<a id="topic-2.1.2.12-3"></a>

###### Phase 2b: medications tapered at enrollment

> “At screening, 84% of participants required tapering prohibited medications, 16% were treatment-naive, and 18% were receiving psychotherapy at the time of enrollment; psychotherapy was allowed to continue through the trial.”
> “Of the participants who required tapering prohibited medications, 43% were taking serotonin reuptake inhibitors, 34% were taking benzodiazepines, and 19% were taking antipsychotics or antiepileptics.”
> “Participants may have tapered multiple medications.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-2.1.2.12-4"></a>

###### Phase 2b: prohibited substances

> “Disclosure or detection of the use of prohibited substances, including tetrahydrocannabinol, was cause for screening failure or discontinuation as was the use of any psychedelic within the past 2 years or more than 10 times within the past 10 years.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-2.1.2.12-5"></a>

###### Monotherapy design and unstudied concomitant use

> “Sixth, the process of tapering participants from prohibited psychoactive medications ensured MM120 was assessed as a monotherapy; however, we did not address concomitant use of other pharmacotherapies.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-2.1.2.12-6"></a>

###### Psychotherapy: phase 2b rules

> “Participants undergoing psychotherapy at the time of screening could enroll but could not discontinue or modify session frequency during the study.”
> “Participants not receiving psychotherapy at screening could not initiate it during the trial.”
> “Engaging in psychotherapy with the participant was explicitly prohibited by the trial protocol (Supplement 1).”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-2.1.2.12-7"></a>

###### Psychotherapy: Phase 3 rules

> “Systematic psychotherapy ≤4 weeks prior to screening or plans to initiate therapy”
> “Psychotherapy was prohibited during dosing sessions.”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-2.1.2.12-8"></a>

###### Psychotherapy: sponsor treatment paradigm

> “DT120 ODT Treatment Paradigm: Standalone Drug Effects with No Psychotherapeutic Intervention”
> “No psychotherapy and no therapeutic intervention beyond study drug”
> “Follow-up visits for assessment only”

Source: [Definium Therapeutics Investor and Analyst Day presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23529/pdf/DFTX+Investor+%26+Analyst+Day+Deck_April+22+2026.pdf)

> “Psychotherapy is not offered or required but may be added outside a dosing session based on a decision between a provider and patient to support individual goals and needs.”

Source: [MindMed corporate presentation (2025)](https://definiumtx.com/wp-content/uploads/2025/11/MindMed-Corporate-Presentation_November-2025.pdf)

<a id="topic-2.1.2.12-9"></a>

###### Concomitant selective serotonin reuptake inhibitor: healthy-participant interaction study

> “The present findings suggest that add‐on treatment with LSD to an SSRI is well‐tolerated.”
> “No signs of serotonergic toxicity occurred in either study.”
> “SSRIs did not increase the psychedelic‐induced cardiovascular stimulation or elevation of body temperature.”

Source: [Becker et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12087691/)

> “Therefore, SSRI therapy has been discontinued before psychedelic administration in clinical Phase II trials, with the exception of one open‐label trial.”
> “However, SSRI discontinuation carries the risk of symptom relapse and withdrawal symptoms, including depressed mood.”

Source: [Becker et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12087691/)

<a id="topic-2.1.2.12-10"></a>

###### Prohibited concomitant medications: regulatory guidance

> “Sponsors should evaluate potential impact of intrinsic and other extrinsic factors on the pharmacokinetics of the psychedelic drug to inform inclusion and exclusion criteria, prohibited concomitant medications for clinical studies, and potential labeling.”

Source: [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Lysergide on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### Anxiety Response at 6 Months (MBHR2) and Use of Anxiety Severity Measure (MBHR1): Merit-based Incentive Payment System registry measures

> “Use of Anxiety Severity Measure (MBHR1)”
> “Measures the percentage of adult patients (18+) with an anxiety disorder diagnosis who complete a standardized anxiety severity tool such as the GAD-7 or BAI during the measurement period.”
> “Anxiety Response at 6 Months (MBHR2)”
> “Evaluates treatment response for adults (18+) with anxiety disorders by measuring symptom improvement over time, defined as a 25% or greater reduction in GAD-7 score at 6 months (+/– 60 days) following an index visit with a positive severity score.”

Source: [Healthmonix 2026 Mental and Behavioral Health Registry announcement (2026)](https://healthmonix.com/2026/02/05/2026-mental-and-behavioral-health-registry-mbhr/)

> “The APA Mental and Behavioral Health Registry (MBHR) was again approved by the Centers for Medicare and Medicaid Services (CMS) to participate in the Merit-Based Incentive Payment System (MIPS) for 2026 as a Qualified Clinical Data Registry (QCDR).”

Source: [American Psychological Association Mental and Behavioral Health Registry measures page (2026)](https://www.apaservices.org/practice/reimbursement/health-registry/measures)

<a id="topic-2.1.2.13-2"></a>

###### Use of High-Risk Medications in Older Adults: benzodiazepine rate and the severe generalized anxiety disorder exception

> “Patients with two or more benzodiazepine prescriptions ordered on different days, and who did not have a diagnosis of seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine withdrawal, ethanol withdrawal, or severe generalized anxiety disorder on or between January 1 of the year prior to the measurement period and the IPSD for benzodiazepines.”

Source: [CMS Use of High-Risk Medications in Older Adults eCQM flow (2025)](https://ecqi.healthit.gov/sites/default/files/ecqm/measures/CMS156-v14.0.000-eCQM-Flow.pdf)

> “The percentage of persons 67 years of age and older who had at least two dispensing events for the same high-risk medication.”
> “The DDE and DAE measures are based on recommendations in the American Geriatrics Society (AGS) 2023 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults”

Source: [NCQA Use of High-Risk Medications in Older Adults measure description](https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/use-of-high-risk-medications-in-older-adults-dae/)

<a id="topic-2.1.2.13-3"></a>

###### Lysergide-specific effect on quality measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Effect sizes of DT120 placed beside approved GAD treatments: company presentation

| Treatment and time point | Effect size |
| --- | --- |
| DT120, phase 2b MMED008, Week 12 | “0.81” |
| DT120 ODT, Voyage, Week 12 | “0.81” |
| DT120 ODT, Panorama, Week 12 | “0.64” |
| DT120, phase 2b MMED008, Week 4 | “0.88” |
| DT120 ODT, Voyage, Week 4 | “0.99” |
| DT120 ODT, Panorama, Week 4 | “0.96” |
| Benzodiazepines | “0.38” |
| SRIs | “0.36” |
| Buspirone | “0.17” |

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

> “DT120 effect size consistently larger than GAD standard of care”
> “The information presented in this slide is derived from multiple clinical trials, each conducted under distinct protocols and settings. As such, these data may not be directly comparable due to the lack of a head-to-head comparison.”
> “Buspirone and benzodiazepines are approved for anxiety disorders which include GAD”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-2.1.2.14-2"></a>

###### Effect sizes of approved GAD drug classes: meta-analysis of 21 placebo-controlled trials cited by the company

> “We conducted an effect size (ES) analysis of 21 double-blind placebo-controlled trials of medications treating DSM-III-R, DSM-IV or ICD-10 GAD using HAM-A change in score from baseline or endpoint score as the main efficacy measure.”
> “comparing all drugs versus placebo, the ES was 0.39. Mean ESs, excluding children, were PGB: 0.50, AH: 0.45, SNRI: 0.42, BZ: 0.38, SSRI: 0.36, AZA: 0.17 and CAM: -0.31.”

Source: [Hidalgo et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17984162/)

<a id="topic-2.1.2.14-3"></a>

###### HAM-A differences from placebo for approved and off-label GAD drugs: network meta-analysis of 89 trials

> “This analysis is based on 89 trials, which included 25 441 patients randomly assigned to 22 different active drugs or placebo.”
> “Duloxetine (MD -3·13, 95% credible interval [CrI] -4·13 to -2·13), pregabalin (MD -2·79, 95% CrI -3·69 to -1·91), venlafaxine (MD -2·69, 95% CrI -3·50 to -1·89), and escitalopram (MD -2·45, 95% CrI -3·27 to -1·63) were more efficacious than placebo with relatively good acceptability.”
> “Quetiapine (MD -3·60 95% CrI -4·83 to -2·39) had the largest effect on HAM-A but it was poorly tolerated (odds ratio 1·44, 95% CrI 1·16-1·80) when compared with placebo.”

Source: [Slee et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30712879/)

<a id="topic-2.1.2.14-4"></a>

###### DT120 HAM-A differences from placebo in the phase 3 trials

> “The Least Squares (LS) mean change from baseline in HAM-A total score at Week 12 in participants who received DT120 ODT 100 µg was -9.8 compared with -4.7 for participants who received placebo, an LS mean difference of -5.1 points (p<0.0001), corresponding to a standardized effect size of d=0.64.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “The Least Squares (“LS”) mean change from baseline in HAM-A total score at Week 12 in participants who received DT120 ODT 100 µg was -11.6 compared with -6.2 for participants who received placebo, an LS mean difference of -5.4 points (p<0.0001), corresponding to a standardized effect size of d=0.81.”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

<a id="topic-2.1.2.14-5"></a>

###### FDA-approved pharmacotherapies for GAD in adults

> “Escitalopram has been approved by the FDA for the treatment of GAD in adults”
> “As an FDA-approved treatment for GAD in adults, immediate release paroxetine has been studied extensively and multiple studies support its efficacy in adults with GAD.”
> “In adults with GAD, venlafaxine (75–225 mg/day) effectively reduces anxiety symptoms [36–38] and was the first FDA-approved antidepressant for the treatment of GAD in this age group.”
> “Duloxetine, a selective 5-HT and norepinephrine reuptake inhibitor, is FDA-approved for the treatment of GAD, MDD, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain.”
> “Buspirone, a non-benzodiazepine anxiolytic and 5-HT1A receptor agonist, is approved for the treatment of GAD in adults”
> “As such, alprazolam is the only benzodiazepine to be formally approved by the FDA for the treatment of GAD.”

Source: [Strawn et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6340395/)

<a id="topic-2.1.2.14-6"></a>

###### Most recent FDA approval of a new drug for GAD: differing company statements

> “Despite the significant personal and societal burden of GAD, there has been little innovation in the treatment of GAD in the past several decades, with the last new drug approval occurring in 2004.”

Source: [MindMed Breakthrough Therapy designation announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/137/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder)

> “Few treatment options have shown robust activity in GAD, with the last new FDA approval occurring in 2007.”

Source: [MindMed end-of-phase 2 meeting announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/149/mindmed-announces-constructive-end-of-phase-2-meeting-with-u-s-fda-for-mm120-in-generalized-anxiety-disorder-gad)

<a id="topic-2.1.2.14-7"></a>

###### Dosing paradigm: single administered dose compared with daily oral therapy

> “Single dose regimen is being studied in pivotal clinical trials with primary and secondary outcome measures through 12 weeks after administration.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

> “Patients with generalized anxiety disorder often work through two or three medications before finding one they can tolerate, and even then, daily dosing brings its own burden, sedation, weight change, sexual side effects, and for some classes of medications, real dependence risk,”
> “What stands out about DT120 ODT is that a single dose has the potential to hold a response for months without the patient managing a pill every day.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “Patients with GAD and MDD are typically treated with a variety of anxiolytic and antidepressant medications, including selective serotonin reuptake inhibitors, serotonin–norepinephrine reuptake inhibitors and benzodiazepines.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-2.1.2.14-8"></a>

###### Monitored-administration model: esketamine nasal spray under the SPRAVATO REMS

> “Risk for sedation, dissociation, and respiratory depression after administration. Monitor patients for at least two hours after administration.”
> “SPRAVATO is only available through a restricted program called the SPRAVATO REMS.”
> “Administer SPRAVATO intranasally under the supervision of a healthcare provider.”

Source: [Janssen SPRAVATO prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf)

<a id="topic-2.1.2.14-9"></a>

###### Monitored-administration model: DT120 session length in the phase 3 trials

> “Participants were monitored for a minimum of 8 hours on dosing day and were assessed hourly beginning 5 hours after dosing on a structured end-of-session checklist (EoSC).”
> “The average time to meet EoSC criteria was 6.2 hours for participants receiving DT120 ODT 100 μg, with a median of 6.0 hours and 94% of participants meeting EoSC criteria by hour 8.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-2.1.2.14-10"></a>

###### Prescriber intent to administer DT120 compared with esketamine: company market research

| Response of high-priority GAD prescribers | DT120 ODT | Esketamine |
| --- | --- | --- |
| Prescribe and administer the treatment in own practice | “51%” | “26%” |
| Refer out (for DT120, the treatment; for esketamine, for esketamine) | “40%” | “61%” |
| Only discuss if a patient raises it (DT120), or refer out for evaluation without specifying esketamine | “9%” | “14%” |

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

> “GAD Target Validation Market Research, 2025. High-priority HCPs represent deciles 7-10 of GAD prescribers. In the conduct of market research, DT120 was blinded as “Treatment X” to respondents.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-2.1.2.14-11"></a>

###### LSD compared with psilocybin: effect duration in healthy participants

| Effect | 15 mg psilocybin | 30 mg psilocybin | 100 µg LSD | 200 µg LSD |
| --- | --- | --- | --- | --- |
| Effect duration (h), mean ± SD | “5.6 ± 2.2” | “6.5 ± 2.4” | “9.3 ± 3.2” | “11 ± 3.7” |

Source: [Holze et al. (2022b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9018810/)

> “The doses of 100 and 200 µg LSD and 30 mg psilocybin produced comparable subjective effects.”
> “LSD at both doses had clearly longer effect durations than psilocybin.”
> “The elimination half-life values of LSD and psilocin were an average of ~4 h and 2.5 h, respectively.”

Source: [Holze et al. (2022b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9018810/)

<a id="topic-2.1.2.14-12"></a>

###### Other psychedelic and serotonergic agents in development for GAD and depressive disorders, as listed by the company

> “A number of companies are developing product candidates with similar mechanisms to DT120 that are intended for the treatment of anxiety and depressive disorders, including AtaiBeckley Inc. (“AtaiBeckley”), Compass Pathways plc (“Compass”), GH Research (“GH Research”), Cybin, Inc. doing business as Helus Pharma (“Helus”), Johnson & Johnson (“J&J”), Otsuka Pharmaceutical Co. Ltd. (“Otsuka”) and others.”
> “Helus is currently evaluating HLP004 (a serotonin receptor agonist) in a Phase 2 trial for the treatment of GAD, with an anticipated topline data readout in the first quarter of 2026. In addition, Otsuka is currently conducting a Phase 2/3 clinical trial of ulotaront (SEP-363856), a trace amine-associated receptor 1 (TAAR1) agonist with 5-HT1A agonist activity, for the treatment of GAD and MDD.”
> “Intra-Cellular Therapies, now a part of J&J (“Intra-Cellular”), is currently developing multiple product candidates that are in various phases of development for the treatment of GAD and MDD, including CAPLYTA (lumateperone), which was approved by the FDA in November 2025 as an adjunctive treatment for adults with MDD, and ITI-1284 ODT-SL for GAD.”
> “Compass is developing COMP360 (a proprietary formulation of psilocybin) that is in Phase 3 clinical trials for the treatment of TRD in adults and is being studied in other psychiatric indications (anorexia nervosa and post-traumatic stress disorder).”
> “There are also many other public and private companies developing therapeutics from the psychedelic drug class at various stages of development, including certain short-acting psychedelic drugs.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-2.1.2.14-13"></a>

###### Head-to-head clinical comparison of DT120 with an approved GAD treatment

No evidence found.

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Definition: persistent, excessive, and difficult-to-control worry about everyday concerns

> “The disorder is characterized by persistent, excessive, and unrealistic worry about everyday concerns. Worry may involve multiple areas, including finances, family, health, and the future. Excessive worry is difficult to control and is often accompanied by nonspecific psychological and physical symptoms. Excessive worry is the central feature of generalized anxiety disorder.”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

> “Generalized anxiety disorder is characterized by excessive anxiety and worry about a variety of events or activities (e.g., work or school performance) that occurs more days than not, for at least 6 months. People with generalized anxiety disorder find it difficult to control their worry, which may cause impairment in social, occupational, or other areas of functioning.”

Source: [National Institute of Mental Health generalized anxiety disorder statistics](https://www.nimh.nih.gov/health/statistics/generalized-anxiety-disorder)

<a id="topic-2.2.1.1-2"></a>

###### Definition: core features of generalized anxiety disorder under DSM-5 and ICD-11

| Feature | Generalised anxiety disorder |
| --- | --- |
| Core emotions or cognitions | “Marked, uncontrollable, and anxious worry and fears about everyday events and problems” |
| Physical symptoms | “Restlessness, fatigue, irritability, difficulty concentrating, muscle tension, sleep disturbance, or autonomic arousal” |
| Behaviour | “Disturbance impairs social, school, work, or other functioning” |
| Median age of onset | “Adulthood (around 30 years)” |

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

<a id="topic-2.2.1.1-3"></a>

###### Classification: one of the anxiety disorders, occurring in childhood and adulthood

> “Anxiety disorders comprise separation anxiety and selective mutism (occurring primarily in childhood; between the ages of 4 years and 18 years), specific phobias, social anxiety disorder, and generalised anxiety disorder (occurring in childhood as well as in adulthood), as well as panic disorder and agoraphobia (occurring primarily in adulthood; from the age of 18 years and older).”
> “Fear is a conscious feeling evoked by threat or impending danger, whereas anxiety involves anticipation of real or imagined future threat or danger.”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

<a id="topic-2.2.1.1-4"></a>

###### Diagnostic history: from DSM-III to the 6-month duration criterion

> “The American Psychiatric Association first introduced the diagnosis of generalized anxiety disorder in the DSM-III.”
> “Based on these findings, the DSM-III-R committee on generalized anxiety disorder recommended increasing the required duration to 6 months. The final version of the DSM-III-R incorporated this change. The DSM-IV subsequently revised the definition of excessive worry and the required number of associated psychophysiological symptoms.”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

<a id="topic-2.2.1.1-5"></a>

###### Etiology: contributing factors

> “The etiology of generalized anxiety disorder may include:”
> “Medical conditions, such as diabetes”
> “Comorbid mental health conditions, such as depression”
> “Genetic factors, with generalized anxiety disorder occurring in approximately 25% of first-degree relatives of affected patients”
> “Environmental factors, such as childhood abuse”
> “Substance use disorder”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

<a id="topic-2.2.1.1-6"></a>

###### Heritability: family and twin studies

> “The calculated summary odds ratios ranged from 4 to 6, depending on the disorder. Only for panic disorder and generalized anxiety disorder could the authors identify more than one large-scale twin study for meta-analysis. These yielded heritabilities of 0.43 for panic disorder and 0.32 for generalized anxiety disorder. For panic disorder, the remaining variance in liability could be attributed primarily to nonshared environment. For generalized anxiety disorder, this was true for men, but for women, a potentially significant role for common familial environment was also seen.”

Source: [Hettema et al. (2001)](https://pubmed.ncbi.nlm.nih.gov/11578982/)

> “Heritability of anxiety disorders can vary, but heritability estimates converge to rates of between around 35% for generalised anxiety disorder and around 50% for social anxiety disorder, panic disorder, and agoraphobia.”
> “The mode of inheritance is complex, with many genetic variants of small effect interacting with, or adding to, other (presumably non-shared environmental) risk factors.”
> “However, genome-wide association studies showed a high genetic correlation (rG>0·6) among people with anxiety, depression, and neuroticism,”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

> “It is estimated that genes contribute 30% to 50%”
> “to the development of an anxiety disorder. Conversely, development of an anxiety disorder due to non-genetic factors is approximately 50% to 70%.”

Source: [Patriquin and Mathew (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5832062/)

<a id="topic-2.2.1.1-7"></a>

###### Common genetic variants: genome-wide association meta-analysis of 122,341 cases of major anxiety disorders

> “The major anxiety disorders (ANX; including generalized anxiety disorder, panic disorder and phobias) are highly prevalent, often onset early and cause substantial global disability.”
> “Here, we present a genome-wide association meta-analysis comprising 122,341 European ancestry ANX cases and 729,881 controls. We identified 58 independent genome-wide significant risk variants and 66 genes with robust biological support.”
> “As predicted by twin studies, we found substantial genetic correlation between ANX and depression, neuroticism and other internalizing phenotypes.”
> “The SNP-based heritability estimated at 10.1% captures approximately one-quarter of the broad-sense heritability from twin studies of adult ANX”

Source: [Strom et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12900644/)

<a id="topic-2.2.1.1-8"></a>

###### Common genetic variants: UK Biobank genome-wide association study of lifetime anxiety disorder

> “Anxiety disorders are common, complex psychiatric disorders with twin heritabilities of 30–60%.”
> “The liability scale common variant heritability estimate for Lifetime Anxiety Disorder was 26%, and for Current Anxiety Symptoms was 31%.”
> “Anxiety showed significant positive genetic correlations with depression and insomnia as well as coronary artery disease, mirroring findings from epidemiological studies.”

Source: [Purves et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7237282/)

<a id="topic-2.2.1.1-9"></a>

###### Common genetic variants: Million Veteran Program genome-wide association study of GAD-2 score

> “The authors identified five genome-wide significant signals for European Americans and one for African Americans on GAD-2 score.”

Source: [Levey et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7869502/)

<a id="topic-2.2.1.1-10"></a>

###### Environmental risk factors: adverse life events and parenting

> “The development of GAD is associated with unexpected negative life events (Nordahl et al. 2010), maltreatment (Moffitt et al. 2007), and loss (Kendler et al. 2003).”
> “In addition to one-time events, as outlined below, those with GAD have increased likelihood of negative experiences that are more chronic in nature, including ongoing abuse, parental rejection, inconsistent parenting, and parental invalidation (Cougle et al. 2010, Moffitt et al. 2007).”
> “GAD symptoms in children and adolescents have also been associated with harsh parental discipline and parenting characterized by strict rules and high expectations (Shanahan et al. 2008) as well as parental overprotection (Beesdo et al. 2010, Nordahl et al. 2010).”

Source: [Newman et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4964851/)

> “Environmental factors that influence the risk for anxiety disorders at multiple timepoints include various stressful life experiences and parenting practices, including childhood trauma, separation from attachment figures, and forms of overprotective parenting that limit children’s opportunities to encounter frightening circumstances in ways that facilitate mastery.”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

<a id="topic-2.2.1.1-11"></a>

###### Temperament: behavioral inhibition

> “Strong findings exist for the temperament of behavioural inhibition, expressed as reduced movement and vocalisation in the presence of novelty.”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

<a id="topic-2.2.1.1-12"></a>

###### Sociodemographic correlates: NESARC, United States adults

> “Data are taken from a large (n=43093) representative sample of the adult USA population.”
> “Being female, middle-aged, widowed/separated/divorced, and low income increased risk, while being Asian, Hispanic, or Black decreased risk.”

Source: [Grant et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16202187/)

<a id="topic-2.2.1.1-13"></a>

###### Sponsor statement on causes of generalized anxiety disorder

> “GAD may run in families, but the exact cause of the disorder is unknown. Research suggests that GAD results from a mix of genetics, brain chemistry, biology, and environment. Researchers have found that external causes, such as experiencing a traumatic event or being in a stressful environment, may put a person at higher risk for developing GAD.”

Source: [Definium Therapeutics GAD fact sheet (2026)](https://definiumtx.com/wp-content/uploads/2026/07/DFTX-FactSheet-GAD-072326.pdf)

Additional sources: [Stein and Sareen (2015)](https://pubmed.ncbi.nlm.nih.gov/26580998/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Generalized anxiety disorder

<a id="topic-2.2.1.2.1-1"></a>

###### United States diagnosed incidence: Komodo Healthcare Map claims, adults, 2020 to 2023

> “We estimated the prevalence and incidence of diagnosed GAD among adults in the U.S. healthcare system using payer-complete closed claims data from the Komodo Healthcare Map™ database from January 1, 2020 to December 31, 2023. Patients with GAD were identified using ICD-10 code F41.1.”
> “The numerator consisted of patients with a new GAD diagnosis in the index year and no documented GAD diagnosis during the prior two calendar years.”
> “The annual incidence of GAD in the U.S. among adults engaging with the healthcare system ranged from 2.1% to 2.3%, using a 2-year pre-index lookback to confirm no prior diagnosis and identify newly diagnosed cases”
> “Claims data represent treatment-seeking patients, which may limit generalizability to a broader population.”

Source: [Ferries et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13019603/)

<a id="topic-2.2.1.2.1-2"></a>

###### United States first incidence of DSM-IV generalized anxiety disorder: NESARC Waves 1 and 2

> “One-year incidence rates of DSM-IV substance, mood and anxiety disorders were highest for alcohol abuse (1.02) alcohol dependence (1.70), major depressive disorder (MDD: 1.51) and generalized anxiety disorder (GAD: 1.12).”
> “The 1-year incidence rates and 1-year incidence rates per 100 py were very similar given the small numbers of incident cases (Table 1), and are reported hereinafter as rates per 100 py at risk.”
> “Only the Netherlands survey reported incidence of DSM-III-R specific phobia (2.20) and generalized anxiety disorder (GAD) (0.72).”

Source: [Grant et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2766434/)

<a id="topic-2.2.1.2.1-3"></a>

###### Predictors of incident generalized anxiety disorder: NESARC

> “Women were at increased risk of all incident anxiety disorders except social phobia (Table 4). Risks of incident panic disorder and social phobia were greater among respondents 20-to-54 years-old, whereas increased risks of specific phobia and GAD were only observed among 30-to-54 year-olds. Except for specific phobia, the risks of incident anxiety disorders were increased among respondents with incomes ≤ $19,999/year. The risk of incident GAD was also greater among respondents who were separated/divorced/widowed and lower among Hispanics.”
> “Increased risk of incident GAD was observed among respondents with baseline MDD, bipolar I, panic disorder, and social phobia, and with schizotypal, borderline, and narcissistic PDs.”
> “One of the most interesting findings of this study was the reciprocal temporal relationships between MDD and GAD, and GAD and panic disorder.”

Source: [Grant et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2766434/)

<a id="topic-2.2.1.2.1-4"></a>

###### Age at onset: NCS-R and NCS-A, United States

> “First, median AOO (i.e. the 50th percentile on the AOO curves) is earliest for the phobias and SAD (ages 15–17) and latest for PD (age 23), MDE (age 25), and GAD (age 30).”
> “MDE, GAD, and PD, at the other extreme, have IQRs in the range 23–27 years.”
> “Indeed, a comparison of cumulative lifetime prevalence estimates as of age 64 with those as of age 17 in Figures 2 and 3 shows that an estimated 69–74% of all lifetime cases of MDE, GAD, and PD have first onsets in the age range 18–64.”

Source: [Kessler et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4005415/)

<a id="topic-2.2.1.2.1-5"></a>

###### Age at onset: meta-analysis of 192 epidemiological studies

| Measure | Generalised anxiety disorder |
| --- | --- |
| No of samples | “24” |
| Peak age at onset (years) | “15.5” |
| Proportion onset by 14 years | “8.6%” |
| Proportion onset by 18 years | “20.4%” |
| Proportion onset by 25 years | “33.0%” |
| 25th percentile age at onset (years) | “20” |
| Median age at onset (years) | “32” |
| 75th percentile age at onset (years) | “42” |

Source: [Solmi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8960395/)

<a id="topic-2.2.1.2.1-6"></a>

###### Global incidence of anxiety disorders (all types combined): Global Burden of Disease Study 2019

> “Globally, the estimated newly-diagnosed anxiety disorders patients increased from 31.13 (95% UI: 25.08, 37.92) million in 1990 to 45.82 (95% UI: 37.14, 55.62) million in 2019, with a relatively stable ASIR of about 5.8 (95% UI: 4.68, 7.03) cases per 1000 population over the past 30 years”
> “The incidence rate of anxiety disorders rose to a peak at age 10–14 years, remained relatively high level until age 40–44 years, and dropped substantially afterward among both sexes in 2019”

Source: [Yang et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8157816/)

<a id="topic-2.2.1.2.1-7"></a>

###### High-income North America incidence of anxiety disorders (all types combined): Global Burden of Disease Study 2019

| Region | Incident cases in 2019, millions (95% UI) | Age-standardised incidence rate per 1000 in 2019 (95% UI) |
| --- | --- | --- |
| High-income North America | “2.86 (2.31, 3.52)” | “8.06 (6.44, 9.87)” |

Source: [Yang et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8157816/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Generalized anxiety disorder

<a id="topic-2.2.1.2.2-1"></a>

###### United States past-year prevalence by clinical interview: MDPS, adults aged 18 to 65, 2020 to 2022

> “The study sample included adults aged 18 to 65 residing in households, prisons, homeless shelters, and state psychiatric hospitals in the United States.”
> “Clinical interviews were conducted with close to 5,700 participants, virtually or in person, between October 2020 and October 2022.”
> “The two most common mental disorders among adults aged 18 to 65 were major depressive disorder (15.5 percent, or approximately 31.4 million adults) and generalized anxiety disorder (10.0 percent, or approximately 20.2 million adults). These prevalence rates are much higher than reported by prior studies.”

Source: [RTI International (2023)](https://www.rti.org/publication/mental-substance-use-disorders-prevalence-study-findings-report)

> “GAD, 10.0 percent (95 percent CI: 8.3 to 12.1 percent)”
> “As shown in Figure 3.B.2, the most common disorders, MDD and GAD, along with OCD and bipolar I disorder, occurred the most frequently in young adults aged 18 to 25.”
> “The MDPS prevalence rates for MDD (15.5 percent) and GAD (10.0 percent) were substantially higher than rates in past nationally representative studies. The most obvious explanation is that the MDPS was conducted during the COVID-19 pandemic.”

Source: [Ringeisen et al. (2023)](https://www.rti.org/publication/mental-and-substance-use-disorders-prevalence-study/fulltext.pdf)

<a id="topic-2.2.1.2.2-2"></a>

###### United States diagnosed prevalence: Komodo Healthcare Map claims, adults, 2020 to 2023

> “Projected annual prevalence increased from 5.4% in 2020–6.6% in 2023, with a 3-year prevalence of 10.3% over the 2021–2023 period.”
> “Importantly, more than one in ten adults met criteria for GAD over a three-year period, exceeding lifetime prevalence estimates from prior general population studies, which have ranged from approximately 5% to almost 8%”
> “When this exclusion criterion was removed, the estimated one-year prevalence of GAD in 2023 increased from 6.6% in the base case to 7.2%.”
> “Demographic analyses across each 1-year time period reveal that females appeared in GAD claims data at more than twice the rate of males.”

Source: [Ferries et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13019603/)

<a id="topic-2.2.1.2.2-3"></a>

###### United States past-year and lifetime prevalence: NCS-R, adults, 2001 to 2003

> “Based on diagnostic interview data from National Comorbidity Survey Replication (NCS-R), Figure 1 shows past year prevalence of generalized anxiety disorder among U.S. adults aged 18 or older.”
> “An estimated 2.7% of U.S. adults had generalized anxiety disorder in the past year.”
> “Past year prevalence of generalized anxiety disorder among adults was higher for females (3.4%) than for males (1.9%).”
> “An estimated 5.7% of U.S. adults experience generalized anxiety disorder at some time in their lives”
> “An estimated 32.3% had serious impairment, 44.6% had moderate impairment, and 23.1% had mild impairment.”

Source: [National Institute of Mental Health generalized anxiety disorder statistics](https://www.nimh.nih.gov/health/statistics/generalized-anxiety-disorder)

<a id="topic-2.2.1.2.2-4"></a>

###### United States 12-month prevalence and severity: NCS-R, adults (n=9282)

| Generalized anxiety disorder, 12-month | Total, % (se) | Serious, % (se) | Moderate, % (se) | Mild, % (se) |
| --- | --- | --- | --- | --- |
| NCS-R | “3.1 (0.2)” | “32.3 (2.9)” | “44.6 (4.0)” | “23.1 (2.9)” |

Source: [Kessler et al. (2005b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2847357/)

> “Anxiety disorders are the most prevalent class (18.1%), followed by mood disorders (9.5%), impulse-control disorders (8.9%), and substance disorders (3.8%).”

Source: [Kessler et al. (2005b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2847357/)

<a id="topic-2.2.1.2.2-5"></a>

###### United States lifetime prevalence and lifetime morbid risk: NCS-R and NCS-A, ages 13 and older

> “The LMR/12‐month prevalence estimates ranked by frequency are as follows: major depressive episode: 29.9%/8.6%; specific phobia: 18.4/12.1%; social phobia: 13.0/7.4%; post‐traumatic stress disorder: 10.1/3.7%; generalized anxiety disorder: 9.0/2.0%”
> “The less common anxiety disorders include GAD (4.3%), panic disorder with or without agoraphobia (PD; 3.8%), agoraphobia with or without panic disorder (2.5%), and OCD (2.3%).”
> “These discrepancies might reflect the fact that GAD has a chronic‐episodic course reflected in intermediate prevalence ratios for all three age groups (roughly 35–50% of lifetime cases in episode in the 12 months before interview)”

Source: [Kessler et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4005415/)

<a id="topic-2.2.1.2.2-6"></a>

###### United States 12-month and lifetime prevalence: NESARC, adults

> “Prevalences of 12-month and lifetime GAD were 2.1% and 4.1%.”

Source: [Grant et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16202187/)

<a id="topic-2.2.1.2.2-7"></a>

###### United States adolescent lifetime prevalence: NCS-A, ages 13 to 18, 2001 to 2004

> “Based on diagnostic interview data from National Comorbidity Survey Adolescent Supplement (NCS-A), Figure 3 shows lifetime prevalence of generalized anxiety disorder among U.S. adolescents aged 13-18”
> “An estimated 2.2% of adolescents had generalized anxiety disorder, and an estimated 0.9% had severe impairment.”
> “The prevalence of generalized anxiety disorder among adolescents was higher for females (3.0%) than for males (1.5%).”

Source: [National Institute of Mental Health generalized anxiety disorder statistics](https://www.nimh.nih.gov/health/statistics/generalized-anxiety-disorder)

<a id="topic-2.2.1.2.2-8"></a>

###### United States primary care prevalence: 15 clinics, 2004 to 2005

> “15 U.S. primary care clinics.”
> “Of the 965 patients, 19.5% (95% CI, 17.0% to 22.1%) had at least 1 anxiety disorder, 8.6% (CI, 6.9% to 10.6%) had posttraumatic stress disorder, 7.6% (CI, 5.9% to 9.4%) had a generalized anxiety disorder”

Source: [Kroenke et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17339617/)

<a id="topic-2.2.1.2.2-9"></a>

###### Cross-national prevalence of DSM-5 generalized anxiety disorder: World Mental Health Surveys, 26 countries, 2001 to 2012

> “Across all surveys, the combined lifetime prevalence of GAD was 3.7%, 12-month prevalence was 1.8%, and 30-day prevalence was 0.8% (Table 1). Lifetime prevalence estimates varied widely across countries, ranging from less than 1% of the populations of Nigeria and Shenzhen, China, to approximately 8% of the populations of Australia, New Zealand, and the United States. Prevalence increased with economic development: lifetime estimates (SE) were lowest in low-income (1.6% [0.1%]), moderate in middle-income (2.8% [0.1%]), and highest in high-income (5.0% [0.1%]) countries.”

Source: [Ruscio et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5594751/)

<a id="topic-2.2.1.2.2-10"></a>

###### United States prevalence of DSM-5 generalized anxiety disorder: World Mental Health Surveys, US survey (n=9282)

| Country | Lifetime prevalence, No. (%) [SE] | 12-mo prevalence, No. (%) [SE] | 30-d prevalence, No. (%) [SE] | 12-mo prevalence among lifetime cases, No. (%) [SE] |
| --- | --- | --- | --- | --- |
| United States | “752 (7.8) [0.3]” | “394 (4.0) [0.2]” | “157 (1.6) [0.2]” | “394 (52.1) [1.8]” |

Source: [Ruscio et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5594751/)

<a id="topic-2.2.1.2.2-11"></a>

###### Sponsor-stated number of United States adults with generalized anxiety disorder

> “Generalized anxiety disorder, or GAD, is one of the most common psychiatric disorders, affecting approximately 26 million U.S. adults”
> “Ringeisen, H., et al. (2023). Mental and Substance Use Disorders Prevalence Study (MDPS): Findings report. RTI International and current U.S. Census data and internal company estimates.”

Source: [Definium Therapeutics GAD fact sheet (2026)](https://definiumtx.com/wp-content/uploads/2026/07/DFTX-FactSheet-GAD-072326.pdf)

> “GAD is one of the most common psychiatric disorders, affecting approximately 26 million U.S. adults”

Source: [Definium Therapeutics Wired for Worry announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/238/definium-therapeutics-launches-wired-for-worry-a-health-care-provider-initiative-to-advance-the-understanding-of-generalized-anxiety-disorder-gad-patient-impact-and-neurobiology)

<a id="topic-2.2.1.2.2-12"></a>

###### Anxiety symptoms measured by GAD-7 (symptoms, not diagnosis): NHIS, adults, 2019

> “The GAD–7 scale is a validated brief self-report measure to screen for GAD and assess the severity of symptoms”
> “Adults with GAD–7 scores of 0–4 are considered to have no or minimal symptoms of GAD, while those with scores of 5–9, 10–14, or 15–21 are considered to have mild, moderate, or severe symptoms, respectively”
> “During 2019, 9.5%, 3.4%, and 2.7% of adults experienced mild, moderate, or severe symptoms of anxiety in the past 2 weeks, respectively, while 84.4% experienced no or minimal symptoms.”
> “The total percentage of adults who experienced any anxiety symptoms in the past 2 weeks decreased with age, from 19.5% among adults aged 18–29, 16.6% among adults aged 30–44, 15.2% among adults aged 45–64, to 11.2% among adults aged 65 and over (Figure 2).”
> “A total of 19.0% of women experienced anxiety symptoms in the past 2 weeks that were either mild, moderate, or severe, compared with 11.9% of men (Figure 3).”

Source: [Terlizzi and Villarroel (2020)](https://www.cdc.gov/nchs/products/databriefs/db378.htm)

<a id="topic-2.2.1.2.2-13"></a>

###### Anxiety symptoms measured by GAD-7 (symptoms, not diagnosis): NHIS, adults, 2019 and 2022

> “During 2022, about one in five adults age 18 and older experienced any symptoms of anxiety (18.2%) or symptoms of depression (21.4%) in the past 2 weeks.”
> “A significant increase was seen in the percentage of adults with anxiety symptoms (from 15.6% to 18.2%, respectively) and depression symptoms (from 18.5% to 21.4%, respectively) between 2019 and 2022.”

Source: [Terlizzi and Zablotsky (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11616099/)

<a id="topic-2.2.1.2.2-14"></a>

###### Positive GAD-7 screen, score of 10 or more (symptoms, not diagnosis): CLIMB cohort, United States adults, 2020 to 2022

> “Using a longitudinal, nationally representative study of US adults, we used generalized estimating equations to estimate the burden of positive screen for GAD (GAD-7 score ≥ 10) over time. The final sample included 1270 adults at least 18 years old who completed the COVID-19 and Life Stressors Impact on Mental Health and Well-being (CLIMB) Study, with data collected in spring 2020, 2021, and 2022. The national prevalence of positive screen for GAD decreased from 24.4% in 2020 to 21.3% in 2022 (P < .05).”

Source: [Ettman et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39123097/)

<a id="topic-2.2.1.2.2-15"></a>

###### Self-reported past-month nervousness (single item, not diagnosis): NSDUH, United States adults, 2008 to 2018

> “This variable was assessed with the item”
> “how often did you feel nervous during the past 30 days”
> “Anxiety increased from 5.12% in 2008 to 6.68% in 2018 (p < 0.0001) among adult Americans. Stratification by age revealed the most notable increase from 7.97% to 14.66% among respondents 18–25 years old (p < 0.001)”

Source: [Goodwin et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7441973/)

<a id="topic-2.2.1.2.2-16"></a>

###### Global prevalence of anxiety disorders (all types combined): Global Burden of Disease Study 2019

> “The accumulated anxiety disorder patients worldwide increased from 194.92 (95% UI: 165.10, 231.23) million in 1990 to 301.39 (95% UI: 252.63, 356.00) million in 2019, and kept a stable ASPR with around 37.8 (95% UI: 31.94, 44.77) per 1000 population during the period”

Source: [Yang et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8157816/)

<a id="topic-2.2.1.2.2-17"></a>

###### Global prevalence of anxiety disorders (all types combined) in 2020: change attributed to the COVID-19 pandemic

> “We also estimated an additional 76·2 million (64·3 to 90·6) cases of anxiety disorders globally (an increase of 25·6% [23·2 to 28·0]), such that the total prevalence was 4802·4 cases (4108·2 to 5588·6)”

Source: [COVID-19 Mental Disorders Collaborators (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8500697/)

Additional sources: [Kessler et al. (2005a)](https://pubmed.ncbi.nlm.nih.gov/15939837/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Age of onset: DSM-5 generalized anxiety disorder in the World Mental Health Surveys

> “Onset before puberty was rare in these surveys, with only 5% of cases developing by age 13 years.”
> “There was a gradual, steady accumulation of new cases over the lifespan, with 25% of all cases emerging by 25 years, 50% of the cases emerging by 39 years, and 75% of the cases emerging by 53 years.”
> “Although the AOO distribution was shifted earlier for high-income countries (median AOO, 36 years) relative to middle- and low-income countries (median AOO, 43 years for both), the distributions were substantively similar across country groups”

Source: [Ruscio et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5594751/)

<a id="topic-2.2.1.3-2"></a>

###### Age of onset and age at presentation: clinical reviews

> “Most studies suggest a peak onset of GAD during late adolescence or early adulthood, but it can also present later in life.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

> “Generalised anxiety disorder, agoraphobia, and panic disorder exhibit more age-of-onset heterogeneity and sometimes present later in life.”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

> “The median age at presentation is 30 years.”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

<a id="topic-2.2.1.3-3"></a>

###### Recovery and recurrence over 12 years: Harvard/Brown Anxiety Disorders Research Program

> “Survival analyses revealed an overall chronic course for the majority of the anxiety disorders.”
> “In comparison, patients with generalized anxiety disorder, panic disorder with agoraphobia, and social phobia had much lower probabilities of achieving recovery over 12 years of follow-up (probabilities of 0.58, 0.48, and 0.37, respectively).”
> “The probability of having a recurrence of social phobia was 0.39 over 12 years, and the probability of recurrence in patients who had recovered from generalized anxiety disorder was 0.45 at the end of the 12 years.”
> “The average time spent in an illness episode during the study period was 80% for social phobia, 78% for panic disorder with agoraphobia, and 74% for generalized anxiety disorder.”
> “These data depict the anxiety disorders as insidious, with a chronic clinical course, low rates of recovery, and relatively high probabilities of recurrence.”

Source: [Bruce et al. (2005)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3272761/)

<a id="topic-2.2.1.3-4"></a>

###### Remission in the first two years: Harvard Anxiety Research Program

> “Analysis of the 164 patients with GAD participating in the Harvard Anxiety Research Program.”
> “The likelihood of remission was 0.15 after one year and 0.25 after two years. The probability of becoming asymptomatic from all psychiatric symptoms was only 0.08.”
> “Likelihood of remission for GAD and any other comorbid condition after one year was half the annual remission rate for GAD alone.”

Source: [Yonkers et al. (1996)](https://pubmed.ncbi.nlm.nih.gov/8833684/)

<a id="topic-2.2.1.3-5"></a>

###### Persistence of lifetime cases: World Mental Health Surveys

> “Generalized anxiety disorder typically begins in adulthood and persists over time, although onset is later and clinical course is more persistent in lower-income countries.”
> “Generalized anxiety disorder was more persistent in low-income (59.5%) and middle-income (56.1%) countries than in high-income countries (45.9%).”
> “Around the world, persistence was higher for earlier-onset GAD cases, for individuals with lower educational levels and family income, and for those not employed outside the home (ie, Other status, homemaker)”

Source: [Ruscio et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5594751/)

<a id="topic-2.2.1.3-6"></a>

###### Two-year remission and chronic recurrent course: Lancet seminar

> “Epidemiological studies show a relatively high ratio of 1 year to lifetime prevalence for anxiety disorders, indicative of a chronic recurrent nature.”
> “Among patients with only one anxiety disorder, 2 year remission rates were around 70% for panic disorder without agoraphobia and generalised anxiety disorder, decreasing to 50–55% for social anxiety disorder and panic disorder with agoraphobia and 43% for those with multiple anxiety disorders.”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

<a id="topic-2.2.1.3-7"></a>

###### Course over 40 years of follow-up: hospital-admitted cohort in Madrid

> “Patients admitted with the diagnosis of anxiety states ('anxious thymopathy' ) to the Lopez Ibor Neuropsychiatric Research Institute between 1950 and 1961 were examined between 1984 and 1988 (n = 65).”
> “At first and second examinations 20% and 17% of subjects were diagnosed as GAD. Improvement was observed in 83%. GAD tended to disappear around age 50, but was replaced by somatization disorders.”
> “Lack of regular treatment compliance, female sex, and onset of GAD before age 25 were variables associated with a worse outcome.”

Source: [Rubio and Lopez-Ibor (2007)](https://pubmed.ncbi.nlm.nih.gov/17430415/)

<a id="topic-2.2.1.3-8"></a>

###### Remission, recurrence, and prognosis: guideline and review statements

> “Anxiety can be a chronic condition characterized by periods of remission and recurrence. However, full recovery may occur.”

Source: [USPSTF anxiety screening recommendation (2023)](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/anxiety-adults-screening)

> “The prognosis for patients with generalized anxiety disorder is guarded.”
> “Relapses are common, and patients often seek clinicians who can better address their needs.”
> “Unfortunately, despite optimal treatment, relapse rates are high.”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

<a id="topic-2.2.1.3-9"></a>

###### Mortality: Danish total-population cohort

> “In total, 1066 (2.1%) people with anxiety disorders died during an average follow-up of 9.7 years. The risk of death by natural and unnatural causes was significantly higher among individuals with anxiety disorders (natural mortality rate ratio (MRR) = 1.39, 95% CI 1.28–1.51; unnatural MRR = 2.46, 95% CI 2.20–2.73) compared with the general population.”
> “Of those who died from unnatural causes, 16.5% had comorbid diagnoses of depression (MRR = 11.72, 95% CI 10.11–13.51).”
> “The risk for natural death was increased among patients with acute stress reaction, generalised anxiety disorder, panic disorder and social phobia.”
> “the risk for unnatural death was more than doubled in patients with acute stress reaction, generalised anxiety disorders, post-traumatic stress disorder and social phobia.”

Source: [Meier et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5082973/)

| Mortality rate ratio (95% CI), 2002 to 2011 | Generalised anxiety disorder |
| --- | --- |
| All causes | “1.62 (1.35–1.93)” |
| Unnatural causes | “2.55 (2.00–3.19)” |
| Natural causes | “1.64 (1.36–1.95)” |

Source: [Meier et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5082973/)

<a id="topic-2.2.1.3-10"></a>

###### Suicidal ideation, attempts, and suicide: meta-analysis of 42 observational studies

> “Forty-two observational studies were included.”
> “Compared to those without anxiety, patients with anxiety were more likely to have suicidal ideations (OR = 2.89, 95% CI: 2.09, 4.00), attempted suicides (OR = 2.47, 95% CI: 1.96, 3.10), completed suicides (OR = 3.34, 95% CI: 2.13, 5.25), or have any suicidal behaviors (OR = 2.85, 95% CI: 2.35, 3.46).”
> “The increase in the risk of suicide was demonstrated for each subtype of anxiety except obsessive-compulsive disorder (OCD). The quality of this evidence is considered low to moderate due to heterogeneity and methodological limitations.”

Source: [Kanwar et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23408488/)

<a id="topic-2.2.1.3-11"></a>

###### Suicidal thoughts and behaviors: meta-analysis of longitudinal prediction studies

> “Results indicated that anxiety is a statistically significant, yet weak, predictor of suicide ideation (OR=1.49, 95% CI: 1.18, 1.88) and attempts (OR=1.64, 95% CI: 1.47, 1.83), but not deaths (OR=1.01, 95% CI: 0.87, 1.18).”
> “Diagnoses of GAD, specific phobia, and social anxiety disorder were also significant predictors of suicide ideation.”
> “Agoraphobia, GAD, OCD, somatic symptom disorder, and specific phobia did not reach the level of statistical significance.”
> “Of note, only 4 suicide ideation prediction cases were used to generate overall ORs for PTSD, specific phobia, and social anxiety disorder, and only 2 cases were used for GAD, thereby limiting the conclusions we can draw from this set of analyses.”

Source: [Bentley et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4771521/)

<a id="topic-2.2.1.3-12"></a>

###### Suicidal ideation by symptom severity: sponsor-funded National Health and Wellness Survey analysis

> “The analysis found that nearly half (48%) of respondents with severe GAD symptoms reported experiencing SI almost every day.”
> “Among those with GAD, 78% with moderate symptoms and 91% of those with severe symptoms reported SI within the past two weeks.”
> “The NHWS is an annual, nationally representative, online-based survey in which all data are self-reported.”
> “This analysis was funded by MindMed.”

Source: [MindMed suicidal ideation study announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/194/new-mindmed-retrospective-study-presented-at-psych-congress-2025-reveals-high-rates-of-suicidal-ideation-si-in-adults-with-generalized-anxiety-disorder-gad)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Threat-response circuitry: anxiety disorders

> “This research suggests that perturbed threat responding in anxiety disorders involves dysfunction in the circuitry that supports core psychological processes, such as attention, emotion, learning, and memory.”
> “Many brain imaging studies have examined the structure of regions that basic neuroscience implicates in threat responding, showing structural alterations in anxiety disorders within medial temporal, prefrontal cortex, and cingulate regions.”
> “With functional MRI, patients who are anxious have an altered response in temporal and prefrontal brain regions, which has also been shown in functional MRI research regarding attention.”
> “When people are exposed to stressors, such as public speaking, scary pictures, or painful stimulation, studies generally report increased stress responses in people with anxiety disorders versus controls across many measures.”
> “For peripheral measures, rarely do effect sizes exceed a Cohen’s d of 0·50, indicating that these are not useful biomarkers that currently guide diagnosis.”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

<a id="topic-2.2.1.4-2"></a>

###### Amygdala subregion connectivity and a compensatory frontoparietal network: resting-state fMRI

> “In GAD patients, BLA and CMA connectivity patterns were significantly less distinct, and increased gray matter volume was noted primarily in the CMA. Across the subregions, GAD patients had increased connectivity with a previously characterized frontoparietal executive control network and decreased connectivity with an insula- and cingulate-based salience network.”
> “In GAD, we find evidence of an intra-amygdalar abnormality and engagement of a compensatory frontoparietal executive control network, consistent with cognitive theories of GAD.”

Source: [Etkin et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12553334/)

<a id="topic-2.2.1.4-3"></a>

###### Amygdala-prefrontal connectivity and physiological arousal

> “The disrupted coordination of brain activity has been proposed as one of the core neurobiological features of GAD,”
> “Findings suggest that across adolescence and adulthood, decreased connectivity between the amygdala and PFC is associated with the diagnosis of GAD.”
> “In general, the psychophysiological literature demonstrates that individuals with GAD are in a more physiologically dysregulated state (e.g., low HRV, high heart rate, higher skin conductance levels) at baseline relative to controls”
> “Yet, this hyperarousal psychophysiological pattern in GAD is not universally observed.”

Source: [Patriquin and Mathew (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5832062/)

<a id="topic-2.2.1.4-4"></a>

###### Task-based affective neuroimaging: variable limbic and prefrontal findings

> “Studies provide evidence for variable presence and directionality of BOLD abnormalities in limbic and prefrontal regions during reactivity to, regulation of, and learning from emotional cues.”
> “We propose that the cardinal symptom of GAD—worry—predominantly reflects stimulus-independent mental processes that impose abnormal, inflexible functional brain configurations, ie, the overall pattern of information transfer among behaviorally relevant neural circuits at a given point in time.”

Source: [Fonzo and Etkin (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5573561/)

<a id="topic-2.2.1.4-5"></a>

###### Brain structure: ENIGMA-Anxiety mega-analysis, 28 sites

> “The main analysis (1020 individuals with GAD and 2999 healthy controls) included random slopes per site and random intercepts per scanner.”
> “The main analysis showed no effect of GAD on brain structure, nor interactions involving GAD, age, or sex.”

Source: [Harrewijn et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8486763/)

<a id="topic-2.2.1.4-6"></a>

###### Emotional hyperreactivity and worry: Contrast Avoidance model

> “A synthesis of these data points to a central role of emotional hyperreactivity, sensitivity to contrasting emotions, and dysfunctional attempts to cope with strong emotional shifts via worry. Consistent with the Contrast Avoidance model, evidence shows that worry evokes and sustains negative affect, thereby precluding sharp increases in negative emotion.”
> “Consistent with this vulnerability, functional magnetic resonance imaging studies of GAD cumulatively suggest hyperresponsivity of the amygdala, the limbic structure that mediates negatively valenced affective reactions, and fear in particular (Schienle et al. 2011).”

Source: [Newman et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4964851/)

<a id="topic-2.2.1.4-7"></a>

###### Neurotransmitter systems: serotonergic and noradrenergic activity

> “The exact mechanism underlying generalized anxiety disorder remains unclear.”
> “Noradrenergic, serotonergic, and other neurotransmitter systems appear to play a role in the body's response to stress. The serotonin and noradrenergic systems are common pathways involved in anxiety. Reduced serotonergic activity and increased noradrenergic activity may contribute to the development of generalized anxiety disorder.”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

<a id="topic-2.2.1.4-8"></a>

###### Serotonin receptor subtypes: 5-HT1A and 5-HT2A signaling in anxiety

> “Like impulsivity and aggression, anxiety appears to be negatively modulated by 5-HT1AR stimulation”
> “The serotonin 2A receptor has also been implicated in anxiety. Serotonin 2A receptor knock-out mice display reduced anxiety which is normalised when its functioning is recovered (Weisstaub et al., 2006). These findings suggest that 5-HT2AR signalling has an anxiogenic effect that is opposite to the anxiolytic effect of postsynaptic 5-HT1AR activation.”
> “Thus, whereas postsynaptic 5-HT1AR activation appears to moderate anxiety and stress, the effect of 5-HT2AR activation is more complex (Carhart-Harris et al., 2016c).”

Source: [Carhart-Harris and Nutt (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5606297/)

<a id="topic-2.2.1.4-9"></a>

###### Serotonin 2A receptor binding and trait anxiety: PET in healthy volunteers

> “Neuroticism correlated positively with frontolimbic serotonin 2A receptor binding [r(79) = .24, p = .028]. Post hoc analysis of the contributions from the six constituent traits of neuroticism showed that the correlation was primarily driven by two of them: vulnerability and anxiety.”

Source: [Frokjaer et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/17884017/)

<a id="topic-2.2.1.4-10"></a>

###### GABAergic signaling: genetic risk for major anxiety disorders

> “Follow-up analyses demonstrated enrichment in all major brain regions and highlighted GABAergic signaling as one potential mechanism implicated in ANX genetic risk.”

Source: [Strom et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12900644/)

<a id="topic-2.2.1.4-11"></a>

###### Inflammation: peripheral inflammatory markers

> “CRP was significantly higher in people with GAD compared with controls, with a small effect size (Cohen’s d=0.38, 0.06–0.69), comparable with that reported in schizophrenia.”
> “There is preliminary evidence to suggest an inflammatory response in GAD, but it remains unclear whether inflammatory cytokines play a role in the aetiology.”

Source: [Costello et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6661660/)

<a id="topic-2.2.1.4-12"></a>

###### Sponsor statement on brain circuitry in generalized anxiety disorder

> “GAD involves disrupted activity, connectivity, or neuroplasticity in key regions of the brain such as the prefrontal cortex, amygdala, and thalamus, leading to impaired emotional regulation and clinical symptoms.”

Source: [Definium Therapeutics GAD fact sheet (2026)](https://definiumtx.com/wp-content/uploads/2026/07/DFTX-FactSheet-GAD-072326.pdf)

> “Wired for Worry is designed to meet a critical need to broaden understanding of GAD through evidence-based education, including how it may result from dysregulated brain circuitry that contributes to chronic symptoms and functional impairment.”

Source: [Definium Therapeutics Wired for Worry announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/238/definium-therapeutics-launches-wired-for-worry-a-health-care-provider-initiative-to-advance-the-understanding-of-generalized-anxiety-disorder-gad-patient-impact-and-neurobiology)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### DSM-5 diagnostic criteria for generalized anxiety disorder

| Criterion | Quoted text |
| --- | --- |
| A: excessive anxiety and worry | “Excessive anxiety and worry (apprehensive expectation), occurring more days than not for at least 6 months, about a number of events or activities (such as work or school performance).” |
| B: difficulty controlling worry | “The individual finds it difficult to control the worry.” |
| C: associated symptoms | “The anxiety and worry are associated with three (or more) of the following six symptoms (with at least some symptoms having been present for more days than not for the past 6 months):” |
| C1 | “Restlessness or feeling keyed up or on edge.” |
| C2 | “Being easily fatigued.” |
| C3 | “Difficulty concentrating or mind going blank.” |
| C4 | “Irritability.” |
| C5 | “Muscle tension.” |
| C6 | “Sleep disturbance (difficulty falling or staying asleep, or restless, unsatisfying sleep).” |
| D: distress or impairment | “The anxiety, worry, or physical symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.” |
| E: substance and medical exclusion | “The disturbance is not attributable to the physiological effects of a substance (e.g., a drug of abuse, a medication) or another medical condition (e.g., hyperthyroidism).” |
| F: other mental disorder exclusion | “The disturbance is not better explained by another mental disorder” |

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

<a id="topic-2.2.1.5-2"></a>

###### Clinical diagnosis without a biomarker

> “Because no blood, genetic, or imaging biomarkers exist, diagnosis rests on mental-state history and examinations, which should therefore be sufficiently monitored by every primary care practitioner.”
> “Categorical diagnostic criteria are clinically useful, but boundaries between anxiety disorders and normative anxiety are often ill-defined. Recognition of distinctions requires clinical judgement of severity, duration, persistence, and, importantly, degree of distress and impairment.”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

<a id="topic-2.2.1.5-3"></a>

###### Structured interviews and rating scales

> “Validated, structured, or semi-structured clinical interviews, such as the DSM-5-based or ICD-11-based composite international diagnostic interview9 or structured clinical interview for DSM disorders,10 can assist in correct diagnostics.”
> “To determine the severity of anxiety disorders and monitor treatment, continuous clinician-rated scales include, for example, the Hamilton Anxiety Scale.”
> “Standardised diagnostics and assessments for outcome monitoring are part of evidence-based care, could prevent underdiagnosis, and lead to effective treatments. However, these diagnostics and assessments are still not widely used in clinical practice.”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

> “Numerous scales have been developed to assess symptom severity and support diagnosis. The Generalized Anxiety Disorder 7-item scale (GAD-7) has been validated as a diagnostic and severity assessment tool.”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

<a id="topic-2.2.1.5-4"></a>

###### Identification and assessment: NICE clinical guideline CG113

> “Be alert to possible anxiety disorders (particularly in people with a past history of an anxiety disorder, possible somatic symptoms of an anxiety disorder or in those who have experienced a recent traumatic event). Consider asking the person about their feelings of anxiety and their ability to stop or control worry, using the 2-item Generalized Anxiety Disorder scale (GAD-2).”
> “Consider the diagnosis of GAD in people presenting with anxiety or significant worry, and in people who attend primary care frequently who:”
> “For people who may have GAD, conduct a comprehensive assessment that does not rely solely on the number, severity and duration of symptoms, but also considers the degree of distress and functional impairment.”
> “For people with GAD and a comorbid depressive or other anxiety disorder, treat the primary disorder first (that is, the 1 that is more severe and in which it is more likely that treatment will improve overall functioning).”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.1.5-5"></a>

###### Exclusion of medical causes and differential diagnosis

> “Initial assessment begins with evaluation of behavioral or somatic symptoms.”
> “The medical history should include previous trauma, psychiatric conditions, and substance use disorder.”
> “The following tests may be obtained to exclude medical causes: Thyroid function tests Blood glucose level Echocardiography Toxicology screen”
> “The differential diagnoses for generalized anxiety disorder include the following: Hyperthyroidism Pheochromocytoma Chronic obstructive pulmonary disease Transient ischemic attack Epilepsy Bipolar disorder Use of caffeine, decongestants, and albuterol”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

> “The symptoms of GAD and PD can suggest medical diagnoses, including hyperthyroidism, arrhythmias, asthma, chronic obstructive pulmonary disease, certain medication use or withdrawal (e.g., albuterol, levothyroxine, decongestants, antidepressants, antianxiety medications), and substance use or withdrawal (e.g., caffeine, alcohol, cocaine, amphetamines, cannabinoids).”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

> “For any patient presenting with increased pathological anxiety, a thorough psychiatric and somatic evaluation should consider whether symptoms reflect other health conditions or effects of substance or medication use.”
> “Laboratory assessment of plasma thyroid-stimulating hormone”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

<a id="topic-2.2.1.5-6"></a>

###### Screening of adults: USPSTF recommendation, June 2023

> “Adults 64 years or younger, including pregnant and postpartum persons: Screen for anxiety. Grade: B”
> “The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for anxiety disorders in older adults.”
> “Anxiety screening tools alone are insufficient to diagnose anxiety disorders. If a screening test result is positive for an anxiety disorder, a confirmatory diagnostic assessment is needed.”
> “The USPSTF found no evidence on the optimal frequency of screening for anxiety disorders.”

Source: [USPSTF anxiety screening recommendation (2023)](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/anxiety-adults-screening)

<a id="topic-2.2.1.5-7"></a>

###### Screening of adults: AFP review statement, August 2022, before the USPSTF recommendation of June 2023

> “There is insufficient evidence to support universal screening for GAD or PD in adults at this time; however, the U.S. Preventive Services Task Force is updating guidelines regarding screening for anxiety, suicidality, and depression.”
> “Evaluation for GAD should be considered for patients who express anxiety, pervasive worry, or recurrent somatic symptoms not related to an underlying physical condition.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

<a id="topic-2.2.1.5-8"></a>

###### Accuracy of the GAD-7 and GAD-2 screening instruments

> “A criterion-standard study was performed in 15 primary care clinics in the United States from November 2004 through June 2005.”
> “A cut point was identified that optimized sensitivity (89%) and specificity (82%).”

Source: [Spitzer et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16717171/)

> “A total of 12 samples were identified involving 5223 participants; 11 samples provided data on the accuracy of the GAD-7 for identifying generalized anxiety disorder (GAD).”
> “Pooled sensitivity and specificity values appeared acceptable at a cutoff point of 8 [sensitivity: 0.83 (95% CI 0.71-0.91), specificity: 0.84 (95% CI 0.70-0.92)] although cutoff scores 7-10 also had similar pooled estimates of sensitivity/specificity.”
> “Pooled sensitivity and specificity values appeared acceptable at a cutoff of 3 [sensitivity: 0.76 (95% CI 0.55-0.89), specificity: 0.81 (95% CI 0.60-0.92)].”

Source: [Plummer et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26719105/)

> “At a cutoff of 10 or greater, the pooled sensitivity to detect generalized anxiety disorder was 0.79 (95% CI, 0.65-0.94; I2 = 77.3%) and the pooled specificity was 0.89 (95% CI, 0.83-0.94; I2 = 94.8%).”
> “At lower cutoffs (≥8; ≥9), sensitivity increased and specificity decreased. In general, the GAD-7 performed as well or better than the GAD-2.”

Source: [USPSTF anxiety screening recommendation (2023)](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/anxiety-adults-screening)

> “Brief screening measures applied in primary care, such as the Generalized Anxiety Disorder-7, can aid in diagnosis of anxiety disorders (sensitivity, 57.6% to 93.9%; specificity, 61% to 97%).”

Source: [Szuhany and Simon (2022)](https://pubmed.ncbi.nlm.nih.gov/36573969/)

<a id="topic-2.2.1.5-9"></a>

###### Detection and treatment gaps in primary care

> “Of the 965 patients, 19.5% (95% CI, 17.0% to 22.1%) had at least 1 anxiety disorder, 8.6% (CI, 6.9% to 10.6%) had posttraumatic stress disorder, 7.6% (CI, 5.9% to 9.4%) had a generalized anxiety disorder”
> “Many patients (41%) with an anxiety disorder reported no current treatment.”
> “Receiver-operating characteristic curve analysis showed that both the GAD-7 scale and its 2 core items (GAD-2) performed well (area under the curve, 0.80 to 0.91) as screening tools for all 4 anxiety disorders.”

Source: [Kroenke et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17339617/)

> “Anxiety disorders are often unrecognized in primary care settings and years-long delays in treatment initiation occur.”

Source: [USPSTF anxiety screening recommendation (2023)](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/anxiety-adults-screening)

> “Monitoring is particularly important because patients who have anxiety disorders often present symptoms other than clear anxiety symptoms”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

Additional sources: [Stein and Sareen (2015)](https://pubmed.ncbi.nlm.nih.gov/26580998/); [Hamilton (1959)](https://pubmed.ncbi.nlm.nih.gov/13638508/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Cognitive symptoms: excessive, uncontrollable worry

> “The disorder is characterized by persistent, excessive, and unrealistic worry about everyday concerns. Worry may involve multiple areas, including finances, family, health, and the future. Excessive worry is difficult to control and is often accompanied by nonspecific psychological and physical symptoms. Excessive worry is the central feature of generalized anxiety disorder.”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

> “Clinically, GAD most commonly presents as excessive worry about minor issues, often manifesting with somatic symptoms and pathologic behavioral changes.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

> “Marked, uncontrollable, and anxious worry and fears about everyday events and problems”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

<a id="topic-2.2.1.6-2"></a>

###### Psychological symptoms: restlessness, irritability, and difficulty concentrating

> “Restlessness or feeling keyed up or on edge.”
> “Difficulty concentrating or mind going blank.”
> “Irritability.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

> “Patients may also describe psychological symptoms, such as excessive nonspecific anxiety and worry, emotional lability, difficulty concentrating, and insomnia.”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

> “Anxiety disorders are characterized by disproportionate and constant fear over everyday events accompanied by behavioral and somatic complaints (eg, restlessness, fatigue, problems concentrating, irritability, or sleep problems).”

Source: [USPSTF anxiety screening recommendation (2023)](https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/anxiety-adults-screening)

<a id="topic-2.2.1.6-3"></a>

###### Somatic symptoms: muscle tension, fatigue, and autonomic complaints

> “Being easily fatigued.”
> “Muscle tension.”
> “Patients with anxiety disorders are more likely than those unaffected to also have other chronic medical problems and are twice as likely to present with somatic symptoms.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

> “Patients with anxiety can pose a diagnostic challenge because somatic symptoms are more common than psychological symptoms. Most patients present with vague or nonspecific somatic concerns, including shortness of breath, palpitations, fatigue, headache, dizziness, and restlessness.”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

> “Restlessness, fatigue, irritability, difficulty concentrating, muscle tension, sleep disturbance, or autonomic arousal”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

> “Anxiety disorders are associated with physical symptoms, such as palpitations, shortness of breath, and dizziness.”

Source: [Szuhany and Simon (2022)](https://pubmed.ncbi.nlm.nih.gov/36573969/)

<a id="topic-2.2.1.6-4"></a>

###### Sleep symptoms: difficulty falling or staying asleep, or restless sleep

> “Sleep disturbance (difficulty falling or staying asleep, or restless, unsatisfying sleep).”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

> “Complications of generalized anxiety disorder can also lead to, or worsen, other mental and physical conditions, including:”
> “Insomnia”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

<a id="topic-2.2.1.6-5"></a>

###### Functional impairment: social, occupational, and role functioning

> “The anxiety, worry, or physical symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

> “Respondents with 12-month GAD reported a mean (SE) of 41.2 days (2.4) out of role due to GAD in the past year. Half (50.6%) of the 12-month cases reported severe functional impairment resulting from GAD”
> “The rate of severe impairment was lower yet still substantial (35.3%) among individuals with GAD who had no comorbid disorders”
> “Respondents rated the extent of interference with home management, work, close relationships, and social life on separate 0-to-10 scales.”

Source: [Ruscio et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5594751/)

> “Increasing scores on the scale were strongly associated with multiple domains of functional impairment (all 6 Medical Outcomes Study Short-Form General Health Survey scales and disability days).”
> “Moreover, GAD and depression symptoms had differing but independent effects on functional impairment and disability.”

Source: [Spitzer et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16717171/)

> “Disability and impairment in pure GAD were equivalent to pure mood disorders, but significantly greater than in pure substance use, and other anxiety and personality disorders.”

Source: [Grant et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16202187/)

| Generalized anxiety disorder, 12-month cases (NCS-R) | Quoted value, % (se) |
| --- | --- |
| Twelve-month prevalence | “3.1 (0.2)” |
| Serious | “32.3 (2.9)” |
| Moderate | “44.6 (4.0)” |
| Mild | “23.1 (2.9)” |

Source: [Kessler et al. (2005b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2847357/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Psychiatric comorbidity: World Mental Health Surveys

> “Lifetime comorbidity is high (81.9% [0.7%]), particularly with mood (63.0% [0.9%]) and other anxiety (51.7% [0.9%]) disorders.”
> “The single most common comorbid condition was major depressive disorder, which was found in 52.6%(0.9%) of lifetime cases and 40.9%(1.3%) of 12-month cases of GAD worldwide.”

Source: [Ruscio et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5594751/)

<a id="topic-2.2.1.7-2"></a>

###### Major depressive episode: onset after generalized anxiety disorder in the National Comorbidity Survey follow-up

> “Data were analyzed from the nationally representative two-wave panel sample of 5001 respondents who participated in the 1990-2 National Comorbidity Survey (NCS) and the 2001-03 NCS follow-up survey.”
> “Baseline MDE significantly predicted subsequent GAD onset but not persistence. Baseline GAD significantly predicted subsequent MDE onset and persistence.”
> “The associations of each disorder with the subsequent onset of the other attenuated with time since onset of the temporally primary disorder, but remained significant for over a decade after this onset.”
> “The OR of temporally primary MDE predicting subsequent first onset of GAD is 2.7 (Table 1, Part I). The OR of temporally primary GAD predicting subsequent first onset of MDE is 3.2 (Table 1, Part II).”

Source: [Kessler et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2745899/)

<a id="topic-2.2.1.7-3"></a>

###### Substance use, mood, anxiety, and personality disorders: National Epidemiologic Survey on Alcohol and Related Conditions

> “GAD was highly co-morbid with substance use, and other anxiety, mood, and personality disorders. Co-morbidity in GAD was not substantially greater than for most other Axis I and II disorders.”
> “Individuals co-morbid for GAD and each mood disorder were more disabled than those with pure forms of GAD or each mood disorder.”

Source: [Grant et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/16202187/)

<a id="topic-2.2.1.7-4"></a>

###### Comorbidity and the course of anxiety disorders

> “Symptoms are generally not pathognomonic of individual anxiety disorders, and anxiety disorder comorbidity is substantial: 48–68% of adults with one anxiety disorder fulfil the criteria for another concurrent anxiety disorder.”
> “people with multiple disorders have higher severity, disability, and a poorer disease course compared with people who have a single anxiety disorder.”
> “Anxiety and depression comorbidity signifies higher disorder severity, burden, and chronicity compared with individual disorders.”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

> “The overall clinical course was worsened by several comorbid psychiatric conditions, including major depression and alcohol and other substance use disorders, and by comorbidity of generalized anxiety disorder and panic disorder with agoraphobia.”
> “Among patients with generalized anxiety disorder, those with comorbid panic disorder with agoraphobia had a significantly lower likelihood of recovering from generalized anxiety disorder, compared to those without comorbid panic disorder with agoraphobia (risk ratio=0.67, p<0.05).”

Source: [Bruce et al. (2005)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3272761/)

<a id="topic-2.2.1.7-5"></a>

###### Cardiovascular disease: incident disease in meta-analyses of population cohorts

> “The meta-analysis comprised 37 papers (n = 1 565 699). The follow-up ranged from 1 to 24 years. Anxiety was associated with a 52% increased incidence of CVD (hazard ratio = 1.52, 95% CI 1.36-1.71). The risk seemed independent of traditional risk factors and depression.”

Source: [Batelaan et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26932485/)

> “Twenty studies reporting on incident CHD comprised 249,846 persons with a mean follow-up period of 11.2 years. Anxious persons were at risk of CHD (hazard ratio [HR] random: 1.26; 95% confidence interval [CI]: 1.15 to 1.38; p < 0.0001) and cardiac death (HR: 1.48; 95% CI: 1.14 to 1.92; p = 0.003), independent of demographic variables, biological risk factors, and health behaviors.”

Source: [Roest et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20620715/)

<a id="topic-2.2.1.7-6"></a>

###### Cardiovascular events in stable coronary heart disease: Heart and Soul Study

> “One thousand fifteen outpatients with stable CHD followed up for a mean (SD) of 5.6 (1.8) years.”
> “The age-adjusted annual rate of cardiovascular events was 9.6% in the 106 participants with GAD and 6.6% in the 909 participants without GAD (P = .03).”
> “After adjustment for demographic characteristics, comorbid conditions (including major depressive disorder), cardiac disease severity, and medication use, GAD remained associated with a 62% higher rate of cardiovascular events (hazard ratio, 1.62; 95% confidence interval, 1.11-2.37; P = .01).”

Source: [Martens et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20603456/)

<a id="topic-2.2.1.7-7"></a>

###### Other somatic conditions

> “with emerging evidence of increased onset risk of other somatic conditions, including stroke, diabetes, arthritis, and lung disease than in the general population.”
> “Patients with diverse somatic illnesses, including cardiovascular, respiratory, or musculoskeletal disease, have an increased risk of comorbid anxiety.”

Source: [Penninx et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9248771/)

<a id="topic-2.2.1.7-8"></a>

###### Complications listed in a clinical review

> “Complications of generalized anxiety disorder can also lead to, or worsen, other mental and physical conditions, including:”
> “Depression (often presents concomitantly with an anxiety disorder)”
> “Drug or alcohol use disorder”
> “Gastrointestinal tract problems”
> “Social isolation”
> “Issues functioning at work or school”
> “Untreated anxiety disorders may contribute to severe depression and alcohol or other substance use disorders.”

Source: [Munir and Takov (2022)](https://www.ncbi.nlm.nih.gov/books/NBK441870/)

<a id="topic-2.2.1.7-9"></a>

###### Multimorbidity and depressive symptoms by symptom severity: sponsor-funded National Health and Wellness Survey analyses

> “Of 43,472 adults included in analyses, 88.8%, 2.2%, 3.5%, 2.8%, and 2.7% were classified as control, GAD with no/minimal, mild, moderate, and severe subgroups, respectively.”
> “While almost 50% of the control group reported no comorbidities, 1.1% of the severe cohort had no comorbidities. 56% and 63% individuals with moderate and severe GAD reported having 4 or more comorbidities, compared to 10% in the control group.”
> “The mild cohort had an adjusted mean of 2.7 times more comorbidities compared to the control group, 3.0 times in moderate and 3.3 times in severe GAD.”
> “Name of Sponsoring Organization(s): MindMed”

Source: [Ferries et al. (2025)](https://www.hmpgloballearningnetwork.com/node/371502)

> “The study also revealed that 65% of those reporting GAD symptoms also reported major depressive disorder (MDD) symptoms.”

Source: [MindMed suicidal ideation study announcement (2025)](https://ir.definiumtx.com/news-events/press-releases/detail/194/new-mindmed-retrospective-study-presented-at-psych-congress-2025-reveals-high-rates-of-suicidal-ideation-si-in-adults-with-generalized-anxiety-disorder-gad)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Generalized anxiety disorder

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Health-related quality of life by GAD symptom severity: 2022 US National Health and Wellness Survey

> “This cross-sectional study analyzed data from the 2022 US National Health and Wellness Survey, a nationally-representative, online-based survey.”
> “Adjusted EQ-5D index scores were significantly lower among mild (0.80, 95% confidence interval [CI]: 0.79-0.81), moderate (0.75, 95%CI: 0.74-0.76), and severe GAD (0.66, 95%CI: 0.65-0.67) than controls (0.84, 95%CI: 0.84-0.84), with scores decreasing as severity worsened.”
> “Compared with controls (45.3, 95%CI: 45.2-45.4), adjusted GHC scores were significantly lower among mild (41.5, 95%CI: 41.0-42.0), moderate (38.3, 95%CI: 37.8-38.9), and severe GAD (35.0, 95%CI: 34.4-35.6), with scores decreasing as severity worsened, and significantly higher among diagnosed patients with no GAD symptoms (46.8, 95%CI: 46.1-47.4).”
> “A similar trend was observed for MHC and PHC scores, but the magnitude of difference for PHC was smaller, suggesting a greater impact of GAD symptom severity on mental health functioning than physical health functioning.”

Source: [Duong et al. (2024a)](https://www.ispor.org/heor-resources/presentations-database/presentation/intl2024-3895/137867)

<a id="topic-2.2.1.8.1-2"></a>

###### Health-related quality of life in likely undiagnosed and diagnosed GAD: 2022 US National Health and Wellness Survey

> “A retrospective, cross-sectional observational study was conducted using data from the 2022 US National Health and Wellness Survey (N = 75,261 adults).”
> “Adults with likely GAD experienced significantly lower HRQoL, greater work productivity loss, activity impairment, emergency room visits, hospitalizations, and healthcare costs (both direct and indirect), than those with diagnosed GAD.”
> “Adults with GAD-whether likely and undiagnosed or diagnosed-had significantly lower HRQoL and higher work productivity loss, activity impairment, healthcare resource use, and healthcare costs than those without GAD.”

Source: [Duong et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41519172/)

<a id="topic-2.2.1.8.1-3"></a>

###### Degree of impairment among U.S. adults with past-year GAD

> “Of adults with generalized anxiety disorder in the past year, degree of impairment ranged from mild to serious, as shown in Figure 2. Impairment was determined by scores on the Sheehan Disability Scale.”
> “An estimated 32.3% had serious impairment, 44.6% had moderate impairment, and 23.1% had mild impairment.”

Source: [National Institute of Mental Health generalized anxiety disorder statistics](https://www.nimh.nih.gov/health/statistics/generalized-anxiety-disorder)

<a id="topic-2.2.1.8.1-4"></a>

###### Functional impairment and health-related quality of life: systematic review of studies in North America and Europe

> “GAD was associated with increased impairments in psychosocial functioning, role functioning, work productivity and health-related quality of life (HRQL).”
> “The HRQL impairments were comparable with those associated with depression or panic disorder.”
> “Patients with GAD and co-morbid depression reported significantly greater impairment in HRQL than did those with either disorder alone.”

Source: [Revicki et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22154706/)

<a id="topic-2.2.1.8.1-5"></a>

###### Role functioning and quality of life compared with other mental disorders: review of 34 studies

> “A review of 34 studies reporting original quantitative data on associations between GAD and role functioning, QOL, and/or economic costs was undertaken.”
> “Large representative studies showed that role impairments of pure GAD were similar in magnitude to those of pure MDD.”
> “Studies of DSM-IV disorders showed that QOL impairments of GAD were at least comparable in magnitude to those of MDD; studies of DSM-III-R disorders showed the opposite pattern.”

Source: [Hoffman et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/17146763/)

<a id="topic-2.2.1.8.1-6"></a>

###### Quality of life in anxiety disorders compared with nonclinical controls: meta-analysis

> “Thirty-two patient samples from 23 separate studies (N=2892) were included in the analysis. The results yielded a large effect size indicating poorer quality of life among anxiety disorder patients vs. controls and this effect was observed across all anxiety disorders.”
> “QOL domains of mental health and social functioning were associated with the highest levels of impairment among anxiety disorder patients.”

Source: [Olatunji et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17343963/)

<a id="topic-2.2.1.8.1-7"></a>

###### Impairment in U.S. primary care patients with anxiety disorders

> “Of the 965 patients, 19.5% (95% CI, 17.0% to 22.1%) had at least 1 anxiety disorder, 8.6% (CI, 6.9% to 10.6%) had posttraumatic stress disorder, 7.6% (CI, 5.9% to 9.4%) had a generalized anxiety disorder, 6.8% (CI, 5.3% to 8.6%) had a panic disorder, and 6.2% (CI, 4.7% to 7.9%) had a social anxiety disorder.”
> “Each disorder was associated with substantial impairment that increased significantly (P < 0.001) as the number of anxiety disorders increased.”
> “Many patients (41%) with an anxiety disorder reported no current treatment.”

Source: [Kroenke et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17339617/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Direct and indirect costs: 2022 US National Health and Wellness Survey, sponsor-funded

> “This cross-sectional study analyzed data from the 2022 US National Health and Wellness Survey (N=75,261), an online self-report survey of adults (aged ≥18) that is representative of US Census on age, sex, and race/ethnicity.”
> “Direct medical costs were calculated using 2021 Medical Expenditure Panel data for outpatient visits, hospitalizations, and emergency department visits. Indirect costs were estimated using the human capital approach.”
> “The adjusted total direct and indirect costs were $9,190 and $6,532, respectively, among no-GAD. Compared with no-GAD, the adjusted total direct costs were 1.27 and 1.96 times higher for diagnosed ($11,711) and undiagnosed GAD ($18,045), respectively (both, p<0.01); and the adjusted total indirect costs were 1.15 and 1.20 times higher for diagnosed ($7,507) and undiagnosed GAD ($7,805), respectively (both, p<0.01).”

Source: [Duong et al. (2024e)](https://www.ispor.org/heor-resources/presentations-database/presentation/euro2024-4015/143843)

<a id="topic-2.2.1.8.2-2"></a>

###### Healthcare resource use, adjusted: 2022 US National Health and Wellness Survey, sponsor-funded

> “Outcomes included health care provider (HCP) visits, emergency room (ER) visits, and hospitalizations within the past 6 months.”
> “Diagnosed GAD had an adjusted average of 3.1 HCP visits, 0.31 ER visits, and 0.19 hospitalizations within the past 6 months.”
> “Compared with diagnosed GAD, undiagnosed GAD had significantly lower rates of HCP visits (IDR: 0.71, 95%CI: 0.66-0.77). However, undiagnosed GAD was 1.64 times more likely to have an ER visit (95%CI: 1.42-1.90) and 1.95 times more likely to have a hospitalization (95%CI: 1.59-2.40) than diagnosed GAD, suggesting significantly greater HCRU among the undiagnosed group.”
> “No-GAD had significantly lower rates of HCP (IDR: 0.64, 95%CI: 0.59-0.68) and ER (IDR: 0.84, 95%CI: 0.73-0.96) visits and similar hospitalization rates (IDR: 0.97, 95%CI: 0.80-1.19) than diagnosed GAD.”

Source: [Duong et al. (2024b)](https://www.ispor.org/heor-resources/presentations-database/presentation/intl2024-3895/138043)

<a id="topic-2.2.1.8.2-3"></a>

###### Healthcare resource use, unadjusted, and payer survey: 2022 US National Health and Wellness Survey, sponsor-funded

> “Supported by funding from MindMed, Inc.”
> “Diagnosed GAD (n=5,526) was defined as reporting either (1) experiencing anxiety symptoms and currently diagnosed with GAD, (2) screened positive with GAD (GAD-7 score ≥10), or (3) previously diagnosed with GAD and using treatment/therapy for GAD.”
> “Similarly, undiagnosed GAD participants had a greater mean number of ER visits (1.3 vs 0.5) and hospitalizations (1.2 vs 0.3) but fewer HCP visits (3.0 vs 8.7; all, p<0.001) in the past 6 months than diagnosed GAD participants”
> “The survey was distributed to a group of payers (n=20) comprised of large national payers (n=7), pharmacy benefit managers (PBM) (n=5), and regional payers (n=8) covering 130.3 million lives.”
> “60% disagreed that GAD is burdensome to employers, and 40% believed that GAD did not present a significant budgetary concern to their payer plan”
> “70% of payers believe the number of diagnosed individuals with GAD seeking reimbursement for treatment will increase in the next 3 years”

Source: [Duong et al. (2024d)](https://d1io3yog0oux5.cloudfront.net/_1e86c849bdc3b52ea5177f8157ee1069/mindmed/db/2265/21481/pdf/MNMD+AMCP+Nexus+2024+Poster.pdf)

<a id="topic-2.2.1.8.2-4"></a>

###### Work productivity and activity impairment: 2022 US National Health and Wellness Survey, sponsor-funded

> “Compared with controls (8.0%, 95% confidence interval [CI]: 7.6%-8.4%), participants with severe GAD had significantly higher absenteeism (11.4%, 95%CI: 8.4%-15.5%).”
> “The severe GAD group reported the highest presenteeism (26.3%, 95%CI: 22.5%-30.7%), overall, followed by the moderate (24.1%, 95%CI: 20.8%-27.8%) and mild (22.6%, 95%CI: 20.1%-25.6%) groups, and controls had significantly lower presenteeism than the other groups (19.3%, 95%CI: 18.8%-19.7%).”
> “Similar trends by GAD symptom severity were observed for overall work productivity loss and activity impairment.”

Source: [Duong et al. (2024c)](https://www.ispor.org/heor-resources/presentations-database/presentation/intl2024-3900/137986)

<a id="topic-2.2.1.8.2-5"></a>

###### Healthcare resource use with and without co-occurring major depressive disorder: U.S. claims 2022 to 2024, sponsor-authored

> “This retrospective analysis used US claims (Komodo; 2022-2024).”
> “The index date was the first GAD or MDD encounter in 2024, and HCRU was assessed 12 months post-index, including the mean number of encounters per patient among those with ≥1 visit.”
> “Cohorts included GAD (n=991,306), MDD (n=1,436,078), and GAD+MDD (n=927,476).”
> “Medicare coverage was most common in MDD (47%), whereas commercial insurance predominated in GAD (60%).”
> “Patients with GAD+MDD had the highest overall healthcare utilization across all settings, including outpatient visits (11.8 vs 8.4 and 9.0), office visits (19.6 vs 15.1 and 15.0), emergency department visits (2.6 vs 2.1 and 2.1), and inpatient visits (3.4 vs 2.6 and 2.4) compared with GAD and MDD, respectively.”

Source: [Louie (2026)](https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-europe-2026/poster-session-1-5/healthcare-resource-utilization-in-patients-with-co-occurring-generalized-anxiety-disorder-and-major-depressive-disorder-a-real-world-claims-analysis)

<a id="topic-2.2.1.8.2-6"></a>

###### U.S. health care spending on anxiety disorders, 2016

| Measure | Anxiety disorders |
| --- | --- |
| Spending rank among 154 health conditions | “21” |
| Health care spending, 2016 $Billion (95% CI) | “42.4 (37.8-47.7)” |
| Age 20 to 64 years, % of spending | “75.3” |
| Public insurance, % of spending | “49.6” |
| Private insurance, % of spending | “41.2” |
| Out-of-pocket payments, % of spending | “9.2” |
| Ambulatory care, % of spending | “55.7” |
| Inpatient care, % of spending | “7.0” |
| Prescribed pharmaceuticals, % of spending | “21.3” |

Source: [Dieleman et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7054840/)

<a id="topic-2.2.1.8.2-7"></a>

###### Incremental direct medical expenditures for anxiety disorders: Medical Expenditure Panel Survey 2009 and 2010

> “Data from the 2009 and 2010 Medical Expenditure Panel Survey (MEPS) were used to estimate the annual incremental healthcare expenditures associated with anxiety disorders, for the ambulatory adult population of the U.S.”
> “The annual overall healthcare expenditure associated with anxiety disorders was estimated at $1657.52 per person (SE: $238.83; p<0.001).”
> “Inpatient visits, prescription medications, and office-based visits together accounted for almost 93% of the overall cost.”
> “Given the prevalence of self-reported anxiety disorders in MEPS, their total direct medical expenditure is estimated at approximately $33.71 billion in 2013 US dollars”

Source: [Shirneshan et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24135257/)

<a id="topic-2.2.1.8.2-8"></a>

###### Out-of-pocket costs for anxiety disorders by insurance type: Medical Expenditure Panel Survey 2011 to 2014

> “Using weighted nationally representative data from the 2011-2014 Medical Expenditure Panel Surveys, total OOP health care costs were assessed for all respondents who indicated that they had an anxiety disorder (N = 9985).”
> “Average annual OOP costs among individuals with anxiety was $1152.”
> “The highest OOP cost were incurred by individuals with private fee-for-service (FFS) insurance ($1356/year, 4.1% of annual income), while individuals enrolled in HMOs with dual Medicare/Medicaid had the lowest OOP cost ($129/year, 6.8% of annual income).”
> “Individuals without insurance had high OOP cost burden ($1309/year, 12.5% of annual income).”

Source: [Tucker et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29935451/)

<a id="topic-2.2.1.8.2-9"></a>

###### Healthcare costs before and after starting pharmacotherapy for GAD: U.S. claims 2003 to 2007

> “Using a large US health insurance database, we identified all patients with evidence of GAD (ICD-9-CM diagnosis code 300.02) who initiated pharmacotherapy with medications commonly used to treat GAD (eg, selective serotonin reuptake inhibitors [SSRIs], venlafaxine, benzodiazepines) between 1/1/2003 and 12/31/2007.”
> “A total of 10,275 patients met all study inclusion criteria.”
> “Mean (SD) total healthcare costs increased from $4812 ($10,006) during pretreatment to $7182 ($22,041) during follow-up (p < 0.01); costs of GAD-related pharmacotherapy during follow-up were $420 ($485).”

Source: [Berger et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3266199/)

<a id="topic-2.2.1.8.2-10"></a>

###### Medical costs of GAD in primary care: systematic review

> “GAD patients had significantly higher median medical costs than primary care patients without GAD (US $2375 versus $1448).”
> “The mean annual medical cost of GAD was $2138 higher than for other anxiety disorders (mean $6475).”
> “GAD is associated with significant burden on patient functioning and well-being, leading to increased health care utilization and medical costs.”

Source: [Revicki et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22154706/)

<a id="topic-2.2.1.8.2-11"></a>

###### Cost-of-illness studies of anxiety disorders: systematic review and meta-analysis

> “We identified 13 top-down and 11 bottom-up COI studies.”
> “In top-down COI studies, direct costs of AD, on average, corresponded to 2.08% of health care costs and 0.22% of GDP, whereas indirect costs, on average, corresponded to 0.23% of GDP.”
> “Subgroup analysis revealed an increase in direct costs by 1.60 (1.16-2.22; p = 0.005) for SAD and 2.60 (2.01-3.36; p < 0.001) for GAD.”

Source: [Konnopka and König (2020)](https://pubmed.ncbi.nlm.nih.gov/31646432/)

<a id="topic-2.2.1.8.2-12"></a>

###### Societal cost of anxiety disorders in the United States, 1990

> “We estimated the annual cost of anxiety disorders to be approximately $42.3 billion in 1990 in the United States, or $1542 per sufferer.”
> “Of the $256 in workplace costs per anxious worker, 88% is attributable to lost productivity while at work as opposed to absenteeism.”

Source: [Greenberg et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10453795/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Generalized anxiety disorder on Families

Not applicable.

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

Not applicable.

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Psychological Therapies

<a id="topic-2.2.2.1.1-1"></a>

###### NICE guideline: low-intensity psychological interventions at step 2

> “For people with GAD whose symptoms have not improved after education and active monitoring in step 1, offer 1 or more of the following as a first-line intervention, guided by the person's preference:”
> “individual non-facilitated self-help”
> “individual guided self-help”
> “psychoeducational groups. [2011]”
> “be based on the treatment principles of CBT”
> “usually consist of 5 to 7 weekly or fortnightly face-to-face or telephone sessions, each lasting 20 to 30 minutes. [2011, amended 2018]”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.1.1-2"></a>

###### NICE guideline: CBT or applied relaxation at step 3

> “For people with GAD and marked functional impairment, or those whose symptoms have not responded adequately to step 2 interventions:”
> “Base the choice of treatment on the person's preference as there is no evidence that either mode of treatment (individual high-intensity psychological intervention or drug treatment) is better. [2011]”
> “If a person with GAD chooses a high-intensity psychological intervention, offer either CBT or applied relaxation. [2011]”
> “usually consist of 12 to 15 weekly sessions (fewer if the person recovers sooner; more if clinically required), each lasting 1 hour. [2011]”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.1.1-3"></a>

###### WFSBP guideline: CBT as first-line psychotherapy

> “Cognitive behavioural therapy (CBT) is the first-line psychotherapy for anxiety disorders.”

Source: [Bandelow et al. (2023)](https://www.tandfonline.com/doi/full/10.1080/15622975.2022.2086295)

<a id="topic-2.2.2.1.1-4"></a>

###### CANMAT guideline: efficacy of CBT and other psychological treatments

> “Meta-analyses clearly demonstrate that CBT significantly reduces GAD symptoms and is markedly more effective than placebo or wait-list control conditions for GAD (Level 1)”
> “Few studies have compared CBT and pharmacotherapy alone in the same trial, but the magnitude of benefits appear to be comparable for both groups”
> “A meta-analysis of five trials found no significant differences between CBT and relaxation therapy”
> “However, more recent studies suggest that applied relaxation has limited efficacy”
> “CBT is an effective first-line option for the treatment of GAD and is as effective as pharmacotherapy. Internet-based and computer-based CBT have also demonstrated efficacy. Evidence does not support the routine combination of CBT and pharmacotherapy, but when patients do not benefit from CBT, a trial of pharmacotherapy is advisable, and vice versa.”

Source: [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)

<a id="topic-2.2.2.1.1-5"></a>

###### CANMAT guideline: durability of benefit after psychological treatment

> “suggest that benefits of psychological treatments are maintained at one to three years follow-up after treatment.”

Source: [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)

<a id="topic-2.2.2.1.1-6"></a>

###### BAP guideline: psychological treatments compared with drug treatment

> “psychological: cognitive-behaviour therapy, applied relaxation [A]”
> “Pharmacological or psychological treatments, when delivered singly, have broadly similar efficacy in acute treatment”
> “The efficacy of CBT and applied relaxation appears superior to that of other psychological interventions”
> “but the comparative efficacy of pharmacological and psychological approaches over the long-term is not established.”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

<a id="topic-2.2.2.1.1-7"></a>

###### U.S. primary care review: psychotherapy techniques and comparative effectiveness

> “Psychotherapy for GAD and PD can include relaxation techniques; cognitive restructuring, including CBT; and exposure therapy.”
> “Psychotherapy is as effective as pharmacotherapy for treating PD and GAD and can be used alone or combined with pharmacotherapy for anxiety disorders, with combination treatment likely to be more effective than either treatment alone.”
> “Of the psychotherapy techniques that have been studied for GAD and PD, CBT appears to be the most effective.”
> “Limited evidence suggests that therapist-supported internet CBT, which can expand access to therapy, is effective, but comparisons with alternative therapies are limited.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

<a id="topic-2.2.2.1.1-8"></a>

###### Meta-analysis of psychotherapy and medication trials: 79 randomized trials

> “Seventy-nine randomized controlled trials (RCT) including 11,002 participants with a diagnosis of GAD were included in a meta-analysis that tested the efficacy of psychotherapies or medications for GAD.”
> “Consistent with prediction, evidence-based psychotherapies outperformed control conditions on primary outcome measures at posttreatment with a medium to large effect size (g = 0.76, 95% CI: 0.61–0.91, p < 0.001).”
> “Within psychotherapy comparisons, pill placebo-controlled studies had the highest effect size (n = 3, g = 1.44, 95% CI: 0.94–1.94, p < 0.001), followed by WL controls (n = 22, g = 0.90, 95% CI: 0.73–1.08, p < 0.001), psychological placebo (n = 10, g = 0.47, 95% CI: 0.25–0.69, p < 0.001), and TAU (n = 5, g = 0.38, 95% CI: 0.05–0.71, p < 0.05;”
> “There was evidence of publication bias in psychotherapy studies.”
> “Because medication studies had more placebo control conditions than inactive conditions compared to psychotherapy studies, effect sizes between the domains should not be compared directly.”

Source: [Carl et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7063818/)

<a id="topic-2.2.2.1.1-9"></a>

###### Meta-analysis of psychotherapy trials: 41 studies

> “A total of 41 studies (with 2132 patients meeting diagnostic criteria for GAD) were identified through systematic searches in bibliographical databases, and were included in the meta-analysis.”
> “Most studies examined the effects of cognitive behavior therapy (CBT).”
> “The pooled effect of the 38 comparisons (from 28 studies) of psychotherapy versus a control group was large (g=0.84; 95% CI: 0.71-0.97) with low to moderate heterogeneity.”
> “There were some indications that CBT was also effective at follow-up and that CBT was more effective than applied relaxation in the longer term.”

Source: [Cuijpers et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24487344/)

<a id="topic-2.2.2.1.1-10"></a>

###### Meta-analysis across anxiety disorders: pre-post effect sizes of psychotherapies and medications

> “Pre-post and treated versus control effect sizes (ES) were calculated for all evaluable randomized-controlled studies (n = 234), involving 37,333 patients.”
> “Medications were associated with a significantly higher average pre-post ES [Cohen's d = 2.02 (1.90-2.15); 28,051 patients] than psychotherapies [1.22 (1.14-1.30); 6992 patients; P < 0.0001].”
> “Individual CBT was more effective than waiting list, psychological placebo and pill placebo.”
> “Pre-post ES for psychotherapies did not differ from pill placebos; this finding cannot be explained by heterogeneity, publication bias or allegiance effects.”

Source: [Bandelow et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25932596/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Selective Serotonin Reuptake Inhibitors

<a id="topic-2.2.2.1.2-1"></a>

###### NICE guideline: an SSRI as the first drug treatment, with sertraline first

> “If a person with GAD chooses drug treatment, offer a selective serotonin reuptake inhibitor (SSRI). Consider offering sertraline first because it is the most cost-effective drug, but note that at the time of publication (January 2011) sertraline did not have UK marketing authorisation for this indication.”
> “Review the effectiveness and side effects of the drug every 2 to 4 weeks during the first 3 months of treatment and every 3 months thereafter. [2011]”
> “If the drug is effective, advise the person to continue taking it for at least a year as the likelihood of relapse is high. [2011]”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.1.2-2"></a>

###### NICE guideline: precautions with SSRIs

> “the risk of activation with SSRIs and SNRIs, with symptoms such as increased anxiety, agitation and problems sleeping”
> “the gradual development, over 1 week or more, of the full anxiolytic effect”
> “Take into account the increased risk of bleeding associated with SSRIs, particularly for older people or people taking other drugs that can damage the gastrointestinal mucosa or interfere with clotting (for example, non-steroidal anti-inflammatory drugs [NSAIDS] or aspirin).”
> “warn them that these drugs are associated with an increased risk of suicidal thinking and self-harm in a minority of people under 30 and”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.1.2-3"></a>

###### WFSBP guideline: SSRIs and SNRIs as first-line medications

> “Selective serotonin reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are first-line medications.”

Source: [Bandelow et al. (2023)](https://www.tandfonline.com/doi/full/10.1080/15622975.2022.2086295)

<a id="topic-2.2.2.1.2-4"></a>

###### CANMAT guideline: first-line, second-line, and third-line agents

> “Agomelatine, duloxetine, escitalopram, paroxetine, paroxetine CR, pregabalin, sertraline, venlafaxine XR”
> “Citalopram, divalproex chrono, fluoxetine, mirtazapine, trazodone”
> “Pharmacotherapeutic approaches should begin with one of the first-line options including an SSRI such as escitalopram, paroxetine, or sertraline,”

Source: [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)

<a id="topic-2.2.2.1.2-5"></a>

###### BAP guideline: SSRIs as first-line pharmacological treatment

> “Consider an SSRI for first-line pharmacological treatment [A]”
> “SSRIs have ‘broad spectrum’ efficacy in both short-term and long-term treatment, and are generally well tolerated; and for these reasons are widely considered to be the first-line pharmacological approach in patients with anxiety disorders or obsessive-compulsive disorder.”
> “Advise the patient that treatment periods of up to 12 weeks may be needed to assess efficacy [S] but recognise that an absence of clinical benefit within four weeks warns that a response to unchanged treatment is unlikely [A]”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

<a id="topic-2.2.2.1.2-6"></a>

###### U.S. primary care review: SSRIs and SNRIs as first-line medications

> “SSRIs and SNRIs are recommended as first-line medications for treating GAD and PD.”
> “Antidepressants, SSRIs and SNRIs in particular, are considered first-line therapies for GAD and PD because they are effective and generally well tolerated.”
> “SSRIs and SNRIs are the mainstay of pharmacotherapy for GAD.”
> “A recent meta-analysis found that escitalopram (Lexapro), duloxetine (Cymbalta), venlafaxine, and pregabalin (Lyrica) appear to be most effective and well tolerated.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

<a id="topic-2.2.2.1.2-7"></a>

###### FDA-approved GAD indication: escitalopram

> “generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older.”
> “The recommended starting dosage of Lexapro in adults is 10 mg once daily. Depending on clinical response and tolerability, dosage may be increased to the maximum recommended dosage of 20 mg once daily at an interval of no less than 1 week.”
> “The efficacy of Lexapro in the treatment of generalized anxiety disorder (GAD) in adults was demonstrated in three, 8-week, multicenter, flexible-dose, placebo-controlled studies that compared Lexapro (10 mg to 20 mg daily) to placebo in outpatients between 18 and 80 years of age who met DSM-IV criteria for GAD. In all three studies, Lexapro showed statistically significant greater mean improvement compared to placebo on the Hamilton Anxiety Scale (HAM-A).”

Source: [Lexapro prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021323s058lbl.pdf)

<a id="topic-2.2.2.1.2-8"></a>

###### FDA-approved GAD indication: paroxetine

> “Generalized anxiety disorder (GAD) in adults”
> “The recommended starting PAXIL dosage in adult patients with generalized anxiety disorder (GAD) is 10 mg once daily. After one week, increase the PAXIL dosage to 20 mg once daily.”
> “There is not sufficient evidence to suggest a greater benefit with a PAXIL dosage higher than 20 mg once daily”
> “The effectiveness of PAXIL in the treatment of generalized anxiety disorder (GAD) in adults was demonstrated in two 8-week, multicenter, placebo-controlled studies (Studies GAD-1 and GAD-2) of adult outpatients with GAD (DSM-IV).”
> “A third study, a flexible-dose study (Study GAD-3) that compared PAXIL 20 mg to 50 mg once daily to placebo once daily, did not demonstrate statistically significant superiority of PAXIL over placebo on the HAM-A total score, the primary outcome.”
> “Patients who were randomized to receive PAXIL experienced a statistically significantly lower relapse rate over the subsequent 24 weeks compared to those who were randomized to receive placebo.”

Source: [Paxil prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/020031s081lbl.pdf)

<a id="topic-2.2.2.1.2-9"></a>

###### FDA-approved agents and SSRIs without a GAD indication

> “As an FDA-approved treatment for GAD in adults, immediate release paroxetine has been studied extensively and multiple studies support its efficacy in adults with GAD.”
> “Escitalopram has been approved by the FDA for the treatment of GAD in adults, and both escitalopram and citalopram have been evaluated in adults with GAD.”
> “In a double-blind, placebo-controlled maintenance study, patients were treated with fixed-dose escitalopram (20 mg/day) over the course of 24–76 weeks, and re-randomization to placebo was associated with a significantly higher risk of relapse (OR: 4; 56% vs. 19%; log-rank test, p<0.001).”

Source: [Strawn et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6340395/)

<a id="topic-2.2.2.1.2-10"></a>

###### Network meta-analysis: escitalopram, sertraline, fluoxetine, and paroxetine

> “This analysis is based on 89 trials, which included 25 441 patients randomly assigned to 22 different active drugs or placebo.”
> “Primary outcomes were efficacy (mean difference [MD] in change in Hamilton Anxiety Scale Score) and acceptability (study discontinuations for any cause).”
> “escitalopram (MD -2·45, 95% CrI -3·27 to -1·63) were more efficacious than placebo with relatively good acceptability.”
> “Mirtazapine, sertraline, fluoxetine, buspirone, and agomelatine were also found to be efficacious and well tolerated but these findings were limited by small sample sizes.”
> “Likewise, paroxetine and benzodiazepines were effective but also poorly tolerated when compared with placebo.”

Source: [Slee et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30712879/)

<a id="topic-2.2.2.1.2-11"></a>

###### Meta-analysis of SSRIs, SNRIs, and benzodiazepines against placebo: effect sizes and response rates

> “A comprehensive literature search yielded 54 articles reporting 56 unique studies with 12,655 participants treated with either pill placebo (6,191 participants), SSRIs (16 trials, 2,712 participants), SNRIs (17 trials, 2,603 participants), or BZs (23 trials, 1,149 participants).”
> “SSRIs (Hedges’ g = 0.33) and SNRIs (Hedges’ g = 0.36) demonstrated significantly lower effect sizes than BZs (Hedges’ g = 0.50).”
> “Randomized-controlled trials suggest that 60-75% of patients respond to SSRIs, compared to 40-60% of patients receiving placebo, with similar response rates for SNRIs and BZs”
> “Side effects of SSRIs during the initial weeks of treatment include nausea, dizziness, headaches, jitteriness, sleep difficulties, and gastrointestinal disturbances.”

Source: [Gomez et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6097846/)

<a id="topic-2.2.2.1.2-12"></a>

###### Escitalopram compared with paroxetine: adverse events and discontinuation

> “A second and longer study (24 weeks) involved double-blind treatment with escitalopram (n=60; 10–20 mg/day) or paroxetine (n=61; 20–0 mg/day) and, while no differences were observed with regard to improvement in anxiety symptoms, treatment-emergent adverse events were more frequent in paroxetine-treated patients compared to those randomized to escitalopram (88.7% vs. 77.0%).”
> “Additionally, significantly fewer escitalopram- compared to paroxetine-treated patients discontinued due to adverse events (6.6% vs. 22.6%; p=0.02)”

Source: [Strawn et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6340395/)

<a id="topic-2.2.2.1.2-13"></a>

###### Adverse reactions with escitalopram in adult GAD trials

> “The most commonly observed adverse reactions in Lexapro patients (incidence of approximately 5% or greater and approximately twice the incidence in placebo patients) were nausea, ejaculation disorder (primarily ejaculatory delay), insomnia, fatigue, decreased libido, and anorgasmia.”
> “Among the 429 GAD patients who received Lexapro 10 to 20 mg/day in placebo-controlled trials, 8% discontinued treatment due to an adverse event, as compared to 4% of 427 patients receiving placebo.”

Source: [Lexapro prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021323s058lbl.pdf)

<a id="topic-2.2.2.1.2-14"></a>

###### Adverse reactions with escitalopram in adult GAD trials: incidence table

| Adverse reaction | Lexapro (N=429) | Placebo (N=427) |
| --- | --- | --- |
| Headache | “24%” | “17%” |
| Nausea | “18%” | “8%” |
| Ejaculation disorder | “14%” | “2%” |
| Somnolence | “13%” | “7%” |
| Insomnia | “12%” | “6%” |
| Dry mouth | “9%” | “5%” |
| Fatigue | “8%” | “2%” |
| Libido decreased | “7%” | “2%” |
| Anorgasmia | “6%” | “<1%” |

Source: [Lexapro prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021323s058lbl.pdf)

<a id="topic-2.2.2.1.2-15"></a>

###### Adverse reactions with paroxetine in adult GAD trials

> “In clinical studies in adults with MDD, SAD, OCD, PD, GAD, and PTSD, 20% (1,199/6,145), 16% (84/522), 12% (64/542), 9% (44/469), 11% (79/735), and 12% (79/676) of PAXIL-treated patients, respectively, discontinued treatment due to an adverse reaction.”
> “Placebo and PAXIL 20 mg and 40 mg once daily in the treatment of adults with GAD were asthenia, constipation, and abnormal ejaculation.”
> “During clinical trials of GAD and PTSD, gradual decreases in the daily PAXIL dosage by 10 mg/day at weekly intervals followed by 1 week at 20 mg/day was used before treatment was discontinued.”

Source: [Paxil prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/020031s081lbl.pdf)

<a id="topic-2.2.2.1.2-16"></a>

###### Boxed warning and discontinuation syndrome in SSRI labeling

> “Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors”
> “During marketing of Lexapro and other SSRIs, there have been spontaneous reports of adverse reactions occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, and hypomania.”

Source: [Lexapro prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021323s058lbl.pdf)

<a id="topic-2.2.2.1.2-17"></a>

###### BAP guideline: adverse effects and discontinuation syndrome with SSRIs

> “However SSRIs have potentially troublesome adverse effects, including initial increased nervousness, insomnia, nausea and sexual dysfunction”
> “When stopped abruptly, and even when tapered slowly, SSRIs can produce a discontinuation syndrome characterised by dizziness, insomnia and flu-like symptoms”
> “this seems more likely with paroxetine and least likely with fluoxetine”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

<a id="topic-2.2.2.1.2-18"></a>

###### Relapse after discontinuation: continuation trials

> “have demonstrated significantly lower relapse rates over six to 18 months in the range of 10-20% with active treatment compared to 40-56% with placebo.”

Source: [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)

> “Although approximately 16% of patients relapse despite continued use of antidepressants, discontinuing antidepressants before one year leads to symptom relapse in up to 50% of patients being treated with an SSRI or SNRI.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

<a id="topic-2.2.2.1.2-19"></a>

###### Relapse after discontinuation: meta-analysis of relapse prevention trials, SSRI subgroup

| Subgroup | Number of studies | Odds ratio of relapse, placebo relative to continued antidepressant (95% CI) |
| --- | --- | --- |
| All anxiety disorders | “28” | “3.11 (2.48 to 3.89)” |
| Generalised anxiety disorder (DSM-IV) | “6” | “4.20 (2.42 to 7.28)” |
| SSRI | “21” | “2.86 (2.17 to 3.78)” |

Source: [Batelaan et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5596392/)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Serotonin-Norepinephrine Reuptake Inhibitors

<a id="topic-2.2.2.1.3-1"></a>

###### NICE guideline: an alternative SSRI or an SNRI after sertraline

> “If sertraline is ineffective, offer an alternative SSRI or a serotonin–noradrenaline reuptake inhibitor (SNRI), taking into account the following factors:”
> “tendency to produce a withdrawal syndrome (especially with paroxetine and venlafaxine)”
> “the risk of suicide and likelihood of toxicity in overdose (especially with venlafaxine)”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.1.3-2"></a>

###### CANMAT guideline: duloxetine and venlafaxine XR as first-line agents

> “an SNRI such as duloxetine or venlafaxine XR, or other antidepressant such as agomelatine.”
> “In head-to-head comparisons, the efficacy of SSRIs and SNRIs appear to be similar”
> “Some data suggest that escitalopram may be less effective than venlafaxine XR”
> “Efficacy of venlafaxine was similar to pregabalin in one RCT”
> “If response to optimal doses is inadequate or the agent is not tolerated, therapy should be switched to another first-line agent before considering second-line medications.”

Source: [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)

<a id="topic-2.2.2.1.3-3"></a>

###### BAP guideline: SNRIs as alternative initial treatments

> “SNRIs and pregabalin may be considered as alternative initial treatments if SSRIs are judged to be unsuitable [A]”
> “The SNRIs duloxetine and venlafaxine have proven efficacy in short-term and long-term treatment of generalised anxiety disorder”
> “Although the tolerability profiles of SSRIs and SNRIs in patients with anxiety disorders are not established fully, systematic reviews of studies in depressed patients suggest that duloxetine and venlafaxine may be less well tolerated than the SSRIs”
> “Both duloxetine and venlafaxine have been associated with discontinuation symptoms after abrupt withdrawal”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

<a id="topic-2.2.2.1.3-4"></a>

###### FDA-approved GAD indication: venlafaxine extended-release

> “Effexor XR is indicated in adults for the treatment of:”
> “Generalized Anxiety Disorder (GAD) [see Clinical Studies (14.2)]”
> “For most patients, the recommended starting dose for Effexor XR is 75 mg per day, administered in a single dose. For some patients, it may be desirable to start at 37.5 mg per day for 4 to 7 days to allow new patients to adjust to the medication before increasing to 75 mg per day. Patients not responding to the initial 75 mg per day dose may benefit from dose increases to a maximum of 225 mg per day.”
> “The efficacy of Effexor XR as a treatment for Generalized Anxiety Disorder (GAD) was established in two 8-week, placebo-controlled, fixed-dose studies (75 to 225 mg per day), one 6-month, placebo-controlled, flexible-dose study (75 to 225 mg per day), and one 6-month, placebo-controlled, fixed-dose study (37.5, 75, and 150 mg per day) in adult outpatients meeting DSM-IV criteria for GAD.”
> “A dose-response relationship for effectiveness in GAD was not clearly established in the 75 to 225 mg per day dose range studied.”

Source: [Effexor XR prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020699s118lbl.pdf)

<a id="topic-2.2.2.1.3-5"></a>

###### Venlafaxine extended-release: HAM-A results of the four adult GAD studies

| Study and treatment group | LS mean change from baseline (SE) | Placebo-subtracted difference (95% CI) |
| --- | --- | --- |
| Study 1, venlafaxine XR 75 mg | “-11.1 (0.95)” | “-1.5 (-3.8, 0.8)” |
| Study 1, venlafaxine XR 150 mg | “-11.7 (0.87)” | “-2.2 (-4.5, 0.1)” |
| Study 1, venlafaxine XR 225 mg | “-12.1 (0.81)” | “-2.6 (-4.9, -0.3)” |
| Study 1, placebo | “-9.5 (0.85)” |  |
| Study 2, venlafaxine XR 75 mg | “-10.6 (0.82)” | “-2.6 (-4.6, -0.5)” |
| Study 2, venlafaxine XR 150 mg | “-9.8 (0.86)” | “-1.7 (-3.8, 0.3)” |
| Study 2, placebo | “-8.0 (0.73)” |  |
| Study 3, venlafaxine XR 37.5 mg | “-13.8” | “-2.8 (-5.1, -0.6)” |
| Study 3, venlafaxine XR 75 mg | “-15.5” | “-4.6 (-6.9, -2.3)” |
| Study 3, venlafaxine XR 150 mg | “-16.4” | “-5.5 (-7.8, -3.1)” |
| Study 3, placebo | “-11.0” |  |
| Study 4, venlafaxine XR 75-225 mg | “-13.4 (0.79)” | “- 4.7 (-6.6, -2.9)” |
| Study 4, placebo | “-8.7 (0.70)” |  |

Source: [Effexor XR prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020699s118lbl.pdf)

<a id="topic-2.2.2.1.3-6"></a>

###### FDA-approved GAD indication: duloxetine

> “Generalized anxiety disorder in adults and pediatric patients 7 years of age and older”
> “For most adults less than 65 years of age with GAD, initiate CYMBALTA 60 mg once daily. For some patients, it may be desirable to start at 30 mg once daily for 1 week, to allow patients to adjust to CYMBALTA before increasing to 60 mg once daily. While a 120 mg once daily dosage was shown to be effective, there is no evidence that doses greater than 60 mg/day confer additional benefit.”
> “The efficacy of CYMBALTA in the treatment of generalized anxiety disorder (GAD) was established in 1 fixed-dose randomized, double-blind, placebo-controlled trial and 2 flexible-dose randomized, double-blind, placebo-controlled trials in adult outpatients between 18 and 83 years of age meeting the DSM-IV criteria for GAD (Studies GAD-1, GAD-2, and GAD-3, respectively).”
> “In all 3 trials, CYMBALTA demonstrated superiority over placebo as measured by greater improvement in the Hamilton Anxiety Scale (HAM-A) total score (see Table 8) and by the Sheehan Disability Scale (SDS) global functional impairment score.”
> “Patients treated with CYMBALTA (N=151) demonstrated significantly greater improvement compared with placebo (N=140) on mean change from baseline to endpoint as measured by the HAM-A total score (see Table 8).”

Source: [Cymbalta prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021427s055s057lbl.pdf)

<a id="topic-2.2.2.1.3-7"></a>

###### Duloxetine: relapse prevention in responders

> “Four hundred and twenty-nine patients who responded to open-label treatment [defined as meeting the following criteria at weeks 24 and 26: a decrease from baseline HAM-A total score by at least 50% to a score no higher than 11, and a Clinical Global Impressions of Improvement (CGI-Improvement) score of 1 or 2] were randomly assigned to continuation of CYMBALTA at the same dosage (N=216) or to placebo (N=213) and were observed for relapse.”
> “Patients taking CYMBALTA experienced a statistically significantly longer time to relapse of GAD than did patients taking placebo”

Source: [Cymbalta prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021427s055s057lbl.pdf)

<a id="topic-2.2.2.1.3-8"></a>

###### FDA approval history and response and remission with venlafaxine and duloxetine

> “Venlafaxine is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) that is FDA-approved for the treatment of GAD, MDD, panic disorder, and social anxiety disorder.”
> “In adults with GAD, venlafaxine (75–225 mg/day) effectively reduces anxiety symptoms”
> “and was the first FDA-approved antidepressant for the treatment of GAD in this age group.”
> “Response rates in patients receiving venlafaxine XR were 69% compared to 46% in patients randomized to placebo (p<0.001)”
> “These trials have recently been subjected to a meta-analysis which revealed superior remission rates for duloxetine (n=2,399, RR = 1.60, 95% CI: 1.43–1.80) and greater improvement in HAM-A scores (n=1,135, MD = 3.34, 95% CI: 2.37–4.32), while finding no differences in discontinuation rates between placebo and duloxetine”

Source: [Strawn et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6340395/)

<a id="topic-2.2.2.1.3-9"></a>

###### Network meta-analysis: duloxetine and venlafaxine

> “Duloxetine (MD -3·13, 95% credible interval [CrI] -4·13 to -2·13)”
> “venlafaxine (MD -2·69, 95% CrI -3·50 to -1·89)”
> “were more efficacious than placebo with relatively good acceptability.”

Source: [Slee et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30712879/)

<a id="topic-2.2.2.1.3-10"></a>

###### SNRIs compared with SSRIs: efficacy and sexual adverse effects

> “SNRIs are very similar to SSRIs in their mechanism of action, side effects, and efficacy rates (Hedges’ g = 0.42, SD=0.12, p<0.0001)”
> “though there is some evidence that SNRIs are associated with less sexual dysfunction side effects than SSRIs”

Source: [Gomez et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6097846/)

<a id="topic-2.2.2.1.3-11"></a>

###### Adverse reactions and discontinuation with venlafaxine extended-release

> “The most commonly observed adverse reactions in the clinical study database in Effexor XR treated patients in MDD, GAD, SAD, and PD (incidence ≥5% and at least twice the rate of placebo) were: nausea (30.0%), somnolence (15.3%), dry mouth (14.8%), sweating (11.4%), abnormal ejaculation (9.9%), anorexia (9.8%), constipation (9.3%), impotence (5.3%), and decreased libido (5.1%).”
> “Combined across short-term, placebo-controlled premarketing studies for all indications, 12% of the 3,558 patients who received Effexor XR (37.5-225 mg) discontinued treatment due to an adverse experience, compared with 4% of the 2,197 placebo-treated patients in those studies.”
> “In controlled trials, there were dose-related increases in systolic and diastolic blood pressure, as well as cases of sustained hypertension”
> “Monitor blood pressure before initiating treatment with Effexor XR and regularly during treatment.”
> “Abrupt discontinuation or dose reduction of venlafaxine at various doses has been found to be associated with the appearance of new symptoms, the frequency of which increased with increased dose level and with longer duration of treatment.”

Source: [Effexor XR prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020699s118lbl.pdf)

<a id="topic-2.2.2.1.3-12"></a>

###### Adverse reactions and discontinuation with duloxetine

> “Approximately 13.7% (139/1018) of the CYMBALTA-treated patients in placebo-controlled adult trials for GAD discontinued treatment due to an adverse reaction, compared with 5% (38/767) for placebo-treated patients.”
> “Common adverse reactions reported as a reason for discontinuation and considered to be drug-related (as defined above) included nausea (CYMBALTA 3.3%, placebo 0.4%), and dizziness (CYMBALTA 1.3%, placebo 0.4%).”
> “The most commonly observed adverse reactions in CYMBALTA-treated patients in all the pooled adult populations (i.e., MDD, GAD, DPNP, FM, OA, and CLBP) (incidence of at least 5% and at least twice the incidence in placebo-treated patients) were nausea, dry mouth, somnolence, constipation, decreased appetite, and hyperhidrosis.”
> “There have been reports of hepatic failure, sometimes fatal, in patients treated with CYMBALTA.”
> “Following abrupt or tapered discontinuation in adult placebo-controlled clinical trials, the following symptoms occurred at 1% or greater and at a significantly higher rate in CYMBALTA-treated patients compared to those discontinuing from placebo: dizziness, headache, nausea, diarrhea, paresthesia, irritability, vomiting, insomnia, anxiety, hyperhidrosis, and fatigue.”

Source: [Cymbalta prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021427s055s057lbl.pdf)

<a id="topic-2.2.2.1.3-13"></a>

###### Relapse after discontinuation: meta-analysis of relapse prevention trials, SNRI subgroup

| Subgroup | Number of studies | Odds ratio of relapse, placebo relative to continued antidepressant (95% CI) |
| --- | --- | --- |
| SNRI | “3” | “5.03 (1.31 to 19.40)” |

Source: [Batelaan et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5596392/)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Pregabalin

<a id="topic-2.2.2.1.4-1"></a>

###### FDA-approved indications of pregabalin in the United States

> “LYRICA is indicated for:”
> “Management of neuropathic pain associated with diabetic peripheral neuropathy”
> “Management of postherpetic neuralgia”
> “Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older”
> “Management of fibromyalgia”
> “Management of neuropathic pain associated with spinal cord injury”

Source: [Lyrica prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021446s046,022488s022lbl.pdf)

<a id="topic-2.2.2.1.4-2"></a>

###### European Union authorization for generalized anxiety disorder

> “Lyrica is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.”
> “The dose range is 150 to 600 mg per day given as two or three divided doses. The need for treatment should be reassessed regularly.”
> “Pregabalin has been studied in 6 controlled trials of 4-6 week duration, an elderly study of 8 week duration and a long-term relapse prevention study with a double-blind relapse prevention phase of 6 months duration.”
> “Relief of the symptoms of GAD as reflected by the Hamilton Anxiety Rating Scale (HAM-A) was observed by Week 1.”
> “In controlled clinical trials (4-8 week duration) 52% of the pregabalin treated patients and 38% of the patients on placebo had at least a 50% improvement in HAM-A total score from baseline to endpoint.”

Source: [EMA Lyrica product information (2026)](https://www.ema.europa.eu/en/documents/product-information/lyrica-epar-product-information_en.pdf)

<a id="topic-2.2.2.1.4-3"></a>

###### CANMAT guideline: first-line agent and second-line adjunctive therapy

> “The anticonvulsant pregabalin is also a recommended first-line therapy.”
> “Pregabalin: The anticonvulsant pregabalin was more effective than placebo in RCTs”
> “Pregabalin was more effective than venlafaxine XR in one RCT”
> “Second-line adjunctive therapies: Adjunctive pregabalin demonstrated good efficacy in a large RCT in patients with GAD who had an inadequate response to prior treatments (Level 2)”

Source: [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)

<a id="topic-2.2.2.1.4-4"></a>

###### NICE guideline: pregabalin when SSRIs and SNRIs are not tolerated

> “If the person cannot tolerate SSRIs or SNRIs, consider offering pregabalin.”
> “As of 1 April 2019, pregabalin is a Class C controlled substance (under the Misuse of Drugs Act 1971) and scheduled under the Misuse of Drugs Regulations 2001 as Schedule 3. Evaluate patients carefully for a history of drug abuse before prescribing and observe patients for development of signs of abuse and dependence (MHRA, Drug Safety Update April 2019).”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.1.4-5"></a>

###### BAP guideline: alternative initial treatment, augmentation, and adverse effects

> “SNRIs and pregabalin may be considered as alternative initial treatments if SSRIs are judged to be unsuitable”
> “Consider pregabalin augmentation after a non-response to initial SSRI or SNRI treatment”
> “Remember that higher daily doses of pregabalin may be associated with greater response rates”
> “Common adverse effects include drowsiness and dizziness”
> “weight gain in approximately 20% of patients”
> “Discontinuation symptoms after abrupt withdrawal of pregabalin have been reported, as has the abuse of pregabalin generally in individuals with a history of other substance abuse”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

<a id="topic-2.2.2.1.4-6"></a>

###### WFSBP guideline: recommended medications and national approval

> “Some of the medications recommended in this guideline may not (or not yet) have received approval for the treatment of anxiety disorders in every country.”

Source: [Bandelow et al. (2023)](https://www.tandfonline.com/doi/full/10.1080/15622975.2022.2086295)

<a id="topic-2.2.2.1.4-7"></a>

###### AAFP review: antidepressants before pregabalin

> “Antidepressants should be tried before pregabalin”
> “which appears effective but may cause weight gain and sedation.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

<a id="topic-2.2.2.1.4-8"></a>

###### Network meta-analysis: HAM-A difference from placebo

> “pregabalin (MD -2·79, 95% CrI -3·69 to -1·91)”

Source: [Slee et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30712879/)

<a id="topic-2.2.2.1.4-9"></a>

###### Meta-analysis of placebo-controlled trials: effect size and dropout

> “We included eight randomized-controlled trials (n=2299) in our study, comparing the use of PGB in different dosages and placebo.”
> “In terms of the main outcome, PGB was found to be superior to the placebo group (Hedges' g=0.37; 95% confidence interval 0.30-0.44).”
> “No difference between PGB and placebo groups was observed in terms of the dropout rates.”
> “PGB was comparable to benzodiazepines in clinical response, but had lower dropout rates than benzodiazepine.”

Source: [Generoso et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27643884/)

<a id="topic-2.2.2.1.4-10"></a>

###### Onset, weight gain, and abuse liability

> “Pregabalin is reported to be generally well-tolerated in adult patients with GAD and has a rapid onset of action compared to many other pharmacotherapies, approximately one week, as well as comparable efficacy to benzodiazepines”
> “The most significant treatment limiting adverse event appears to be the weight gain associated with pregabalin.”
> “However, pharmacovigilance data suggest that both pregabalin (and gabapentin) have abuse liability and are associated with overdose fatalities”

Source: [Strawn et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6340395/)

<a id="topic-2.2.2.1.4-11"></a>

###### Controlled substance schedule, abuse, and dependence: U.S. prescribing information

> “LYRICA is a Schedule V controlled substance.”
> “In controlled clinical studies in over 5500 patients, 4 % of LYRICA-treated patients and 1 % of placebo-treated patients overall reported euphoria as an adverse reaction, though in some patient populations studied, this reporting rate was higher and ranged from 1 to 12%.”
> “In clinical studies, following abrupt or rapid discontinuation of LYRICA, some patients reported symptoms including insomnia, nausea, headache or diarrhea”

Source: [Lyrica prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021446s046,022488s022lbl.pdf)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Buspirone

<a id="topic-2.2.2.1.5-1"></a>

###### FDA-approved indication and duration of demonstrated efficacy

> “BuSpar is indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety.”
> “The efficacy of BuSpar has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD).”
> “The effectiveness of BuSpar in long-term use, that is, for more than 3 to 4 weeks, has not been demonstrated in controlled trials.”

Source: [BuSpar prescribing information (2010)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018731s051lbl.pdf)

<a id="topic-2.2.2.1.5-2"></a>

###### Adverse events and discontinuation in premarketing trials

> “The more commonly observed untoward events associated with the use of BuSpar not seen at an equivalent incidence among placebo-treated patients include dizziness, nausea, headache, nervousness, lightheadedness, and excitement.”
> “Approximately 10% of the 2200 anxious patients who participated in the BuSpar premarketing clinical efficacy trials in anxiety disorders lasting 3 to 4 weeks discontinued treatment due to an adverse event.”

Source: [BuSpar prescribing information (2010)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018731s051lbl.pdf)

<a id="topic-2.2.2.1.5-3"></a>

###### Abuse and dependence potential

> “BuSpar (buspirone hydrochloride) is not a controlled substance.”
> “In human and animal studies, buspirone has shown no potential for abuse or diversion and there is no evidence that it causes tolerance, or either physical or psychological dependence.”

Source: [BuSpar prescribing information (2010)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018731s051lbl.pdf)

<a id="topic-2.2.2.1.5-4"></a>

###### CANMAT guideline: second-line agent

> “Buspirone was more effective than placebo and as effective as benzodiazepines in several RCTs (Level 1)”
> “Limited effectiveness in clinical practice relegates buspirone to a second-line agent.”

Source: [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)

<a id="topic-2.2.2.1.5-5"></a>

###### BAP guideline: acute efficacy without relapse-prevention evidence

> “The azapirone drug buspirone is efficacious in the acute treatment of generalised anxiety disorder”
> “though neither has published evidence of efficacy in the prevention of relapse.”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

<a id="topic-2.2.2.1.5-6"></a>

###### Cochrane review of azapirones

> “Thirty six trials were included in the review, reporting on 5908 participants randomly allocated to azapirones and/or placebo, benzodiazepines, antidepressants, psychotherapy or kava kava. Azapirones, including buspirone, were superior to placebo in treating GAD. The calculated number needed to treat for azapirones using the Clinical Global Impression scale was 4.4 (95% confidence interval (CI) 2.16 to 15.4). Azapirones may be less effective than benzodiazepines and we were unable to conclude if azapirones were superior to antidepressants, kava kava or psychotherapy. Azapirones appeared to be well tolerated. Fewer participants stopped taking benzodiazepines compared to azapirones. The length of studies ranged from four to nine weeks, with one study lasting 14 weeks.”
> “Longer term studies are needed to show that azapirones are effective in treating GAD, which is a chronic long‐term illness.”

Source: [Chessick et al. (2006)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8915394/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Benzodiazepines

<a id="topic-2.2.2.1.6-1"></a>

###### FDA-approved indication: alprazolam

> “XANAX is indicated for the:”
> “acute treatment of generalized anxiety disorder (GAD) in adults.”
> “XANAX was significantly better than placebo at each of the evaluation periods of these 4-week studies”

Source: [Xanax prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018276s059lbl.pdf)

<a id="topic-2.2.2.1.6-2"></a>

###### Approval status and off-label use of individual benzodiazepines

> “As such, alprazolam is the only benzodiazepine to be formally approved by the FDA for the treatment of GAD. However, clonazepam, lorazepam, and diazepam are often used to treat GAD in adults”
> “Benzodiazepines such as diazepam and clonazepam (both of which are long-acting agents) may be efficacious in treating GAD, although many clinicians choose to limit their use due to concerns about the risks regarding possible misuse and dependence.”

Source: [Strawn et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6340395/)

<a id="topic-2.2.2.1.6-3"></a>

###### FDA boxed warning for the benzodiazepine class, September 2020

> “To address the serious risks of abuse, addiction, physical dependence, and withdrawal reactions, the U.S. Food and Drug Administration (FDA) is requiring the Boxed Warning be updated for all benzodiazepine medicines.”
> “However, even when taken at recommended dosages, their use can lead to misuse, abuse, and addiction.”
> “Physical dependence can occur when benzodiazepines are taken steadily for several days to weeks, even as prescribed. Stopping them abruptly or reducing the dosage too quickly can result in withdrawal reactions, including seizures, which can be life-threatening.”
> “Benzodiazepines are a class of medicines approved to treat generalized anxiety disorder, insomnia, seizures, social phobia, and panic disorder.”

Source: [FDA benzodiazepine boxed warning (2020)](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class)

<a id="topic-2.2.2.1.6-4"></a>

###### Benzodiazepine prescribing, misuse, and overdose data

> “In 2018, an estimated 50% of patients who were dispensed oral benzodiazepines received them for a duration of two months or longer.”
> “In 2018, an estimated 5.4 million U.S. individuals 12 years and older abused or misused benzodiazepines in the previous year.”
> “Benzodiazepine-involved overdose deaths increased from 1,298 in 2010 to 11,537 in 2017.”

Source: [FDA benzodiazepine boxed warning (2020)](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class)

<a id="topic-2.2.2.1.6-5"></a>

###### Boxed warning in the alprazolam prescribing information

> “The use of benzodiazepines, including XANAX, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death.”
> “The continued use of benzodiazepines, including XANAX, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose.”
> “In some cases, benzodiazepine users have developed a protracted withdrawal syndrome with withdrawal symptoms lasting weeks to more than 12 months”

Source: [Xanax prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018276s059lbl.pdf)

<a id="topic-2.2.2.1.6-6"></a>

###### NICE guideline: short-term use during crises only

> “Do not offer a benzodiazepine for the treatment of GAD in primary or secondary care except as a short-term measure during crises.”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.1.6-7"></a>

###### CANMAT guideline: second-line agents for short-term use

> “While these agents have level 1 evidence for efficacy, they are recommended as second-line therapy, and usually only for short-term use, because of side effects, dependence, and withdrawal issues.”
> “Within these second-line agents, benzodiazepines would be considered first in most cases, except where there is a risk of substance abuse, while bupropion XL would likely be reserved for later.”
> “Second-line choices include bupropion XL, buspirone, hydroxyzine, imipramine, quetiapine XR, vortioxetine, as well as the benzodiazepines, alprazolam, bromazepam, diazepam, and lorazepam.”

Source: [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)

<a id="topic-2.2.2.1.6-8"></a>

###### BAP guideline: use after nonresponse to other treatments

> “Benzodiazepines will usually be reserved for the further treatment of patients who have not responded to at least three previous treatments (such as after non-response to both an SSRI and an SNRI and a psychological intervention)”
> “Consider use of benzodiazepines after a non-response to SSRI, SNRI, pregabalin and buspirone treatment”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

<a id="topic-2.2.2.1.6-9"></a>

###### AAFP review: onset, dependence, and position in therapy

> “Benzodiazepines have the benefit of quick onset and are effective in treating symptoms of anxiety; however, they are associated with withdrawal, rebound anxiety, and dependence and are not recommended for long-term use.”
> “Benzodiazepines are not more effective than anti-depressants for anxiety disorders and should not be used as first-line therapy.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

<a id="topic-2.2.2.1.6-10"></a>

###### Meta-analysis: benzodiazepines compared with SSRIs and SNRIs

> “A comprehensive literature search yielded 54 articles reporting 56 unique studies with 12,655 participants treated with either pill placebo (6,191 participants), SSRIs (16 trials, 2,712 participants), SNRIs (17 trials, 2,603 participants), or BZs (23 trials, 1,149 participants).”
> “SSRIs (Hedges’ g = 0.33) and SNRIs (Hedges’ g = 0.36) demonstrated significantly lower effect sizes than BZs (Hedges’ g = 0.50).”

Source: [Gomez et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6097846/)

<a id="topic-2.2.2.1.6-11"></a>

###### Network meta-analysis: tolerability

> “Likewise, paroxetine and benzodiazepines were effective but also poorly tolerated when compared with placebo.”

Source: [Slee et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30712879/)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Hydroxyzine

<a id="topic-2.2.2.1.7-1"></a>

###### FDA-approved indication

> “For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested.”
> “The effectiveness of hydroxyzine as an antianxiety agent for long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies.”

Source: [Vistaril prescribing information (2014)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/011459s048,011795s025lbl.pdf)

<a id="topic-2.2.2.1.7-2"></a>

###### CANMAT guideline: second-line agent

> “Hydroxyzine has demonstrated efficacy superior to placebo and similar to benzodiazepines and buspirone in RCTs (Level 1)”
> “however, clinical experience with this agent in the treatment of GAD remains limited.”

Source: [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)

<a id="topic-2.2.2.1.7-3"></a>

###### Cochrane review of hydroxyzine

> “We included five studies in the review with a total of 884 participants.”
> “The data from the included studies provide some evidence that hydroxyzine is more effective than placebo for GAD (odds ratio (OR) 0.30, 95% CI 0.15 to 0.58)”
> “In terms of side effects, hydroxyzine was associated with a higher rate of sleepiness/drowsiness than the active comparators (OR 1.74, 95% CI 0.86 to 3.53). There was, however, a high risk of bias in the included studies.”
> “Even though more effective than placebo, due to the high risk of bias of the included studies, the small number of studies and the overall small sample size, it is not possible to recommend hydroxyzine as a reliable first‐line treatment in GAD.”

Source: [Guaiana et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13139711/)

<a id="topic-2.2.2.1.7-4"></a>

###### AAFP review: comparison with benzodiazepines

> “Limited evidence suggests hydroxyzine may be as effective as benzodiazepines”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Second-generation Antipsychotics

<a id="topic-2.2.2.1.8-1"></a>

###### FDA-approved indications of quetiapine extended release

> “SEROQUEL XR is an atypical antipsychotic indicated for the treatment of:”
> “SEROQUEL XR is indicated for the treatment of schizophrenia.”
> “SEROQUEL XR is indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex.”
> “SEROQUEL XR is indicated for the acute treatment of depressive episodes associated with bipolar disorder.”
> “SEROQUEL XR is indicated for use as adjunctive therapy to antidepressants for the treatment of MDD.”

Source: [Seroquel XR prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022047s048lbl.pdf)

<a id="topic-2.2.2.1.8-2"></a>

###### CANMAT guideline: quetiapine XR as second-line monotherapy

> “Quetiapine XR: There is good evidence for the efficacy of quetiapine XR for the management of GAD (Level 1)”
> “However, quetiapine was associated with more weight gain and sedation, and higher dropout rates due to adverse events compared with placebo or antidepressants”
> “Due to tolerability and long-term safety concerns with atypical antipsychotics, this treatment is recommended as a second-line option for patients who cannot be provided antidepressants or benzodiazepines.”

Source: [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)

<a id="topic-2.2.2.1.8-3"></a>

###### CANMAT guideline: adjunctive antipsychotics as third-line therapy

> “Third-line adjunctive therapies: A meta-analysis of five RCTs of adjunctive atypical antipsychotics found no significant improvement in response rates but higher discontinuation rates versus placebo in patients with refractory GAD”
> “Because of the limited evidence for efficacy and their potential for weight gain and metabolic side effects, atypical antipsychotics should be reserved for highly treatment-refractory cases of GAD, and other than quetiapine XR, used only as an adjunctive treatment.”

Source: [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)

<a id="topic-2.2.2.1.8-4"></a>

###### NICE guideline: antipsychotics in primary care

> “Do not offer an antipsychotic for the treatment of GAD in primary care.”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.1.8-5"></a>

###### BAP guideline: reserved for nonresponse to other interventions

> “The tolerability profile of antipsychotic drugs is such that they should generally be reserved for treatment after a non-response to other interventions”
> “but the evidence for quetiapine augmentation is inconsistent”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

<a id="topic-2.2.2.1.8-6"></a>

###### AAFP review: effectiveness and augmentation

> “Limited evidence suggests that antipsychotics have poor effectiveness and cause several adverse effects.”
> “There is no evidence of overall benefit to augmentation of antidepressant therapy with benzodiazepines, atypical antipsychotics, or buspirone (Buspar) in treatment-resistant anxiety disorders.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

<a id="topic-2.2.2.1.8-7"></a>

###### Meta-analysis of quetiapine randomized trials

> “A total of 2,248 randomized participants in three RCTs were included.”
> “Unfortunately, the response and the remission rates in only 50 and 150 mg/day of quetiapine-XR (extended-release) were better than those of the placebo.”
> “The rates of pooled overall discontinuation and discontinuation due to adverse events of quetiapine-XR were greater than placebo.”
> “Based on the pooled discontinuation rate due to adverse events of the quetiapine-treated group being significantly higher than that of the placebo-treated group, with RR (95% CI) of 3.18 (2.52, 4.00), I2=0%, it suggests that quetiapine is less tolerable than placebo in the treatment of GAD”
> “Based on the evidence included in this meta-analysis, the significant adverse events consist of somnolence, sexual dysfunction, and extrapyramidal symptoms.”

Source: [Maneeton et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4716733/)

<a id="topic-2.2.2.1.8-8"></a>

###### Network meta-analysis: effect size and tolerability of quetiapine

> “Quetiapine (MD -3·60 95% CrI -4·83 to -2·39) had the largest effect on HAM-A but it was poorly tolerated (odds ratio 1·44, 95% CrI 1·16-1·80) when compared with placebo.”

Source: [Slee et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30712879/)

<a id="topic-2.2.2.1.8-9"></a>

###### Fixed-dose trial of quetiapine XR

> “Among patients randomized to fixed-dose treatment (quetiapine XR: 50 mg/day, n=234; 150 mg/d, n=241; 300 mg/d, n=241) or placebo (n=235) quetiapine was statistically superior to placebo except at the 300 mg/day dose, wherein side effects were significantly greater”

Source: [Strawn et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6340395/)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 Other Antidepressants

<a id="topic-2.2.2.1.9-1"></a>

###### CANMAT guideline: agomelatine, imipramine, bupropion XL, vortioxetine, mirtazapine, and trazodone

> “Other antidepressants: In two 12-week, double-blind RCTs, agomelatine was found to be more effective than placebo (Level 1)”
> “In RCTs, imipramine was superior to placebo and as effective as benzodiazepines for the treatment of GAD (Level 1)”
> “However, because of side effects and potential toxicity in overdose, imipramine is recommended as a second-line option.”
> “While there are little data on bupropion XL (Level 2), in a 12-week RCT in patients with GAD it was as effective as escitalopram (a first-line option), supporting its use as a second-line option”
> “Results from two similar, eight-week, placebo-controlled RCTs with vortioxetine were conflicting, with one trial being positive”
> “In a RCT, trazodone was as effective as diazepam (Level 2)”

Source: [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)

<a id="topic-2.2.2.1.9-2"></a>

###### BAP guideline: tricyclic antidepressants, agomelatine, and mirtazapine

> “TCAs are associated with a greater burden of adverse effects than either SSRIs or SNRIs”
> “TCAs should be avoided in patients considered to be at risk of suicide, due to their potential fatal toxicity after overdose”
> “elevations of hepatic enzymes occur in more than 1% of treated patients and regular monitoring of liver function tests is required in the early months of treatment”
> “The evidence for the efficacy of mirtazapine in patients with anxiety disorders is limited and inconsistent”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

<a id="topic-2.2.2.1.9-3"></a>

###### Network meta-analysis: mirtazapine and agomelatine

> “Mirtazapine, sertraline, fluoxetine, buspirone, and agomelatine were also found to be efficacious and well tolerated but these findings were limited by small sample sizes.”

Source: [Slee et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30712879/)

<a id="topic-2.2.2.1.9-4"></a>

###### Imipramine and trazodone compared with diazepam

> “In this study response rates were 73% for imipramine-treated patients, compared to 69% for patients receiving trazodone and 66% for those receiving diazepam, and 47% for the placebo group.”
> “While the use of TCAs has largely been supplanted by the use of SSRIs for the treatment of GAD, they still represent a viable option for patients who fail to respond after multiple trials of SSRIs, SNRIs, and adjunctive psychopharmacologic interventions.”

Source: [Strawn et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6340395/)

<a id="heading-2.2.2.1.10"></a>

###### 2.2.2.1.10 Limitations of Current Therapies

<a id="topic-2.2.2.1.10-1"></a>

###### Summary

Up to 50% of patients with GAD have an inadequate response to available agents, and 50 to 67% respond adequately to a first treatment trial. Reported response and remission rates are 60% to 68% and 30% to 36% with SSRIs and 56% to 58% and 31% to 38% with SNRIs; another review gives SSRI response in randomized trials as 60% to 75% against 40% to 60% with placebo. One source advises telling patients that treatment periods of up to 12 weeks may be needed to assess efficacy. SSRI and SNRI discontinuation rates are 20% to 23%, associated with nausea, sexual dysfunction, and slow onset. Across 28 anxiety disorder studies (n=5233), relapse prevalence was 36.4% in placebo groups and 16.4% in antidepressant groups; in 6 GAD studies, the odds ratio for relapse after discontinuation was 4.20 (95% CI 2.42 to 7.28). Benzodiazepines carry a class boxed warning for abuse, addiction, physical dependence, and withdrawal; pregabalin is a Schedule V controlled substance; buspirone efficacy beyond 3 to 4 weeks has not been demonstrated in controlled trials. The prescribing information of escitalopram, paroxetine, venlafaxine extended-release, duloxetine, and alprazolam lists GAD among their indications. The indication lists in the prescribing information of pregabalin, a recommended first-line therapy in one source, and of quetiapine extended-release, a second-line choice in the same source, do not include GAD.

Source: [Generoso et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27643884/); [Domschke et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10785995/); [Maneeton et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4716733/); [Gomez et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6097846/); [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf); [Batelaan et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5596392/); [FDA benzodiazepine boxed warning (2020)](https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class); [Lyrica prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021446s046,022488s022lbl.pdf); [BuSpar prescribing information (2010)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018731s051lbl.pdf); [Lexapro prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021323s058lbl.pdf); [Paxil prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/020031s081lbl.pdf); [Effexor XR prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020699s118lbl.pdf); [Cymbalta prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021427s055s057lbl.pdf); [Xanax prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018276s059lbl.pdf); [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/); [Seroquel XR prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022047s048lbl.pdf)

<a id="topic-2.2.2.1.10-2"></a>

###### Nonresponse to available treatments

> “Although numerous agents from various drug classes are available to treat GAD, as many as 50% of patients have inadequate response, constituting an important medical frontier.”

Source: [Generoso et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27643884/)

> “only 50 to 67% of patients show an adequate clinical response after the first treatment trial”

Source: [Domschke et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10785995/)

> “Many patients do not respond to first-line pharmacological or psychological interventions.”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

<a id="topic-2.2.2.1.10-3"></a>

###### Response and remission rates with SSRIs and SNRIs

> “However, numerous GAD patients do not achieve remission or response despite adequate dose and duration of SSRIs and SNRIs.”
> “Regularly, the rates of response and remission for GAD patients treated with SSRIs are 60%–68% and 30%–36%”
> “In addition, GAD patients treated with SNRIs have demonstrated response and remission rates of 56%–58% and 31%–38%”

Source: [Maneeton et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4716733/)

> “Randomized-controlled trials suggest that 60-75% of patients respond to SSRIs, compared to 40-60% of patients receiving placebo, with similar response rates for SNRIs and BZs”

Source: [Gomez et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6097846/)

<a id="topic-2.2.2.1.10-4"></a>

###### Delayed onset of antidepressant effect

> “the gradual development, over 1 week or more, of the full anxiolytic effect”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

> “It should be emphasised that treatment response is not immediate; that a transient worsening of symptoms can sometimes occur; that prolonged courses are needed to maintain an initial treatment response”
> “Advise the patient that treatment periods of up to 12 weeks may be needed to assess efficacy”
> “but recognise that an absence of clinical benefit within four weeks warns that a response to unchanged treatment is unlikely”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

<a id="topic-2.2.2.1.10-5"></a>

###### Adverse effects, adherence, and discontinuation of antidepressants

> “Additionally, several GAD patients discontinue the antidepressant therapy. Based on recent evidences, the overall discontinuation rates for SSRIs and SNRIs are 20%–23%”
> “The low acceptability and tolerability of SSRIs and SNRIs are possibly associated with unfavorable side effects of SSRIs and SNRIs including nausea and sexual dysfunction, as well as slow onset of their action.”

Source: [Maneeton et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4716733/)

> “Some of these side effects are similar to the symptoms of anxiety, which can lead to premature termination before the medication has had enough time to reach maximum efficacy”

Source: [Gomez et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6097846/)

> “For these reasons, many of those who might benefit from treatment do not receive it, and many of those who do undergo treatment stop it early because of the emergence of unwanted effects.”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

<a id="topic-2.2.2.1.10-6"></a>

###### Patient concerns about tolerance and dependence

> “Others fear developing a tolerance or becoming dependent on medication, and so are reluctant to start, let alone continue, pharmacological treatment.”
> “dependence can occur (especially in predisposed patients) with prolonged use: and it is hard to identify those patients at risk of developing long-term problems”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

> “Common concerns about taking medication, such as fears of addiction, should be addressed.”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.1.10-7"></a>

###### Relapse after antidepressant discontinuation

> “The meta-analysis included 28 studies (n=5233) examining relapse with a maximum follow-up of one year.”
> “Discontinuation increased the odds of relapse compared with continuing antidepressants (summary odds ratio 3.11, 95% confidence interval 2.48 to 3.89).”
> “Summary relapse prevalences were 36.4% (30.8% to 42.1%; n=28 studies) for the placebo group and 16.4% (12.6% to 20.1%; n=28 studies) for the antidepressant group”

Source: [Batelaan et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5596392/)

| Subgroup | Studies | Odds ratio for relapse after discontinuation (95% CI) |
| --- | --- | --- |
| Generalised anxiety disorder (DSM-IV) | “6” | “4.20 (2.42 to 7.28)” |

Source: [Batelaan et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5596392/)

> “Although approximately 16% of patients relapse despite continued use of antidepressants, discontinuing antidepressants before one year leads to symptom relapse in up to 50% of patients being treated with an SSRI or SNRI.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

> “If the drug is effective, advise the person to continue taking it for at least a year as the likelihood of relapse is high.”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.1.10-8"></a>

###### Treatment-resistant anxiety disorder: consensus definition

> “The definition of pharmacological treatment resistance in anxiety disorders should rest on at least two failed trials of pharmacological monotherapy with first‐line agents approved for the treatment of anxiety disorders and recommended by guidelines (two different classes, e.g. one SSRI plus one SNRI, clomipramine or pregabalin, in the case of GAD) using at least the minimal approved dose, for the duration of at least 6‐8 weeks each, ideally with documented therapy adherence.”

Source: [Domschke et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10785995/)

> “Patients who do not respond to multiple courses of therapy are considered to have treatment-refractory illness.”
> “This disorder is reportedly frequently under-recognized with less than one-third of patients being adequately treated”

Source: [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)

<a id="topic-2.2.2.1.10-9"></a>

###### Evidence for combination and augmentation strategies

> “evidence for the effectiveness of combination treatments is lacking and”
> “side effects and interactions are more likely when combining and augmenting antidepressants.”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary: anticipated population and place in treatment

Lysergide (DT120 ODT) is investigational; the sponsor anticipates an NDA filing in the first half of 2027, states that its clinical trials are currently the appropriate way to receive the drug, and is evaluating when expanded access may be made available. The sponsor's 2026 corporate presentation counts 4.2 million U.S. adults with GAD or MDD failed by two or more prescription treatments, of 13 million treated with prescription drugs. In the Voyage trial, 78 of 214 participants (36%) had two or more past GAD medications, 65 (30%) had one, and 71 (33%) had none. The sponsor reports that payers expect to manage use with prior authorization in line with other branded psychiatric products. The NICE guideline places complex treatment-refractory GAD at step 4, managed with specialist care such as complex drug or psychological regimens and multi-agency input. One author names, as conditions for adoption, full peer-reviewed reporting of the Voyage and Panorama topline results, formulation bridging, durability and retreatment data, management of functional unblinding, and a scalable model of monitored care.

Source: [Definium Therapeutics third quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/259/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights); [Definium Therapeutics expanded access policy (2025)](https://definiumtx.com/expanded-access-policy/); [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf); [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf); [Definium Therapeutics Investor and Analyst Day presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23529/pdf/DFTX+Investor+%26+Analyst+Day+Deck_April+22+2026.pdf); [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations); [Cubała (2026)](https://pubmed.ncbi.nlm.nih.gov/42848417/)

<a id="topic-2.2.2.2-2"></a>

###### Summary: care setting, monitoring, and scheduling

The studied paradigm is a single dosing visit with no psychotherapy, continuous monitoring by dosing session monitors, an end of session when checklist criteria are met, and follow-up visits for assessment only. The Phase 3 trials required 8 hours of monitoring; average time to checklist clearance was 5.8 to 6.4 hours across Emerge, Voyage, and Panorama (Part A), and normal activities, including driving, resume the next day. The sponsor proposes 5 to 8 hours of monitoring through the checklist, which it intends to reflect requirements under a potential REMS. It plans delivery through certified third-party treatment sites, citing ~4,000 interventional psychiatry clinics (about half of the estimated Spravato REMS sites), and is engaged with the VA. Lysergide is a Schedule I substance: after FDA approval, the DEA and states must reschedule the product before it can be marketed, state scheduling may delay sale, and the active ingredient would remain subject to manufacturing quotas.

Source: [Definium Therapeutics Investor and Analyst Day presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23529/pdf/DFTX+Investor+%26+Analyst+Day+Deck_April+22+2026.pdf); [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf); [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm); [Definium Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.mitrade.com/insights/news/live-news/article-8-2243334-20261110)

<a id="topic-2.2.2.2-3"></a>

###### Target population named by the company: adults failed by two or more treatments

| Population | Quoted count | Quoted description |
| --- | --- | --- |
| U.S. adults with GAD or MDD | “50 million” | “US Adults with GAD / MDD” |
| Diagnosed | “26 million” | “Diagnosed with GAD / MDD” |
| Treated with prescription drugs | “13 million” | “Rx Treated” |
| Failed by two or more prescription treatments | “4.2 million” | “Failed by 2+ Rx” |

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

> “4.2 million patients have been failed by 2 or more treatments”
> “Assuming median Spravato® surrogate pricing range; the price of DT120 has not been established.”

Source: [Definium Therapeutics Investor and Analyst Day presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23529/pdf/DFTX+Investor+%26+Analyst+Day+Deck_April+22+2026.pdf)

<a id="topic-2.2.2.2-4"></a>

###### Treatment history of participants in the Voyage trial

| Number of past GAD medications | DT120 ODT (n = 107) | Placebo ODT (n = 107) | Overall (N = 214) |
| --- | --- | --- | --- |
| None | “35 (33)” | “36 (34)” | “71 (33)” |
| One | “31 (29)” | “34 (32)” | “65 (30)” |
| Two or more | “41 (38)” | “37 (35)” | “78 (36)” |

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-2.2.2.2-5"></a>

###### Guideline step for treatment-refractory GAD: NICE stepped care

> “STEP 4: Complex treatment-refractory generalised anxiety disorder (GAD) and very marked functional impairment, such as self-neglect or a high risk of self-harm”
> “Highly specialist treatment, such as complex drug and/or psychological treatment regimens; input from multi-agency teams, crisis services, day hospitals or inpatient care”
> “When treating people with complex and treatment-refractory GAD, inform them of relevant clinical research in which they may wish to participate, working within local and national ethical guidelines at all times.”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.2-6"></a>

###### Treatment paradigm: single administration without psychotherapy

> “DT120 ODT Treatment Paradigm: Standalone Drug Effects with No Psychotherapeutic Intervention”
> “Pre-treatment activities consist of a comprehensive informed consent process”
> “Continuous monitoring by DSMs”
> “Concludes when EOSC criteria met”
> “Follow-up visits for assessment only”
> “No psychotherapy and no therapeutic intervention beyond study drug”

Source: [Definium Therapeutics Investor and Analyst Day presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23529/pdf/DFTX+Investor+%26+Analyst+Day+Deck_April+22+2026.pdf)

<a id="topic-2.2.2.2-7"></a>

###### Session length and real-world delivery model

> “Efficient single-visit model with full-session reimbursement streamlines administrative burden”
> “Dosing and monitoring paradigm based on Phase 3 clinical protocols. Required monitoring period for all participants in pivotal studies is 8 hours and requires that participants clear the End of Session Checklist.”
> “Existing coding systems could potentially be applied or be changed for DT120. Reimbursement and coding for DT120 have yet to be established.”
> “Average time to EoSC was 5.8 hours in the Emerge study (Part A) , 6.4 hours in the Voyage study (Part A)., and 6.2 hours in the Panorama study (Past A).”
> “Normal activities resume the next day, including driving”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-2.2.2.2-8"></a>

###### Monitoring duration proposed for commercial use

> “EOSC intended to inform & reflect requirements under potential REMS program”
> “Refined based on discussions with the FDA”
> “5-8 Hour Monitoring via EOSC”
> “to Inform Real-World Conditions of Safe Use”
> “12-hour monitoring requirement based on inclusion of 200 µg dose of DT120 in Phase 2b”

Source: [Definium Therapeutics Investor and Analyst Day presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23529/pdf/DFTX+Investor+%26+Analyst+Day+Deck_April+22+2026.pdf)

<a id="topic-2.2.2.2-9"></a>

###### Care setting: interventional psychiatry clinics

| Item | Quoted value |
| --- | --- |
| Slide title | “Modest Adoption Yields Significant Opportunity Given Large and Growing Delivery Ecosystem” |
| Interventional psychiatry clinics | “~4,000” |
| Basis for the clinic count | “Represents approximately half of estimated number of sites in the Spravato® REMS program.” |
| Price assumption | “Assumes midpoint of surrogate pricing range for Spravato®. The price of DT120 ODT has not been established.” |

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-2.2.2.2-10"></a>

###### Supervised treatment model and referral pathways: third quarter 2026 earnings call

> “We have advanced our market access strategy, distribution planning, patient services, commercial operations, and field deployment plans, while continuing to build the infrastructure needed to support the supervised treatment model.”
> “Provider and site readiness are critical to a successful launch. We are engaging the established and growing ecosystem of interventional psychiatry providers to assess capacity, workflow, and infrastructure needs.”
> “But it is incumbent on us to build the story in the psychiatrist offices.”
> “There are GAD patients in the clinics today being treated.”

Source: [Definium Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.mitrade.com/insights/news/live-news/article-8-2243334-20261110)

<a id="topic-2.2.2.2-11"></a>

###### Department of Veterans Affairs as a care setting

> “we are very much engaged with the VA, with a number of stakeholders and connected to that care setting as well.”

Source: [Definium Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.mitrade.com/insights/news/live-news/article-8-2243334-20261110)

<a id="topic-2.2.2.2-12"></a>

###### Monotherapy as the studied use and combination use as anticipated practice

> “we fully expect to run these studies as a monotherapy as we have in other indications.”
> “And we intend to continue to demonstrate our primary evidence as monotherapy while demonstrating that the drug can be used safely.”

Source: [Definium Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.mitrade.com/insights/news/live-news/article-8-2243334-20261110)

<a id="topic-2.2.2.2-13"></a>

###### Payer expectations reported by the company

> “Payers expect to manage use of DT120 with prior authorizations in line with other branded psychiatric products”
> “Standard components of patient and HCP support services that are being considered for DT120 launch.”

Source: [Definium Therapeutics Investor and Analyst Day presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23529/pdf/DFTX+Investor+%26+Analyst+Day+Deck_April+22+2026.pdf)

<a id="topic-2.2.2.2-14"></a>

###### Session monitoring expected by FDA in clinical investigations of psychedelic drugs

> “Observation by two monitors for the duration of the treatment session.”
> “A health care provider with graduate-level professional training and clinical experience in psychotherapy, licensed to practice independently, serving as the lead monitor.”
> “An assistant monitor with a nursing or bachelor’s degree and at least 1 year of clinical experience in a licensed mental health care setting.”
> “If the lead monitor is not a physician, availability of a licensed on-call physician able to reach the clinical site within 15 minutes in the event of a medical emergency.”
> “The treatment paradigm used in the trials may be described in product labeling.”

Source: [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-2.2.2.2-15"></a>

###### Supervised-administration analog: esketamine REMS

> “Esketamine will be made available through a Risk Evaluation and Mitigation Strategy (REMS) program that requires dosing and monitoring in an approved clinic.”
> “Clinicians attending the roundtable noted that the burden of administering the REMS program for esketamine may not be adequately compensated by insurers through normal outpatient provider payments.”
> “The additional time required to administer and monitor patients after treatment may impose a financial burden on providers and limit availability of the drug to patients in need.”

Source: [ICER esketamine final evidence report (2019)](https://icer.org/wp-content/uploads/2020/10/ICER_TRD_Final_Evidence_Report_062019.pdf)

<a id="topic-2.2.2.2-16"></a>

###### Procedure codes for monitoring during psychedelic medication therapy

| Code | Quoted description |
| --- | --- |
| 0820T | “Continuous in-person monitoring and intervention (e.g. psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; first physician or other QHP, each hour” |
| +0821T | “Continuous in-person monitoring and intervention (e.g. psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; second physician or other qualified health care professional, concurrent with first physician or other QHP, each hour” |
| +0822T | “Continuous in-person monitoring and intervention (e.g. psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; clinical staff under the direction of a physician or other QHP, concurrent with the first physician or other QHP, each hour” |

Source: [BrainFutures CPT and HCPCS coding guide (2023)](https://www.brainfutures.org/wp-content/uploads/2023/09/A-Guide-to-CPT-and-HCPCS-Codes-for-Psychedelic-Assisted-Therapy_Charts.pdf)

<a id="topic-2.2.2.2-17"></a>

###### Conditions for adoption named in a drug review

> “The phase 2b dose-finding study provides a credible signal of rapid and durable anxiolytic activity after one 100 microgram administration without protocol-mandated psychotherapy.”
> “Adoption will depend on full peer-reviewed reporting of the positive Voyage and Panorama phase 3 topline results, formulation bridging, durability and retreatment data, management of functional unblinding, and a scalable monitored-care model.”

Source: [Cubała (2026)](https://pubmed.ncbi.nlm.nih.gov/42848417/)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Baseline severity and antidepressant efficacy in GAD: individual participant data

> “For GAD and PD, severity moderated antidepressant efficacy. The antidepressant–placebo difference was 1.4 (95% CI: 0.4–2.5; SMD: 0.21) Hamilton Anxiety Rating Scale (HAM‐A) points for participants with mild GAD (baseline HAM‐A = 10), increasing to 4.0 (3.4–4.6; SMD: 0.45) or greater for severely ill participants (HAM‐A ≥ 30).”
> “Half of the GAD trials specified a minimum HAM‐A score of 20, for instance, even though most primary care patients with GAD have scores below 20 (Rollman et al., 2005).”

Source: [de Vries et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6667912/)

<a id="topic-2.2.2.3-2"></a>

###### Age as a moderator of psychotherapy and medication effects

> “Mean age of the sample was a significant moderator of psychotherapy outcomes. A lower mean age predicted a larger treatment effect size in psychotherapy (β = −0.013, p < 0.05).”
> “Mean age was not associated with outcome in medication studies (p > 0.05).”
> “There was no significant relationship between effect size and treatment dose (number of sessions or medication dosage), treatment quality, year of publication, fixed versus flexible dose, percent comorbidity, percent female, or pretreatment severity (all p > 0.10).”

Source: [Carl et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7063818/)

<a id="topic-2.2.2.3-3"></a>

###### Older adults

> “Twenty-seven trials (14 pharmacological, 13 psychotherapeutic) fulfilled the inclusion criteria, reporting results from 2373 baseline participants.”
> “Pooled treatment effects for pharmacological (OR=0.32, 95% CI: 0.18, 0.54) and psychotherapeutic (OR=0.33, 95% CI: 0.17, 0.66) trials were similar, with findings in each case favoring active interventions over control conditions.”

Source: [Gonçalves and Byrne (2012)](https://pubmed.ncbi.nlm.nih.gov/21907538/)

<a id="topic-2.2.2.3-4"></a>

###### DT120 in Voyage: change in HAM-A score at Week 12 by subgroup

| Subgroup | Placebo-adjusted LS mean change (SE) |
| --- | --- |
| All participants | “−5.4 (1.0)” |
| Time since GAD symptoms began, less than 22 years (n = 107) | “−5.9 (1.4)” |
| Time since GAD symptoms began, 22 years or more (n = 107) | “−4.7 (1.5)” |
| Previous GAD medications, fewer than 2 (n = 136) | “−4.2 (1.2)” |
| Previous GAD medications, 2 or more (n = 78) | “−5.6 (1.7)” |
| Male (n = 77) | “−7.1 (1.7)” |
| Female (n = 137) | “−5.5 (1.2)” |

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

> “The treatment effect was maintained across key subgroups, including in participants with ≥2 previous trials of medications for GAD (Figure 5)”

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-2.2.2.3-5"></a>

###### DT120 in Panorama: subgroups and stability of subgroup estimates

> “Treatment Effect Maintained Across Key Subgroups”
> “Including Those Failed by 2+ Prior Treatments”
> “Subgroup analysis of ITT population; 100 µg and placebo groups only.”
> “If the number of patients is small for a subgroup, the treatment difference will not be stable as it would be highly sensitive to outliers.”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-2.2.2.3-6"></a>

###### Dose and functional unblinding in Panorama

> “Week 4: 50% less separation at 50 µg”
> “Week 12: 29% less separation at 50 µg”
> “91% and 95% of participants at 50 and 100 µg correctly guessed assignment to drug”
> “Results support the conclusion that DT120 dose response is not attributable to functional unblinding”

Source: [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf)

<a id="topic-2.2.2.3-7"></a>

###### Functional unblinding and dose in the phase 2b trial

> “All doses of MM120 produced transient perceptual, cognitive, and emotional effects leading to participant unblinding.”
> “Central rater blinding was preserved in more than 80% of HAM-A assessments,31 despite approximately 85% of participants correctly identifying assignment to active treatment.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-2.2.2.3-8"></a>

###### Expectancy and blinding in psychedelic trials

> “While psychedelic RCTs have generally shown promising results, with large effect sizes reported, we argue that treatment effect sizes in psychedelic RCTs are likely over-estimated due to de-blinding of participants and high levels of response expectancy.”
> “We suggest that psychedelic RCTs should routinely measure de-blinding and expectancy.”

Source: [Muthukumaraswamy et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34038314/)

<a id="topic-2.2.2.3-9"></a>

###### Prior psychedelic exposure: FDA recommendation

> “enrolling individuals with prior psychedelic drug exposure raises the possibility of expectation bias given that participants who have prior experience with psychedelic drugs are more likely to recognize their subjective effects (i.e., leading to functional unblinding) and anticipate a treatment benefit.”

Source: [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-2.2.2.3-10"></a>

###### Prior psychedelic exposure in the DT120 phase 3 trials

> “Exclusion criteria related to prior use of psychedelics was later amended to any lifetime use of psychedelics based on FDA feedback.”
> “Baseline expectancy was measured in participants, and perceived treatment was recorded for both participants and central raters”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

| Past psychedelic use in Voyage | DT120 ODT (n = 107) | Placebo ODT (n = 107) | Overall (N = 214) |
| --- | --- | --- | --- |
| Any psychedelic | “18 (17)” | “27 (25)” | “45 (21)” |
| LSD | “10 (9)” | “9 (8)” | “19 (9)” |

Source: [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf)

<a id="topic-2.2.2.3-11"></a>

###### Functional unblinding in a health technology assessment of another psychedelic treatment

> “Because of the effects of MDMA, the trials were, essentially, unblinded with nearly all patients who received MDMA correctly identifying that they were in the MDMA arm of the trials.”
> “As such, we conclude that the current publicly-available evidence for MDMA-AP is insufficient”

Source: [Mustafa et al. (2024)](https://icer.org/wp-content/uploads/2024/06/PTSD_Final-Report_For-Publication_06272024.pdf)

<a id="topic-2.2.2.3-12"></a>

###### Company statement on heterogeneous populations

> “as we have shown now in GAD and MDD, we seem to be able to demonstrate efficacy across a range of heterogeneous populations.”

Source: [Definium Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.mitrade.com/insights/news/live-news/article-8-2243334-20261110)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Stepped care for GAD: NICE

> “Follow the stepped-care model, offering the least intrusive, most effective intervention first.”
> “STEP 1: All known and suspected presentations of GAD”
> “Identification and assessment; education about GAD and treatment options; active monitoring”
> “STEP 2: Diagnosed GAD that has not improved after education and active monitoring in primary care”
> “Low-intensity psychological interventions: individual non-facilitated self-help, individual guided self-help and psychoeducational groups”
> “STEP 3: GAD with an inadequate response to step 2 interventions or marked functional impairment”
> “Choice of a high-intensity psychological intervention (cognitive behavioural therapy [CBT]/applied relaxation) or a drug treatment”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.4-2"></a>

###### Monitoring of drug treatment: NICE

> “Review the effectiveness and side effects of the drug every 2 to 4 weeks during the first 3 months of treatment and every 3 months thereafter.”
> “If the drug is effective, advise the person to continue taking it for at least a year as the likelihood of relapse is high.”
> “Develop a comprehensive care plan in collaboration with the person with GAD that addresses needs, risks and functional impairment and has a clear treatment plan.”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.4-3"></a>

###### Collaborative care in primary care: the CALM trial

> “Between June 2006 and April 2008, 1004 primary care patients with PD, GAD, SAD, and/or PTSD were enrolled in the CALM study.”
> “CALM allowed choice of cognitive behavioral therapy (CBT), medication, or both; included real-time web-based outcomes monitoring to optimize treatment decisions and a computer-assisted program to optimize delivery of CBT by non-expert care managers who also assisted primary care providers in promoting adherence and optimizing medications.”
> “At 12 months, response and remission rates (CALM vs. UC) were 63.66% (58.95–68.37) vs. 44.68% (39.76–49.59), and 51.49% (46.60–56.38) vs. 33.28% (28.62–37.93), with a number needed to treat (NNT) of 5.27 (4.18–7.13) for response and 5.5 (4.32–7.55) for remission.”

Source: [Roy-Byrne et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2928714/)

<a id="topic-2.2.2.4-4"></a>

###### Collaborative care for anxiety: Cochrane review

> “The results also demonstrated significantly greater improvement in anxiety outcomes for adults with anxiety treated with the collaborative care model in the short‐term (SMD ‐0.30, 95% CI ‐0.44 to ‐0.17; RR 1.50, 95% CI 1.21 to 1.87), medium‐term (SMD ‐0.33, 95% CI ‐0.47 to ‐0.19; RR 1.41, 95% CI 1.18 to 1.69), and long‐term (SMD ‐0.20, 95% CI ‐0.34 to ‐0.06; RR 1.26, 95% CI 1.11 to 1.42).”
> “Collaborative care is associated with significant improvement in depression and anxiety outcomes compared with usual care, and represents a useful addition to clinical pathways for adult patients with depression and anxiety.”

Source: [Archer et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11627142/)

<a id="topic-2.2.2.4-5"></a>

###### Symptom-triggered retreatment after a single dose in the DT120 phase 3 trials

> “Open-label treatment in Part B was based on prespecified symptom severity, which allowed for assessment of retreatment patterns and durability of response in a real-world fashion (Figure 2)”
> “To maintain data integrity, participants who met retreatment thresholds and had no safety concerns were required to re-treat”
> “ePRO score ≥10 may prompt unscheduled central assessment”
> “HAM-A ≥16 or MADRS ≥20”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-2.2.2.4-6"></a>

###### Patient, provider, and site support planned by the company

> “Referral & Treatment Coordination”
> “Treatment-Day Logistics”
> “INTEGRATED COMMERCIAL SUPPORT MODEL”
> “Connecting patients, providers and sites of care”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Summary: symptom change, response, and remission

In the phase 3 trials, which compared a single dose of DT120 ODT 100 µg with placebo and have reported company topline results, the LS mean HAM-A total score decreased by 11.6 points (Voyage) and 9.8 points (Panorama) at Week 12, compared with 6.2 and 4.7 points with placebo. The placebo-adjusted differences of 5.4 and 5.1 points compare with a minimal clinically important difference of 2.5 points used in the phase 2b trial. At Week 12, 43% (Voyage) and 32% (Panorama) of participants given DT120 had a response (HAM-A improvement of 50% or more) and 14% and 15% a remission (HAM-A of 7 or less), compared with 16% and 14% (response) and 4% and 4% (remission) with placebo. In the phase 2b trial, which used capsules, response at Week 12 occurred in 26 of 40 participants (65.0%) given 100 µg and 12 of 39 (30.8%) given placebo, and remission in 19 (47.5%) and 8 (20.5%).

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder); [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder); [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/); [Robison et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12412041/bin/jama-e2513481-s003.pdf)

<a id="topic-2.2.2.7-2"></a>

###### Summary: onset, durability, and the dosing session

Differences from placebo were present early: CGI-S change at Day 2 differed by -0.8 in both phase 3 trials, and HAM-A change at Week 1 by -7.7 (Voyage) and -5.3 (Panorama) points. The controlled comparison covers 12 weeks after one dose. In the 40-week extensions participants could receive open-label DT120 ODT (in Voyage, up to four additional doses based on symptom severity); in interim analyses of partial data (cutoffs July 15, 2026 and August 11, 2026), 60% of 37 Voyage participants and 48% of 27 Panorama participants given DT120 in Part A had a HAM-A response at Week 28. FDA guidance asks sponsors to follow participants beyond Week 12 for symptom recurrence or a need for repeat dosing. Transient perceptual, affective, and emotional effects occurred primarily on the dosing day. Participants were observed by dosing session monitors for at least 8 hours and until they cleared an end-of-session checklist; mean time to clearance was 6.4 hours in Voyage and 6.2 hours in Panorama, and by hour 8, 92% (topline announcement) or 90% (poster) of Voyage participants, 94% of Panorama participants, and 97% across more than 1,000 phase 3 sessions through September 10, 2026 had cleared it. The sponsor states that normal activities, including driving, resume the next day.

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder); [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder); [Definium Therapeutics Voyage topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23544/pdf/Voyage+Study+Readout_August+2026.pdf); [Definium Therapeutics Panorama topline presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23555/pdf/Panorama+Data+Release_September+2026.pdf); [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm); [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download); [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf); [Thielking et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035F_Psych-Congress-2026-Voyage-top-line-DN-Poster_Final-Draft_09Sept2026_For-Print_v2.pdf); [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf); [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-2.2.2.7-3"></a>

###### Definitions of response and remission in anxiety disorders

> “Response is generally regarded as a clinically meaningful improvement in symptoms, while remission, the goal of treatment, is generally thought of as the absence or near absence of symptoms following illness, accompanied by a return to premorbid levels of functioning.”
> “While no universally accepted criteria exist, a commonly used threshold for response is a >50% improvement in the total score, while for remission, various cutoff points have been used.”

Source: [Bandelow (2006)](https://pubmed.ncbi.nlm.nih.gov/17008827/)

<a id="topic-2.2.2.7-4"></a>

###### HAM-A severity bands and minimal clinically important difference

> “score range, 0-56; higher scores indicate greater severity; ≤7 indicates no or minimal anxiety; 8-14, mild; 15-23, moderate; and ≥24, severe”
> “The minimal clinically important difference was 2.5 points.”

Source: [Robison et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412041/)

<a id="topic-2.2.2.7-5"></a>

###### Expected HAM-A differences from placebo with existing drugs: network meta-analysis

> “This analysis is based on 89 trials, which included 25 441 patients randomly assigned to 22 different active drugs or placebo.”
> “Duloxetine (MD -3·13, 95% credible interval [CrI] -4·13 to -2·13), pregabalin (MD -2·79, 95% CrI -3·69 to -1·91), venlafaxine (MD -2·69, 95% CrI -3·50 to -1·89), and escitalopram (MD -2·45, 95% CrI -3·27 to -1·63) were more efficacious than placebo with relatively good acceptability.”
> “Quetiapine (MD -3·60 95% CrI -4·83 to -2·39) had the largest effect on HAM-A but it was poorly tolerated (odds ratio 1·44, 95% CrI 1·16-1·80) when compared with placebo.”

Source: [Slee et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30712879/)

<a id="topic-2.2.2.7-6"></a>

###### Pooled effect sizes of psychotherapy and medication

> “Psychotherapy showed a medium to large effect size (g = 0.76) and medication showed a small effect size (g = 0.38) on GAD outcomes.”
> “Because medication studies had more placebo control conditions than inactive conditions compared to psychotherapy studies, effect sizes between the domains should not be compared directly.”

Source: [Carl et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7063818/)

<a id="topic-2.2.2.7-7"></a>

###### DT120 in Voyage: response and remission at Week 12

| Outcome at Week 12 | DT120 ODT | Placebo ODT | Placebo-adjusted difference |
| --- | --- | --- | --- |
| HAM-A response rate (≥50%) | “43%” | “16%” | “27% (p<0.0001)” |
| HAM-A remission rate (≤7) | “14%” | “4%” | “10% (p=0.0222)” |

Source: [Definium Therapeutics Voyage topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/243/definium-therapeutics-announces-positive-topline-results-from-phase-3-voyage-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-2.2.2.7-8"></a>

###### DT120 in Panorama: response and remission at Week 12

| Outcome at Week 12 | DT120 ODT 100 µg | Placebo ODT | Placebo-adjusted difference |
| --- | --- | --- | --- |
| HAM-A response rate (≥50%) | “32%” | “14%” | “18% (p<0.05)” |
| HAM-A remission rate (≤7) | “15%” | “4%” | “12% (p<0.05)” |

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-2.2.2.7-9"></a>

###### Durability after a single dose: outcomes beyond Week 12

> “Single dose regimen is being studied in pivotal clinical trials with primary and secondary outcome measures through 12 weeks after administration.”
> “Voyage - HAM-A Scores Improve Further with Additional Treatments in Part B”
> “Based on interim analysis as of July 15, 2026. ITT Part A+B population with treatment policy strategy. Interim analysis based on partial data and subject to change.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-2.2.2.7-10"></a>

###### Durability and repeat dosing: FDA recommendations

> “Although it has been hypothesized that one or a few doses of a psychedelic drug will produce lasting therapeutic benefit, many of the conditions that these drugs are purported to treat typically persist for months or years.”
> “Sponsors should continue to follow subjects beyond the Week 12 endpoint to monitor for symptom recurrence or, potentially, the need for repeat dosing.”

Source: [FDA psychedelic drugs clinical investigations guidance (2026)](https://www.fda.gov/media/169694/download)

<a id="topic-2.2.2.7-11"></a>

###### Expected acute effects on the dosing day

> “Transient clinically significant perceptual, affective, and emotional effects that primarily occurred on dosing day”
> “Clinically insignificant physiological effects”

Source: [Malberg et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035H_Psych-Congress-2026_Encore-Safety-Poster_10Sep2026_For-Print.pdf)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
